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1. Introduction 
 
1.1. The G-Protein coupled receptors (GPCRs) 
The G-Protein coupled receptors (GPCRs) represent the largest group of membrane 
integrated receptors in the human genome. (Lagerström and Schiöth, 2008) By now, 
roughly 800 GPCRs have been identified (Fredriksson et al., 2003) that are divided 
into two groups: about 400 GPCRs belong to the family of the endoGPCRs that are 
addressed by peptides, lipids, prostanoids, neurotransmitters, nucleosides and 
nucleotides, whereas about 400 GPCRs belong to the family of csGPCRs 
(chemosensory GPCRs) that respond to external signals like odors, tastes, photons or 
pheromones. (Vassilatis et al., 2003, Kristiansen, 2004) For more than 260 
endoGPCRs endogenous ligands have been identified whereas the remaining 140 
endoGPCRs are counted among the group of “orphan receptors” as their endogenous 
ligands have not yet been conclusively identified. (Sharman et al., 2013)  
GPCRs are the target of about 30 % of the drugs prevalent on the current drug market 
(Overington et al., 2006, Stevens et al., 2013) and play important roles in a long row 
of physiological and pathophysiological processes. (Fang et al., 2003) Therefore, it is 
not surprising that GPCRs are still of major interest in pharmacological research and 
drug discovery.  
 
1.1.1. Structure and classification of GPCRs 
All GPCRs are characterized by a common architecture: an extracellular N-terminus, 
seven transmembrane α-helices (TM1 – TM7) and an intracellular C-terminus. The 
counter-clockwisely arranged transmembrane α-helices share a very high degree of 
sequence conservation and are linked by three intra- and three extracellular loops (ICL 
1 – 3, ECL 1 -3) that distinctly differ in their size and complexity. Transmembrane and 
extracellular regions are involved in ligand binding, whereas the intracellular regions 
are responsible for the signal transduction in the cell. (Ji et al., 1998) The name G-
protein coupled receptor results from the classical way of signaling that consists of 
coupling to heterotrimeric G-proteins located at the intracellular surface. (Fredriksson 
et al., 2003, Kobilka, 2007, Lagerström and Schiöth, 2008)  
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Due to structural differences, mammalian GPCRs are grouped into five receptor 
families, also known as “GRAFs system” (Fredriksson et al., 2003): rhodopsin, 
secretin, adhesion, glutamate and frizzled/taste2. A former GPCR classification system 
dividing the GPCRs into classes A – F (Kolakowski, 1994) is used by the International 
Union of Pharmacology, Committee on Receptor Nomenclature and Classification 
(NC-IUPHAR) (Foord et al., 2005). This system differs from the GRAFs system by 
comprising the adhesion and secretin family in class B and by dividing the taste 
receptors into two sections, one as part of the glutamate and a second as part of the 
frizzled/taste2 group. 
The rhodopsin receptor family (class A) is subdivided in four groups (α, β, γ and δ) and 
represents the largest subfamily (672 GPCRs, including both endo- and csGPCRs). 
The secretin-like receptor family (class B) comprises 15 GPCRs that respond to 
peptides like secretin, calcitonin and parathyroid hormone. The adhesion receptor 
family (class B) represents with 33 members the second largest receptor family among 
which the majority is counted to the group of the “orphan receptors”. (Civelli et al., 
2013, Sharman et al., 2013) The glutamate receptor family (class C) includes 22 
GPCRs that contain very large C- and N-terminal tails. The latter was found to bear a 
cavity formed by two lobes of the region, a so called Venus flytrap module (Kunishima 
et al., 2000) that represents the binding site. Finally, the frizzled/taste2 receptor family 
comprises 10 frizzled and 25 taste GPCRs that are either involved in cell development 
and proliferation or in the detection of the bitter taste of compounds, respectively. 
(Fredriksson et al., 2003, Kristiansen, 2004, Jacoby et al., 2006, Lagerström and 
Schiöth, 2008, Luttrell, 2008, Davies et al., 2011)  
In newer literature, the GPCRs are often referred to as “seven transmembrane 
receptors” (7 TM receptors) as in recent research G-protein independent signal 
pathways were described for some of these receptors (see 1.1.3). (Ritter and Hall, 
2009, Kenakin and Miller, 2010)  
 
1.1.2. GPCRs on a molecular level 
The crystal structure of bovine rhodopsin published in 2000 provided a first insight into 
the three dimensional structure of a representative class A GPCR on a molecular level 
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(Palczewski et al., 2000). However, as it was bound to the inverse agonist 11-cis 
retinal, this crystal structure represented an inactive receptor model.  
In 2007, the crystal structure of the first aminergic GPCR, the β2-adrenergic receptor, 
was resolved, revealing specific differences with regard to the “ionic look” of the 
inactive state of rhodopsin. (Cherezov et al., 2007) The first receptor that was 
crystallized in its active state was opsin, the ligand free form of rhodopsin. (Park et al., 
2008, Scheerer et al., 2008) In 2011, Rasmussen et al. published the crystal structure 
of the active state of the β2-adrenergic receptor by replacing the G-protein by a 
nanobody (Rasmussen et al., 2011a) as well as in form of the active state ternary 
complex containing the nucleotide free heterotrimeric G-protein. (Rasmussen et al., 
2011b) These milestones in GPCR research represented precursors for the in the 
meantime resolved 18 crystal structures of different class A GPCRs (Venkatakrishnan 
et al., 2013), among others the turkey β1-adrenergic receptor (Warne et al., 2008), the 
human dopamine D3 receptor (Chien et al., 2010) and the human histamine H1 receptor 
(Shimamura et al., 2011).  
Regarding drug design and receptor investigation, the crystal structure of GPCRs 
bound to signaling proteins other than the G-protein will be of major interest in future 
research as it provides new starting points for the investigation of ligand-receptor 
interactions on a molecular level. (Granier and Kobilka, 2012) 
 
1.1.3. The G-protein cycle 
GPCR-mediated G-protein dependent intracellular signaling is prevalently known as 
the G-Protein cycle (figure 1.1). By binding to either the extracellular loop or the 
transmembrane domain of the GPCR, the agonist evokes a conformational change of 
the intracellular surface of the receptor. As a consequence, heterotrimeric G-proteins 
(consisting of a Gα subunit, a Gβγ complex and a GDP nucleotide (Gilman, 1987, 
Offermanns, 2003)) are able to bind to the GPCR. This binding evokes the release of 
the G-protein bound GDP nucleotide, forming a ternary complex of agonist, receptor 
and nucleotide-free G-protein that is characterized by a very high affinity for the 
agonist. In a next step, GTP binds to the Gα subunit, leading to a conformational 
change of the G-protein and thus to a disruption of the ternary complex. The Gα-GTP 
subunit dissociates from the Gβγ complex and each interact with (different) effector 
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proteins (e.g., enzymes or ion channels) to give biochemical signals. After a certain 
period of time, the intrinsic GTPase activity of Gα terminates the Gα-induced signal and 
the bound GTP is hydrolyzed to GDP and inorganic phosphate (Pi). The now GDP-
bound Gα-subunit re-associates with the Gβγ-subunit to the inactive heterotrimeric state 
that leads over to the next G-protein cycle. (Hermans, 2003, Schneider and Seifert, 
2010)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The G-protein cycle (adapted from Schneider and Seifert, 2010). 
 
Some GPCRs turned out to reveal the active state although no agonist is bound. As a 
consequence, they bind to the G-protein complex and evoke biochemical signals, what 
is prevalently known as “constitutive activity” of a receptor. (Seifert and Wenzel-Seifert, 
2002) The activity of G-proteins is moreover influenced by so called “regulators of G-
protein signaling” proteins (Zhu et al., 2001) that stimulate the GTPase activity of the 
α-subunit. (Ross and Wilkie, 2000, De Vries et al., 2000, Neubig and Siderovski, 2002) 
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Based on the knowledge of the G-protein cycle, several approaches to investigate the 
GPCR activity on a molecular level are established: firstly, binding studies using 
fluorescent or radio-labeled ligands to determine the high-affinity binding to a GPCR 
(referred to as competition binding assay in this work), secondly, the application of 
radio-labeled non-hydrolysable GTP analogs like, e.g., guanosine 5’-[γ-
thio]triphosphate to detect the dissociation of the ternary complex (referred to as 
[35S]GTPγS binding assay in this work) as well as thirdly, the measuring of the 
hydrolysis of radio-labeled GTP to GDP and Pi to determine the intrinsic GTPase 
activity of the Gα subunit (referred to as [33P]GTPase activity assay in this work). 
(Schneider and Seifert, 2010) 
In recent research not only the classical G-protein-dependent signaling of GPCRs was 
reported, but also other signal pathways independent from the G-protein (Luttrell, 
2008) as, e.g., the GPCR signaling via β-arrestins 1 and 2 that are ubiquitously 
prevalent in tissues of the human body (Lefkowitz and Whalen, 2004). Although 
originally regarded as modulators of GPCR desensitization through internalization into 
clathrin-coated pits (Lefkowitz and Shenoy, 2005, Lefkovitz et al., 2005, Evans et al., 
2010), important cellular processes like gene transcription, cell proliferation and 
differentiation are accounted to these molecules (Rajagopal et al., 2010) and β-arrestin 
signaling is considered to be pro-survival, cytoprotective and anti-apoptotic. (Violin and 
Lefkowitz, 2007) 
 
1.1.4. Signal transduction pathways of GPCRs 
Based on their structure and signaling pathway, G-proteins are grouped into four main 
families with regard to their Gα subunit: Gαs, Gαi/o, Gαq/11 and Gα12/13. (Cabrera-Vera 
et al., 2003) The different signaling pathways are described in the following.  
Characteristic of the Gαs family is the activation of adenylyl cyclases (AC 1-9) what 
leads to an increase of the second messenger cAMP (3’,5’-cyclic adenosine 
monophosphate) in the cell. By contrast, inverse effects are observed for the Gαi/o 
family, as they are known to inhibit the activity of the adenylyl cyclases (AC 5 and AC 
6). (Hanoune and Defer, 2001, Pavan et al., 2009) Derived from ATP, the second 
messenger cAMP is responsible, e.g., for the activation of the protein kinase A (PKA) 
or the mitogen-activated protein kinase (MAPK) pathway and as a consequence for 
the modulation of gene expression. (Marinissen and Gutkind, 2001) The signal 
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transduction is terminated by the inactivation of cAMP (e.g., though 
phosphodiesterases (PDE)). 
The Gαq/11 family regulates the activity of phospholipase C (PLCβ) leading to the 
hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) into inositol-1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG), both second messengers that are 
responsible for various intracellular effects. For instance, the increase of IP3 levels 
induces the release of Ca2+ ions into the cytosol (Mikoshiba, 2007) that, together with 
DAG, stimulate the proteinkinase C (PKC) and thereby modulate the function of cellular 
proteins by phosphorylation. (Thomsen et al., 2005)  
The last family, the Gα12/13 family, interferes with the cytosceletal assembly by 
interaction with Rho-GEFs (Ras homology guanine nucleotide exchange factors). 
(Cabrera-Vera et al., 2003, Kristiansen, 2004, Birnbaumer, 2007, Luttrell, 2008) 
Moreover, not only the Gα-subunit but also the Gβγ-heterodimer can regulate certain 
effectors like PLCβ and ion channels (K+ and Ca2+ regulated). (Cabrera-Vera et al., 
2003) 
An overview of the families, subtypes and evoked pharmacological effects is given in 
table 1.1.  
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Subunit Family Subtypes Effector(s) 
α αs Gαs, Gαolf AC ↑ 
 αi/o Gαi1, Gαi2, Gαi3 AC ↓ 
  GαoA, GαoB K+ channels ↑ 
  Gαt1, Gαt2 PDE ↑ 
  Gαz PDE ↑, AC ↓ 
 αq/11 Gαq, Gα11, Gα14-16 PLC ↑ 
 α12/13 Gα12, Gα13 Rho-guanine-nucleotide-exchange 
factors ↑ 
β and γ β1-5 and γ1-12 various βγ complexes AC ↑/↓, PLC ↑, PI3K ↑, PKC and 
PKD ↑, GPCR kinases ↑, Ca2+ and 
K+ channels 
 
Table 1.1. G-Protein subunits and their effectors according to Hermans, 2003, 
Worzfeld et al., 2008 and Smrcka, 2008, adapted from Brunskole (PhD Thesis, 
University of Regensburg, 2011). 
 
1.1.5. Receptor activation and ligand classification 
In the past, several models have been set up to describe the mechanism of the 
activation of GPCRs in dependence of appropriate ligands. A first model, the “ternary 
complex model” (TCM, figure 1.2 I) (De Lean et al., 1980), describes the agonist 
promoted interaction of the receptor and the transducer proteins (later identified as G-
proteins) (Gilman, 1987). In this model, however, agonist binding to the receptor is 
necessary to activate the transducer and as a consequence, constitutive activity as 
well as inverse agonism cannot be explained.  
The more suitable “extended ternary complex model” (ETCM, figure 1.2 II) (Samama 
et al., 1993, Leff, 1995) explains the pharmacodynamic activities of the majority of 
interacting ligands: receptors exist in both inactive (R) and active (R*) conformations, 
whereby the latter couples to the transducer protein (R*T) and induces signaling. 
Inactive receptors (R) are allowed to isomerize to the active conformation (R*), be it 
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spontaneously or in complex with an agonist (LR*). The spontaneous activation of the 
receptor independent from agonist binding is referred to as constitutive activity.  
A third and thermodynamically more complex model, the “cubic ternary complex 
model” (CTCM, figure 1.2 III) (Weiss et al., 1996c, Weiss et al., 1996a, Weiss et al., 
1996b) increases the number of conformations compared to the ETCM by including 
the interaction between the inactive receptor (R) and the transducer (RT) independent 
from agonist binding.  
 
All three ternary complex models (TCM, ETCM and CTCM) are displayed in figure 1.2. 
 
Figure 1.2. Models of GPCR signaling: I. ternary complex model (TCM); II. extended 
ternary complex model (ETCM); III. cubic ternary complex model (CTCM) (adapted 
from Rajagopal et al., 2010, Nordemann, PhD Thesis, University of Regensburg, 
2013).  
 
A further distinction is made with regard to the kind of the binding ligand and its 
influence on the equilibrium between the active and the inactive state of the receptor 
(figure 1.3): agonists reveal a higher affinity to the active receptor conformation (R*), 
whereas inverse agonists prefer the interaction with the inactive state of the receptor 
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(R). Neutral antagonists bind to the active as well as to the inactive conformation with 
the same affinity without having an impact on the equilibrium. Partial (inverse) agonists 
are less effective than full (inverse) agonists as they only bind to some extent to the 
active or inactive state of the receptor, respectively. (Kenakin, 2002b, Kenakin, 2002a)  
 
 
 
Figure 1.3. Ligand classification according to their impact on the equilibrium between 
both the active and the inactive receptor state as well as differential responses in an 
effector system upon binding of different ligand classes (full / partial (inverse) agonist 
and antagonist) (adapted from Seifert and Wenzel Seifert, 2002). 
 
1.1.6. GPCR oligomerization and dimerization: bivalent ligands and their 
interaction with the receptors 
GPCRs were identified to appear not only as monomers but also as homo-oligomers 
(two or more identical GPCRs forming a complex) and hetero-oligomers (two or more 
different GPCRs forming a complex). (Smith and Milligan, 2010) Although their 
physiological relevance could not yet be sufficiently proved, an important role for 
GPCRs’ trafficking, folding, internalization and activation is postponed. (Nikbin et al., 
2003) 
In order to investigate this phenomenon on a molecular level, different techniques 
including cross-linking, immunoblotting and co-immunoprecipitations, radioligand 
binding studies as well as optical methods like FRET (fluorescence induced resonance 
energy transfer), BRET (bioluminescence induced resonance energy transfer) and 
atomic force microscopy were applied. Regarding the receptor-receptor interaction, 
three regions of interest are obvious: extracellular loops, transmembrane regions as 
well as intracellular loops that can all interact via covalent and non-covalent bonds. 
(George et al., 2002, Nikbin et al., 2003)  
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Several class A and C GPCRs were identified to form receptor homo-dimers, among 
others dopamine (D2R, D3R) (Nimchinsky et al., 1997, Lee et al., 2000), opioid (Cvejic 
and Devi, 1997, Jordan and Devi, 1999, McVey et al., 2001) and histamine receptors 
(H1R, H2R, H3R, H4R) (Fukushima et al., 1997, Carrillo et al., 2003, Bakker et al., 2004, 
Shenton et al., 2005, van Rijn et al., 2006) as well as the 5-HT1D serotonin receptor 
(Lee et al., 2000). Furthermore, also receptor hetero-dimers like, e.g., the 
GABAB1/GABAB2 receptors (Kaupmann et al., 1998) or the δ/κ-opioid receptors (Jordan 
and Devi, 1999) were found and interestingly, there is growing evidence that above all 
receptor-hetero-dimers reveal a modified signaling pathway as well as a modified 
ligand binding relative to the individual monomeric receptors. (George et al., 2000, 
Kristiansen, 2004)  
Provided there is an adequate monomeric lead compound as well as a proper 
attachment point of a sufficiently long spacer, bivalent ligands represent a promising 
approach to either investigate the pharmacological profile of dimeric GPCRs as well 
as to improve the potency, selectivity and pharmacokinetic profile of compounds. 
(Halazy, 1999, Shonberg et al., 2011, Lezoualc'h et al., 2009) Characteristically, 
bivalent ligands are linked by a spacer and contain either two (different) 
pharmacophoric entities or, in the broader sense, one pharmacophoric group and a 
non-pharmacophoric recognition unit. (Portoghese, 1989, Portoghese, 2001)  
In dependence of the spacer length, different binding modes are suggested (figure 
1.4): if the spacer is too short to link two neighboured GPCRs (be it homo- or 
heterodimeric) (I), the binding to an accessory binding site next to the orthosteric 
binding site of the monomeric GPCR is postulated. If the spacer is of sufficient length 
to bridge the two neighboured GPCRs (II), each pharmacophoric entity of the bivalent 
ligand may interact with the (orthosteric) binding site of one receptor. (Portoghese, 
1989, Jones et al., 1998, Halazy, 1999, Portoghese, 2001, Messer, 2004) 
Introduction 
___________________________________________________________________ 
12 
 
 
Figure 1.4. A bivalent ligand binding to a GPCR with an accessory binding site (I) or 
to a GPCR dimer (II). Adapted from Portoghese (1989), Portoghese (2001) and Igel 
(2008). 
 
1.2. Histamine and the histamine receptor family 
Reviewing more than 100 years of histamine research, beginning with the first technical 
histamine synthesis (Windaus and Vogt, 1908) plus the first isolation out of ergot 
(Claviceps purpurea) (Barger and Dale, 1910) and culminating in the first crystallization 
of an H1R (Shimamura et al., 2011), histamine and its receptors have been intensively 
investigated. (Parsons and Ganellin, 2006)  
As a biogenic amine, histamine (2-(1H-imidazol-4-yl)ethanamine) (figure 1.5) was 
found to be a local mediator, immunomodulator as well as a neurotransmitter targeting 
four histamine receptor subtypes that were successively discovered: the H1R (Ash and 
Schild, 1966), the H2R (Black et al., 1972), the H3R (Arrang et al., 1983) and the 
recently and by several research groups more or less simultaneously found H4R (Oda 
et al., 2000, Nakamura et al., 2000, Liu et al., 2001, Morse et al., 2001, Nguyen et al., 
2001, Zhu et al., 2001). All four histamine receptor subtypes represent rhodopsin like 
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(class A) GPCRs with different signaling related to their G-protein coupling. A more 
detailed description of their signaling pathway as well as an overview over selected 
(selective) ligands will be given in the following. 
 
Figure 1.5. Biosynthesis of histamine (HDC = histidine decarboxylase) (Haas et al., 
2008). 
 
In the human body, histamine is synthesized from the amino acid L-histidine (figure 
1.5) and plays a major role in physiological and pathophysiological processes like 
inflammatory reactions, the modulation of immune responses as well as the regulation 
of gastrointestinal and circulatory functions. (Dy and Schneider, 2004) Moreover, it was 
found to have impact on a number of brain functions as, e.g., the sleep-wake cycle, 
learning and memory processes, anxiety or neuroendocrine regulation (Passani et al., 
2007). Histamine accumulates in tissues of the skin, the lungs and the gastrointestinal 
tract and is stored in neurons, endothelial cells, mast cells, basophil granulocytes as 
well as in the enterochromaffin like (ECL) cells in the stomach. (Riley and West, 1952, 
Graham et al., 1955, Hakanson et al., 1974, Karnushina et al., 1980, Schwartz et al., 
1980, Saxena et al., 1989, Falcone et al., 2006) 
During allergic conditions, histamine is released from the secretory granules in mast 
cells and basophiles, resulting in vasodilatation, smooth muscle contraction and an 
increase of vascular permeability. Histamine released from ECL cells regulates the 
secretion of gastric acid in the parietal cells. (Mössner and Caca, 2005) Macrophages, 
dendritic cells, neutrophils and T-cells were furthermore found to release histamine 
after de novo synthesis. (Thurmond et al., 2008) 
 
1.2.1. The histamine H1 receptor 
The human histamine H1R consists of 487 amino acids and is expressed in a huge 
number of tissues in the human body (smooth muscle cells of blood vessels, airways 
and the gastrointestinal tract, endothelial cells, lymphocytes, leukocytes, dendritic cells 
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as well as in the cardiovascular system and the brain). (Hill, 1990) It plays an important 
role in the pathophysiology of allergic and inflammatory reactions like, e.g., bronchial 
asthma, allergic rhinitis, urticaria and histamine induced itch, explained by the H1R 
signaling pathway on a molecular level: as the H1R couples to pertussis-toxin 
insensitive Gαq/11 proteins, phospholipase C (PLC) is activated. Subsequently, Ca2+ is 
released from intracellular stores (leading to a contraction of smooth muscles like, e.g., 
of the airways) and the protein kinase C (PKC) is activated (regulating the gene 
expression by phosphorylation). (Leurs et al., 1995) The contraction of endothelial cells 
leads to an increase of vascular permeability and thus to typical allergic reactions like 
urticaria and itching. (Majno and Palade, 1961) Moreover, the release of nitric oxide 
(NO) from endothelial cells is induced, resulting in the dilatation of smooth muscles of 
the blood vessels and thus to the decrease of blood pressure. (Vandevoorde and 
Leusen, 1983, Toda, 1984) (Figure 1.6) 
 
Figure 1.6. Signaling pathways of the H1R. 
Both agonists and antagonists addressing the H1R are known: whereas agonists are 
rather used as pharmacological tools or in the pharmacotherapy of Menière’s disease 
(inner ear disorder reflected in vertigo, tinnitus and hearing loss) (Barak, 2008), 
antagonists are widespread and well-known anti-allergic drugs (so called 
“antihistamines”). 
H1R agonists can be divided into four classes: firstly, small histamine-like molecules 
like, e.g., 2-methylhistamine or the only therapeutically used H1R agonist betahistine 
(Aequamen®, treatment of Menière’s disease) that reveal to some extent an H1R 
subtype selectivity but a rather poor potency compared to histamine. (Durant et al., 
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1976, Durant et al., 1975) Secondly, the so called “2-phenylhistamines”, histamine-
derived molecules with aromatic substituents in position 2 of the imidazole ring like, 
e.g., 2-(3-trifluoromethylphenyl)histamine, that reveal a potency similar and in some 
cases superior to histamine. (Zingel et al., 1990, Leschke et al., 1995, Seifert et al., 
2003b, Strasser et al., 2009) A third group comprises the highly potent and selective 
group of the histaprodifens, bearing a characteristic 3,3-diphenylpropyl substituent (Elz 
et al., 2000a, Elz et al., 2000b, Seifert et al., 2003b, Strasser et al., 2008a), among 
which suprahistaprodifen, consisting of histaprodifen and histamine, represents the 
most potent member, revealing a 36-fold higher potency than histamine. (Menghin et 
al., 2003) A fourth and last group represent hybrid compounds resulting from the 
coupling of phenylhistamines to a histaprodifen partial structure, the so called 
“phenoprodifens”. The potency of these compounds is comparable to 
suprahistaprodifen. (Strasser et al., 2008b, Strasser et al., 2009, Wittmann et al., 2011, 
Strasser et al., 2013) 
For decades, H1R antagonists have been successfully used in the treatment of allergic 
diseases like allergic rhinitis (so called “hay-fever”) or histamine induced itch and are 
divided into first and second generation antagonists: the first generation antagonists 
like mepyramine or diphenhydramine are known for more than 50 years, however, due 
to their high lipophilicity, penetration through the blood-brain barrier causes sedation 
as an undesired side effect. As a consequence, these drugs were replaced by the 
newer second generation antagonists like, e.g., cetirizine that are characterized by a 
more polar structure and thus a reduced sedating effect. (Hill et al., 1997) 
Nevertheless, radio-labeled mepyramine ([3H]mepyramine) still plays an important role 
as a pharmacological tool and is, e.g., used as radioligand in H1R binding assays. (Hill 
et al., 1977, Seifert et al., 2003b) 
 
An overview of selected H1R ligands as well as their classification is provided in figure 
1.7. 
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Figure 1.7. Selected H1R ligands (agonists and antagonists). 
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1.2.2. The histamine H2 receptor 
The human histamine H2R consists of 358 amino acids and is located on gastric 
parietal cells as well as in cells of the brain, the heart, the uterus and of the 
hematopoietic system. (Gantz et al., 1991, Hill et al., 1997, Dove et al., 2004) It 
regulates the histamine dependent secretion of gastric acid from parietal cells (Black 
et al., 1972, Gespach et al., 1982) and is known to have a positive inotropic and 
chronotropic effect (cardiac H2Rs) in atrial and ventricular tissues (Levi and Alloatti, 
1988). Moreover, it is involved in the immune system (Schneider et al., 2002, Akdis 
and Simons, 2006, Bäumer and Rossbach, 2010) as well as in the relaxation of smooth 
muscle cells in blood vessels, uterus and airway. (Black et al., 1972, Levi and Alloatti, 
1988) 
The histamine H2R couples to Gαs proteins and therefore activates the formation of the 
second messenger cAMP through adenylyl cyclases (AC). (Hill et al., 1997) cAMP, in 
turn, activates protein kinase A (PKA), which is responsible for altered gene 
transcription by modulation of the transcription factor termed cAMP response element 
binding protein (CREB). (Bakker and Leurs, 2005) Moreover, the H2R was found to 
couple to Gαq/11 proteins in some specific cell systems. (Seifert et al., 1992, Kühn et 
al., 1996, Leopoldt et al., 1997, Wellner-Kienitz et al., 2003) As a consequence, the 
intracellular Ca2+-concentration increases mediated by the phospholipase C (PLC). 
(Figure 1.8) 
 
Figure 1.8. Signaling pathways of the H2R (adapted from Brunskole (2011)). 
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According to their chemical structure, H2R agonists can be divided into two groups: 
small amine-type agonists and guanidine-type agonists. 5-Methylhistamine as well as 
dimaprit (a non-imidazole) represent H2R agonists of the small amine-type. (Parsons 
et al., 1977, Durant et al., 1977) Interestingly, 5-methylhistamine, the first H2R agonist 
reported in literature that showed H2R selectivity over the H1R (Durant et al., 1975), 
was recently reported to be selective for the H4R. (Lim et al., 2005) Highly potent and 
selective H2R agonists like impromidine (Durant et al., 1985) and arpromidine 
(Buschauer, 1989, Buschauer et al., 1992) belong to the guanidine-type family, among 
which the imidazolylpropylguanidine moiety was found to be crucial for H2R agonism. 
(Dove et al., 2004) Derived from this, the replacement of the highly basic guanidine 
group by an acylguanidine moiety resulted in a new group of H2R agonists, termed the 
acylguanidine-type family (Ghorai et al., 2008, Kraus et al., 2009). Recently, the 
bivalent ligand approach was successfully applied to the acylguanidines, yielding 
highly selective and potent dimeric H2R agonists. (Birnkammer et al., 2012) 
By contrast to the - by now only as pharmacological tool used - H2R agonists described 
above, the H2R antagonists represent blockbuster drugs in the treatment of peptic ulcer 
and gastro-oesophageal reflux disease. (Parsons and Ganellin, 2006) The first H2R 
antagonist available on the drug market was cimetidine, followed by more potent 
analogues like ranitidine or famotidine. (Hill et al., 1997) Moreover, radio-labeled 
[3H]tiotidine is used as pharmacological tool in radioligand binding studies. (van der 
Goot and Timmerman, 2000) 
 
An overview of selected H2R ligands as well as their classification is provided in figure 
1.9. 
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Figure 1.9. Selected H2R ligands (agonists and antagonists). 
 
1.2.3. The histamine H3 receptor 
The physiologically dominant human histamine H3R isoform consists of 445 amino 
acids and is prevalent both in the central and the peripheral nervous system of the 
human body, however, about 20 isoforms have been found due to introns and exons 
in the H3R encoding gene. (Lovenberg et al., 1999, Wiedemann et al., 2002, Leurs et 
al., 2005, Bongers et al., 2007, Berlin et al., 2011) Located in the hippocampus, the 
cortical area, basal ganglia (central nervous system (CNS), (Martinez-Mir et al., 1990)) 
as well as in cells of the gastrointestinal tract, the cardiovascular system and the 
airways (peripheral nervous system (PNS), (Wijtmans et al., 2007)) it plays an 
important role in the pathophysiology of sleep and cognitive disorders, obesity and 
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pain. (Leurs et al., 1998, Bakker, 2004, Parmentier et al., 2007) It acts both as a 
presynaptic autoreceptor regulating the release of histamine and as a heteroreceptor 
regulating the release of several non-histaminergic neurotransmitters, like, e.g., 
dopamine, serotonin and acetylcholine, among others. (Hill et al., 1997, Gemkow et 
al., 2009) 
The H3R couples to pertussis-toxin sensitive Gαi/o proteins, leading to an inhibition of 
adenylyl cyclase (AC). Moreover, it was found to interfere with phospholipase A2 
(PLA2), mitogen-activated protein kinase (MAPK) and phosphatidyl inositol-3 kinase 
(PI3K) as well as to inhibit the Na+/H+ exchanger and to lower intracellular Ca2+ levels 
(figure 1.10). (Clark and Hill, 1996, Leurs et al., 2005, Bongers et al., 2007) 
 
Figure 1.10. Signaling pathways of the H3R. 
 
All H3R agonists bear an imidazole moiety as it was found to be crucial for H3R 
agonism. (Leurs et al., 2005) Examples are R-α-methylhistamine as well as Nα-
methylhistamine or immepip. (Arrang et al., 1987, De Esch and Belzar, 2004) However, 
due to the high sequence homology with the H4R (≈ 58% sequence identity in 
transmembrane α-helices (Nakamura et al., 2000, Oda et al., 2000, Coge et al., 2001)), 
no selectivity over the H4R was revealed for these compounds. Structural modifications 
of immepip resulted in immethridine and methimmepip, both selective and potent H3R 
agonists. (Kitbunnadaj et al., 2004) Nevertheless, radio-labeled [3H]Nα-
methylhistamine is used in radioligand binding studies. (van der Goot and Timmerman, 
2000).  
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Therapeutically, H3R agonists could due to their auto- and hetero-regulatory properties 
be used for the treatment of pathophysiological conditions traced back to elevated 
neurotransmitter levels like, e.g., migraine, inflammation, insomnia or pain. (Berlin et 
al., 2011) 
H3R antagonists can be divided in imidazole-type and non-imidazole-type ligands: 
clobenpropit (van der Goot et al., 1992) and thioperamide (Arrang et al., 1987) 
represent imidazole-type H3R antagonists. However, no selectivity over the H4R is 
given as also the H4R is addressed by these molecules. (Lim et al., 2005) Pitolisant, 
former known as BF 2.649, represents a non-imidazole H3R antagonist / inverse 
agonist that is clinically used for the treatment of narcolepsy. (Schwartz, 2011) 
Furthermore, H3R antagonists / inverse agonists undergo clinical evaluations for the 
treatment of mental diseases as, e.g., Alzheimer’s disease, schizophrenia, ADHD 
(attention deficit hyperactivity disorder) or epilepsy. (Parmentier et al., 2007, Sander et 
al., 2008, Gemkow et al., 2009, Leurs et al., 2011, Berlin et al., 2011)  
An overview of selected H3R ligands as well as their classification is provided in figure 
1.11. 
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Figure 1.11. Selected H3R ligands ((inverse) agonists and antagonists). 
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1.2.4. The histamine H4 receptor 
The human histamine H4R consists of 390 amino acids and is mainly expressed in 
cells of the immune system such as neutrophils, eosinophils, basophils, dendritic cells, 
mast cells, monocytes, T-cells as well as in cells of the nasal mucosa and of the central 
and intrinsic nervous system. (Leurs et al., 2009) Two further non signaling isoforms 
of the H4R were found on the intracellular surface of eosinophils and mast cells that 
are – alike already reported for the human H3R – traced back to the existence of two 
introns and three exons in the encoding gene. (van Rijn et al., 2008) Also similar to the 
H3R, it displays a high constitutive activity. (Morse et al., 2001, Schneider et al., 2009)  
The H4R plays a major role in immunological and inflammatory reactions and is 
involved in the chemotaxis of eosinophils, dendritic cells, mast cells and T-cells as well 
as in the cytokine release of cells of the immune system. (Morse et al., 2001, Takeshita 
et al., 2003, de Esch et al., 2005, Zhang et al., 2007, Damaj et al., 2007) As a 
consequence, inflammatory diseases like rheumatoid arthritis, systemic lupus 
erythematosus or multiple sclerosis as well as type I allergic diseases like bronchial 
asthma, rhinitis or conjunctivitis are supposed to be linked to the H4R. (Jablonowski et 
al., 2004, Thurmond et al., 2008, Deml et al., 2009, Zampeli and Tiligada, 2009, Leurs 
et al., 2011) 
The H4R mediated signaling is coupled to pertussis-toxin sensitive Gαi/o proteins and 
inhibits adenylyl cyclase, resulting in reduced cAMP formation and CREB (cAMP 
response element binding protein) mediated gene-transcription. (Leurs et al., 2009) 
Moreover, it activates MAPK (mitogen activated protein kinase) pathways (Morse et 
al., 2001) and contributes to the intracellular Ca2+ mobilization in mast cells and 
eosinophils. (Hofstra et al., 2003, Buckland et al., 2003) Besides, G-protein 
independent signaling was recently reported for several ligands (β-arrestin pathway). 
(Seifert et al., 2011, Nijmeijer et al., 2012) (Figure 1.12) 
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Figure 1.12. Signaling pathways of the H4R (adapted from Brunskole (2011)). 
 
Because of the high sequence homology of the H3R and the H4R, several above all 
imidazole-bearing compounds addressing the H3R are often also targeting the H4R. 
(Lim et al., 2005) However, with intent to investigate the pathophysiological role of the 
H4R, selective H4R ligands are needed.  
The first reported selective H4R agonist was OUP-16, a chiral tetrahydrofuran analog 
derived from the H3R agonist imifuramine. (Hashimoto et al., 2003) Moreover, 5-
methylhistamine that was originally reported to be a selective H2R agonist turned out 
to display a distinct H4R selectivity over the other histamine receptor subtypes. (Lim et 
al., 2005) Recently, new cyanoguanidine-type H4R agonists like UR-PI376 were 
developed and found to reveal a high potency and selectivity. (Igel et al., 2009, Geyer 
and Buschauer, 2011) 
Thioperamide, an H3R antagonist, was proved to be an imidazole-type inverse H4R 
agonist. (Lim et al., 2005) The first non-imidazole-type selective H4R antagonist was 
JNJ7777120, an indole-2-carboxamide discovered in a high throughput screening 
campaign of Johnson & Johnson laboratories. (Jablonowski et al., 2003) In radioligand 
binding studies at H4R, radio-labeled [3H]JNJ7777120 is applied, among others. (Lim 
et al., 2005) Further highly potent and (to some extent) selective H4R antagonists / 
inverse agonists represent the group of the 2-aminopyrimidines (Bacon et al., 2005, 
Altenbach et al., 2008, Sander et al., 2009, Smits et al., 2009) as well as the 
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quinazoline- and quinoxaline derived series developed by Smits et al.. (Smits et al., 
2008a, Smits et al., 2008b)  
An overview of selected H4R ligands is provided in figure 1.13. 
 
 
Figure 1.13. Selected H4R ligands ((inverse) agonists and antagonists).  
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1.3. Antipsychotic drugs 
Known as “antipsychotics” or “neuroleptics”, antipsychotic drugs are prevalently used 
for the treatment of mental disorders like schizophrenia or bipolar disorder. Derived 
from promethazine, an H1R antihistamine, the first antipsychotic drug chlorpromazine 
was marketed for the pharmacotherapy of schizophrenia about sixty years ago (as a 
so called “major tranquillizer”). (Healy, 2004) On a molecular level, a dopaminergic 
hyperactivity in schizophrenic subjects is postulated and consequently, the 
suppression of dopamine activity via dopaminergic receptors (DxRs, mostly D2R and 
D4R) is the target of antipsychotic treatment. (Carlsson, 1978)  
Nevertheless, not only DxRs are affected by antipsychotic drugs. For example, as all 
four HxRs are expressed in the CNS (Hill et al., 1997, Connelly et al., 2009), 
antipsychotic drugs also reveal affinity to HxRs, above all to the H1R that was identified 
to be responsible for their sedative effects. (Richelson, 1979) Moreover, an 
involvement of histaminergic signaling in the pathophysiology of schizophrenia is 
suggested. (Haas et al., 2008, Appl et al., 2012) 
The discovery of chlorpromazine was succeeded by the release of several drugs with 
functional enhancements concerning neuroleptic potency and efficacy, chemical 
structure and mode of action that will be described in the following. 
 
1.3.1. Classification 
According to their side effect profile, antipsychotic drugs are roughly divided into two 
groups: typical antipsychotics of the first generation that were found to reveal higher 
extrapyramidal side effects than the so called “atypical” antipsychotics of the second 
generation. (Ahmed et al., 2008) Examples for EPS are, e.g., dyskinesia, akinesia or 
akathisia, comprised as movement disorders of the human body. 
 
The family of the typical antipsychotics is further divided into four subgroups: 
phenothiazines like, e.g., chlorpromazine that, besides D2R antagonism, reveal distinct 
antihistaminergic and anticholinergic effects. Similar findings are reported for the group 
of the thioxanthenes like, e.g., chlorprothixene. Most pronounced EPS appear during 
the pharmacotherapy with butyrophenones (e.g., haloperidol) and 
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diphenylbutylpiperidines (e.g., pimozid) because of their high affinity to the D2R. 
(Aktories et al., 2005) (Figure 1.14) 
 
 
Figure 1.14. Selected typical antipsychotic drugs. 
 
By contrast, atypical antipsychotics like, e.g., clozapine, olanzapine or risperidone are 
characterized by an improved side effect profile regarding the EPS rate. Although the 
molecular mode of action is by now not entirely understood, in case of clozapine this 
can be explained by the predominant interaction with D4R and 5-HT2AR and thus by a 
reduced influence on the D2R that is supposed to cause EPS. (Aktories et al., 2005) 
(Figure 1.15) 
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Figure 1.15. Selected atypical antipsychotic drugs. 
 
1.3.2. Clozapine and its interaction with multiple molecular targets (“dirty drug” 
problem) 
The binding of the multi-target drug clozapine to a broad variety of GPCRs as well as 
the associated both desired and adverse effects have been intensively investigated in 
the last years. (Fitzsimons et al., 2005, Flanagan and Dunk, 2008, Nooijen et al., 2011) 
For instance, binding data are reported for dopaminergic (D1-4), adrenergic (α1,2), 
serotonergic (5-HT2A,C), cholinergic (M1-5) and histaminergic (H1,4) receptors. 
(Baldessarini and Frankenburg, 1991, Zorn et al., 1994, Michal et al., 1999) The 
pharmacological discrepancies between the four histamine receptor subtypes H1-4R 
are intriguing: whereas it acts as an inverse agonist / antagonist on most GPCRs 
including the histamine H1R, the H2R and the H3R, a partial agonism at the hH4R was 
revealed recently. (Richelson and Nelson, 1984, Lim et al., 2005, Appl et al., 2012). 
Moreover, compared to the high affinity of clozapine to the H1R (pKi (hH1R) = 8.59 ± 
0.14, (Appl et al., 2012)), the H4R binding is by two to three orders of magnitude lower 
(pKi (hH4R) = 5.93 ± 0.12, (Appl et al., 2012)). This can be traced back to a different 
orientation of clozapine in the binding pocket of the active hH4R compared to the 
inactive hH1R. (Appl et al., 2012) 
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Although clozapine is characterized by a good clinical efficacy as well as a decreased 
EPS rate, serious side effects like neutrophenia or agranulocytosis were found to occur 
during the first weeks of clozapine pharmacotherapy. Agranulocytosis is an acute 
condition characterized by a lowered neutrophil count in the circulating blood, reflected 
in a severe suppression of the immune system. (Ryabik et al., 1993) As a 
consequence, its use is predominantly allowed for patients revealing 
unresponsiveness or intolerance regarding typical neuroleptics under strict 
surveillance of the neutrophil count in the blood (drug monitoring). 
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2. Scope and objectives 
 
Both, the H1R and the H4R were recently reported to play an important role in allergic 
inflammation. (Thurmond et al., 2008) A study on the acute murine asthma model 
performed by Deml et al. revealed that the combined application of mepyramine (H1R-
antagonist) and JNJ7777120 (H4R-antagonist) had a synergistic inhibitory effect on the 
eosinophil-accumulation in the bronchoalveolar lavage fluid. (Deml et al., 2009) These 
results indicate an involvement of both, the H1R and H4R in type I allergic diseases 
like, e.g., chronic pruritus or bronchial asthma. As a consequence, a synergy between 
H1R and H4R antagonists in the form of molecules bearing pharmacophores that 
address both, the H1R and the H4R are in great demand for future research. 
With regard to the design of this kind of ligands, two different strategies of molecule 
design can be pursued: firstly, an H1R antagonist can be linked to an H4R antagonist 
by spacers of different type and length, obtaining bivalent hybrid compounds. 
Examples can be found in the work of Wagner et al.: therein, the H4R antagonist 
JNJ7777120 was linked with different kinds of spacers to (parts of) either mepyramine 
or astemizole. (Wagner et al., 2011) However, the resulting molecules did not show 
the desired affinity to both targets. Although some of the resulting hybrid compounds 
revealed high affinity to H1R, the effects at the H4R were rather of a lower range.   
A second strategy consists of either the screening for molecules that already address 
the H1R and the H4R and as a consequence contain a (as the case may be common) 
H1R and H4R pharmacophore, or of the development of new compounds meeting these 
conditions. These lead structures can then be further modified and refined in order to 
get ligands with the desired pharmacological effects. 
The antipsychotic drug clozapine exhibits (among others) antagonistic affinity to the 
H1R and partial agonistic affinity to the H4R (Appl et al., 2012). Related to this, a dutch 
group around Leurs developed the optimized compound VUF 6884 with on the first 
sight only minor structural modifications compared to clozapine (Smits et al., 2006): 
the nitrogen in position 5 was replaced by an oxygen and the Cl substituent in position 
8 was shifted to position 7 (figure 2.1). As a consequence, this optimized ligand 
revealed a distinctly increased partial agonistic affinity to H4R as well as a constantly 
high antagonistic affinity to H1R. (Smits et al., 2006) 
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Figure 2.1. Clozapine and the “optimized” clozapine derivative VUF 6884. 
Based on this, the aim of this work was to prepare a series of VUF 6884 derived 
compounds that were modified regarding their substitution pattern, the rigidization of 
the piperazine moiety and the central heterocycle in the molecule.  
In a first part of the project, the VUF 6884 molecule was reduced to the core: the central 
oxazepine ring was opened and the rigid basic amine moiety consisting of an N-
methylpiperazine on top of the molecule was replaced by different flexible 
ethylenediamine derivatives with varying alkyl substituents (1) (figure 2.2). A further 
series of these “opened” compounds contained a rigid N-methylpiperazine moiety as 
well as various modifications of the substitution pattern (2). The highest analogy to 
VUF 6884 was given within a third series of compounds (3), however, by a modification 
of either the substitution pattern or the piperazine moiety the pharmacological 
behaviour could be distinctly influenced. (Figure 2.2) 
 
Figure 2.2. Structural modifications of VUF 6884. 
Furthermore, the compounds showing the most promising pharmacological results 
were, in accordance with the work of McRobb et al., transferred into dimeric molecules, 
linked by different spacer types and lengths in different positions of the molecule (4). 
(McRobb et al., 2012) (Figure 2.3).  
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Figure 2.3. Dimeric VUF 6884 derivatives. 
 
Pharmacological characterization of the resulting compounds in several different 
testing systems provided a closer insight into structure activity relationships (SARs) at 
H1R and H4R. 
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3. Chemical section 
 
3.1. Ligand design related to VUF 6884 (Smits et al., 2006) 
The chemical section of this work aimed at the modification and structural investigation 
of molecules related to VUF 6884, a potent histamine H1-/ H4-receptor ligand that was 
developed by Smits et al. (2006) (figure 3.1). Several modifications of either the 
substitution pattern, the piperazine moiety, the heterocycle in the center of the 
molecule or the molecule size (i.e., dimerization of the modified molecules) were 
carried out with intent to get a closer insight into structure-activity relationships at hH1R 
and hH4R as well as at other GPCRs that were described in the pharmacological 
section.  
 
Figure 3.1. Lead structure VUF 6884. 
Starting from fairly simplified VUF 6884 derivatives, the molecule was re-built bit by bit 
so that pharmacological effects related to the respective parts of the molecule could 
be investigated. Furthermore, several series of different VUF 6884 derived dimeric 
molecules were prepared with intent to address either homo- and hetero-oligomeric 
histamine H1 / H4 receptors (provided a sufficient spacer length) or to address a further 
binding pocket in the extracellular region of the receptors. (Figure 3.2) 
 
Figure 3.2. Structural modifications of the lead structure VUF 6884. 
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3.2. Synthesis of the “open” phenylbenzamidines: opening up the rigid 
aromatic ring system in the center of the molecule 
A first series of truncated compounds was prepared that will be referred to as “open” 
compounds in the following. Formally, they are derived from the tricyclic parent 
compounds by ring-opening of the central heterocycle. As a consequence, the two 
aromatic rings in the central core of the molecule are released from rigidisation and 
thus able to rotate around the single bonds adjacent to the imino-bond. Hence, the 
respective substituents in, e.g., m-position of the rings are able to possess different 
positions in the binding pocket of the target receptors.  
A map of the resulting molecules was set up to provide an overview of the modifications 
of the substitution pattern (figure 3.3). The substituents were inserted in para (p-) or 
meta (m-) position of either the aniline or the benzoic acid moiety, terms that are 
derived from the pursued synthesis strategy that will be described in 3.2.2.  
 
Figure 3.3. Molecule map of the “open” VUF 6884 derivatives. 
 
3.2.1. VUF 6884 reduced to the core: (E)-N-(2-aminoethyl)-N'-phenylbenzamidine 
derivatives 
Among the “open” series of compounds, three of them focused on the very basic 
elements of VUF 6884: with intent to provide an increase of flexibility in the central core 
as well as in the basic amine part of the molecule, the “open” phenylbenzamidine-core 
was linked to differently substituted ethylenediamine derivatives instead of the rigid N-
methypiperazine moiety.  
The desired compounds were easily accessible pursuing the following synthesis 
strategy: firstly, commercially available benzanilide was converted in-situ to the imide 
chloride by using PCl5, to which in a second step and without further purification the 
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pertinent ethylenediamine derivatives (22: N,N-dimethylethylenediamine, 23: N,N-
diethylethylenediamine and  25: N,N,N’-trimethylethylenediamine) were added (Wu et 
al., 2005). (Figure 3.4) 
 
i: benzene, PCl5, 2 h reflux; ii: benzene, 2 h RT 
 
Figure 3.4. Synthesis pathway of the (E)-N-(2-aminoethyl)-N'-phenylbenzamidine 
derivatives. 
 
The resulting ethylenediamine substituted phenylbenzamidines 22, 23, and 25 were 
purified by column chromatography over silica gel (EtOAc / NH3 (7 N in MeOH) 9:1) 
and were obtained as colorless solids. (Table 3.1) 
 
 
R1 R2 R3 Cpd. 
H -CH3 -CH3 22 
H -C2H5 -C2H5 23 
-CH3 -CH3 -CH3 25 
 
Table 3.1. “Open” VUF 6884 derivatives with ethylenediamine moiety. 
 
3.2.2. “Open” VUF 6884 derivatives with modified substitution pattern: detecting 
the influence of kind and position of the substituents 
By analogy with the above described procedure and in the style of Jensen and 
Pedersen (1979) , the “open” VUF 6884 analogues carrying a rigid N-methylpiperazine 
moiety were obtained from the corresponding benzanilide building blocks which were 
either commercially available or conveniently accessible by coupling substituted 
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benzoic acid chlorides (benzoic acid moiety) with substituted aniline derivatives (aniline 
moiety) under nitrogen atmosphere in the presence of NEt3 (Sun et al., 2009). The 
resulting amines revealed different colors depending on their substitution pattern and 
were all obtained as crystalline solids after re-crystallization from acetone. 
After converting the amides with PCl5 in situ to the corresponding imide chlorides, N-
methylpiperazine was added in the presence of NEt3 and, as soon as the reaction was 
completed, purified by column chromatography over silica gel (EtOAC : MeOH 1:1 ). 
Except from NO2-substituted molecules that invariably revealed shades of yellow, all 
compounds were obtained as colorless solids. (Figure 3.5) 
 
i: NEt3, N2, DCM, 6 h RT, 12 h reflux; ii: PCl5, benzene / ACN, 2 h reflux; iii: NEt3, benzene / ACN, 12 h reflux 
Figure 3.5. Synthesis pathway of the “open” VUF 6884 derivatives with N-
methylpiperazine moiety. 
 
As VUF 6884 and clozapine both carry a Cl-substituent in different positions of the 
molecule, this kind of substituent found itself in the spotlight of interest and was 
introduced in various positions at both the aniline and the benzoic acid moiety. 
Nevertheless, also other halide (Br) and pseudohalide (CN) substituents as well as 
NH2 groups were introduced with intent to get a closer insight into the structure activity 
relationships (SARs) in dependence of the kind of substituent and the resulting 
substitution pattern. Mono- as well as di-substituted compounds were prepared and, 
referred to the map of the molecule shown in figure 3.3, are summarized in table 3.2. 
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R Cpd.  
         
R Cpd. 
H 28 p-CN 58 
p-Br 64 p-Cl 70 
p-Cl 67 p-NO2 55 
p-NO2 50 m-Cl 76 
m-Cl 73 
 
 
R Cpd. 
 
R Cpd. 
p-Cl 79 p-Cl 108 
p-Br 61 m-Cl 109 
m-Cl 102   
  
 
 
R Cpd. 
p-Cl 180 
m-Cl 181 
Table 3.2. Mono- and di-substituted “open” VUF 6884 analogues with modified 
substitution pattern. 
For the compounds bearing an NO2 substituent, a final reduction step was added to 
obtain the desired NH2 substitution. Attempts using BOC-protected NH2-substituted 
starting material failed as well as the use of NH2-substituted aniline or benzoyl chloride 
derivatives (figure 3.6). However, the insertion and later reduction of NO2-substituted 
starting material provided a convenient method to obtain the desired compounds. 
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i: PCl5, benzene / ACN, 2 h reflux; ii: NEt3, DCM, 6 h RT, 12 h reflux 
Figure 3.6. Failed synthetic attempts on the way to NH2-substituted “open” 
compounds. 
Using SnCl2 to reduce the NO2-substituted molecules according to Chao et al. (2009) 
resulted in the desired NH2-substituted compounds (figure 3.7). The compounds were 
purified by column chromatography over silica gel (EtOAc : MeOH 1:1) and were 
obtained as slightly yellow solids.  
 
i: SnCl2 · 2 H2O, EtOH, 12 h reflux 
Figure 3.7. General procedure for the reduction of the NO2-substituted compounds 
according to Chao et al. (2009). 
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An overview of the synthesized mono- and di-substituted NH2-bearing compounds is 
provided in table 3.3: 
 
 
R Cpd.  
 
R Cpd. 
H 56 H 52 
p-Br 62 m-Cl 110 
p-Cl 80 p-Cl 111 
m-Cl 103   
 
Table 3.3. Mono- and di- substituted NH2-bearing “open” VUF 6884 analogues. 
 
 
3.2.3. Acylated open VUF 6884 derivatives: an attempt to increase the hH4R 
affinity 
Within a series of several quinoxaline and quinazoline derived compounds, an increase 
of hH4R affinity was determined that could be traced back to the insertion of an 
additional aromatic substituent located at the central core of the respective molecules. 
(Smits et al., 2008a, Smits et al., 2008b) Based on this and on the flexible alignment 
study of two further structurally related hH4R ligands (JNJ7777120 and VUF 6884), a 
three-pocket pharmacophore model for the hH4R was postulated: therein, the two 
pockets for the N-methylpiperazine moiety and the central aromatic heterocycle are 
completed by a third, hydrophobic pocket to which the additional aromatic substituent 
is suggested to bind to. (Smits et al., 2008a). 
As the “open” VUF 6884 derived compounds show analogy to the molecules described 
above, a short series of compounds was prepared in which a similar strategy was 
pursued in order to increase the affinity to the hH4R (figure 3.8): 
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Figure 3.8. Structural similarities between quinoxaline / quinazoline derived hH4R 
ligands and the acylated “open” VUF 6884 analogues. (Smits et al., 2008a, Smits et 
al., 2008b) 
According to literature (Smits et al., 2008a), the above described quinazolines were 
linked to the aromatic substituent by nucleophilic displacement in a microwave 
reaction. However, due to the structural conditions prevalent in the “open” VUF 6884 
analogues, neither NH2- nor Cl-substituted starting material led to the desired 
compounds (figure 3.9).  
 
i: DIPEA, EtOAC; 120 °C, 25 min microwave reaction 
Figure 3.9. Failed synthetic attempts to add a benzyl substituent to the “open” VUF 
6884 analogues. 
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Therefore, in order to stick to a similar chain-length of the substituent, an amide 
coupling between NH2-substituted “open” VUF 6884 derivatives and pertinent acid 
chlorides was performed (figure 3.10). The acylated compounds were easily 
accessible: in the presence of NEt3, different acid chlorides were added to the 
respective compounds bearing an NH2 substitution in p-position of the benzoic acid 
moiety (Sun et al., 2009) with intent to interact with the free amine of the NH2 group by 
amide coupling.  
Two different kinds of acid chlorides were therefore used: firstly, short linear carboxylic 
acid chlorides (114, 116: acetylchloride, 115: propionylchloride) and secondly, benzoic 
acid chlorides (99, 117: benzoylchloride, 112: 4-chlorobenzoylchloride) which were all 
commercially available. The reaction was performed under nitrogen atmosphere and 
the resulting compounds were purified by column chromatography over silica gel 
(EtOAc : MeOH 1:1). 
 
i: NEt3, N2, DCM, 6 h RT, 12 h reflux 
Figure 3.10. General procedure for the preparation of the acylated open VUF 6884 
derivatives. 
 
Acylated compounds with Cl-substitution in p- as well as in m- position of the aniline 
moiety were prepared and are summarized in table 3.4.  
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R1 p-Cl p-Cl p-Cl p-Cl m-Cl m-Cl 
R2 
   
 
 
 
 
 
 
 
Cpd. 99 112 114 115 116 117 
 
Table 3.4. Acylated “open” VUF 6884 analogues bearing Cl substituents in p- and m-
position of the aniline moiety. 
 
3.3. Synthesis of the closed VUF 6884 derivatives: return to a rigid aromatic 
ring system in the center of the molecule 
In order to determine the role of the central heterocycle in the SARs, a series of 
compounds was synthesized that were directly derived from VUF 6884 and differ only 
with respect to their substitution pattern and piperazine moiety. Due to their closed and 
thus rigid central heterocyclic core these compounds will be referred to as the “ring-
closed” compounds in the following. (Figure 3.11) 
 
Again, Cl substitution was in the spotlight of interest and therefore intensively 
investigated in several positions of the molecule. Moreover, with regard to the 
dimerization project described in 3.4, compounds bearing an NH2 substituent in 
position 3 were prepared to enable the connection with different kinds of spacers by 
amide coupling.  
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Figure 3.11. Molecule map of the “closed” VUF 6884 derivatives. 
 
3.3.1. “Ring-closed” VUF 6884 derivatives with modified substitution pattern: 
determining the key role of the closed central heterocycle in synergy with 
the substitution pattern 
All VUF 6884 derived “ring-closed” compounds were synthesized according to a 
slightly modified synthesis pathway described by Smits et al. (2006) (figure 3.12). The 
modifications refer to the reaction conditions during the last nucleophilic displacement 
step as well as to slight changes in the composition of the used solvents. 
The first step of the reaction consisted of an amide coupling of a (substituted) 
commercially available 2-aminophenol with a (substituted) commercially available 2-
fluorobenzoic acid chloride in the presence of NEt3 in THF under nitrogen atmosphere. 
In some cases, the 2-fluorobenzoic acid chloride was not commercially available and 
had to be converted from the corresponding commercially available 2-fluorobenzoic 
acid by the use SOCl2 in THF prior to the amide coupling. The resulting 2-fluorobenzoic 
acid chlorides were then used without further purification. 
After the amide coupling was successfully carried out, water was added to stop the 
reaction. The pH-dependently precipitated amide could be separated by filtration and 
was used without further purification in the next reaction step. This consisted of a ring 
closure that was carried out by the addition of freshly pulverized NaOH and heating at 
reflux in DMF. To stop the reaction, the mixture was poured into water and the 
precipitated dibenzo[b,f][1,4]-oxazepin-11(10H)-one could be separated by filtration.  
Copious amounts of water were bound to the precipitate that had to be completely 
removed before the in-situ conversion to the iminochloride, as the required POCl3 and 
the desired product are known to be very sensitive to contact with water. It turned out 
to be very important that this reaction step is carried out for at least 12 - 15 hours, as 
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otherwise the nucleophilic displacement in the next step did not take place to a 
satisfying degree.  
Finally, nucleophilic displacement of chloride with a 10-fold excess of N-
methylpiperazine, that had to be carried out for at least 4 hours, resulted in the desired 
VUF 6884 derived compounds. If the last step was stopped earlier (e.g., after 2 hours 
as reported by Smits et al. (2006)), the yield was significantly decreased. After the 
completion of the reaction, the mixture was partitioned between EtOAc and a solution 
of Na2CO3 in water to separate excess N-methylpiperazine, and the organic layer was 
concentrated and purified by column chromatography over silica gel (EtOAc : MeOH 
1:1). The resulting “ring-closed” VUF 6884 derivatives were obtained as colorless to 
light yellow solids (depending on the substitution pattern). (Table 3.5) 
i: SOCl2, THF, 2 h reflux; ii: NEt3, THF, 12 h RT, iii: NaOH, DMF, 5 h reflux; iv: POCl3, TOL / ACN, 12 h reflux; v: 
TOL / ACN, 4 h reflux; vi: SnCl2 · 2H2O, EtOH, 5 h reflux (for R3 = NO2) 
Figure 3.12. Synthesis pathway for the preparation of the “ring-closed” VUF 6884 
derivatives bearing an N-methylpiperazine moiety. 
 
Compounds bearing an NO2 substituent were converted to the corresponding NH2 
substitution by reduction with SnCl2 ∙2 H2O (Chao et al., 2009) as already described in 
3.2.2. 
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R H      
H 
H     
8-Cl                                                    
H     
7-Cl
3-Cl   
H
3-NO2 
H
3-NO2 
7-Cl 
3-NO2 
8-Cl 
3-Cl 
8-Cl 
3-Cl 
8-Cl 
Cpd. 141 88 92 149 135 127 126 158 159 
 
Table 3.5. “Closed” VUF 6884 analogues bearing an N-methylpiperazine moiety. 
 
 
As for all “ring-closed” compounds described above a pertinent “open” counterpart was 
synthesized and pharmacologically characterized, the SAR evoked by the ring-closure 
in the central core of the molecule could distinctly be investigated and will be reported 
in the pharmacological section (4.4). 
 
 
R Cpd. 
H 136 
7-Cl 128 
8-Cl 129 
  
Table 3.6. “Closed” VUF 6884 analogues carrying NH2 groups in 3-position. 
 
Compounds with NH2 substitution are summarized in table 3.6 and were inter alia used 
to prepare a series of dimeric molecules linked at this position with different spacers 
(see section 3.4). 
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3.3.2. “Closed” VUF 6884 derivatives with a modified piperazine moiety: 
exchanging N-methylpiperazine by piperazine 
A short series of compounds was prepared in which the N-methypiperazine moiety was 
replaced by piperazine with intent to get a closer insight into the role of either a tertiary 
or a secondary amine in hH1R and hH4R binding, respectively. Moreover, these 
compounds were used to prepare a series of dimeric compounds that were linked at 
the piperazine moiety with either polar or nonpolar spacers of different types and 
lengths (3.4). 
All piperazine-bearing “ring-closed” VUF 6884 derivatives were synthesized by 
analogy with the synthesis pathway described above for the N-methylpiperazine 
bearing compounds (figure 3.13). Instead of N-methylpiperazine, piperazine was 
added in the last nucleophilic displacement step, again in a 10-fold excess to improve 
the yield. The reaction conditions as well as the modifications regarding the reaction 
time described above remained equal. However, before the addition of piperazine, it 
had to be dissolved in MeOH quantum satis as it was not soluble in reasonable 
amounts of the reaction solvent mixture acetonitrile / toluene.  
 
i: SOCl2, THF, 2 h reflux; ii: NEt3, THF, 12 h RT, iii: NaOH, DMF, 5 h reflux; iv: POCl3, TOL / ACN, 12 h reflux; v: 
TOL / ACN, 4 h reflux 
Figure 3.13. Synthesis pathway of the “ring closed” VUF 6884 derivatives bearing a 
piperazine moiety. 
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Except compounds with NH2 group in position 3, for all N-methylpiperazine bearing 
compounds described in 3.3.1 a piperazine bearing counterpart was synthesized with 
intent to determine the effect of the rigid basic amine moiety in dependence of the 
substitution pattern. Furthermore, as the free amine of the piperazine moiety allowed 
dimerization by either nucleophilic displacement or amide coupling, a series of dimeric 
compounds was accessible from these molecules (see section 3.4). A summary of the 
piperazine bearing molecules with modified substitution pattern is provided in table 3.7. 
 
R H           
H                                                
H           
8-Cl 
H           
7-Cl
3-Cl       
H 
3-Cl         
7-Cl 
3-Cl         
8-Cl 
Cpd.  233 234 235 232 193 196 
 
Table 3.7. “Ring-closed” VUF 6884 analogues bearing a piperazine moiety. 
 
3.4. Dimeric dibenzo[b,f][1,4]oxazepines: an approach to address homo- and 
hetero-oligomeric histamine H1 and H4 receptors 
Both the hH1R and the hH4R are known to generate receptor homo-oligomers at 
physiological expression levels (Bakker et al., 2004, van Rijn et al., 2006). 
Furthermore, H1R-H4R hetero-oligomers were reported to be formed. Although the 
detection of H1R-H4R hetero-oligomers was achieved only at higher H1R expression 
levels and as a consequence they are most likely not physiologically relevant (van Rijn 
et al., 2006), these results provide an important account to pharmacological research. 
Due to their molecule size, all previously described compounds are supposed to 
address only monomeric histamine H1 and H4 receptors by binding to specific binding 
pockets. With intent to bind to the binding pockets of the receptors belonging to the 
above described receptor homo- or hetero-oligomers or to bind to the binding pocket 
as well as to the extracellular surface of the respective histamine receptors, a series of 
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“ring-closed” VUF 6884 derived compounds was prepared that were linked with 
spacers of different type and length.  
The spacers, consisting of either nonpolar alkyl chains or polar piperazine / 
homopiperazine bearing di-carboxylic acids, were inserted in different positions of the 
molecule (i.e., at the piperazine moiety or the NH2 group in position 3, yielding new 
differently substituted dimeric molecules with high molecular weight (Mr 806.65 – 
988.76). The molecule size and the resulting difficulties in solubility may not lead to 
physiologically and therapeutically relevant new compounds, however, in principle, 
they can be used as pharmacological tools to investigate the receptor homo- and 
hetero-dimerization of a broad variety of GPCRs. 
A map of the resulting different dimeric compounds is provided in figure 3.14. 
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Dibenzo[b,f][1,4]-oxazepines linked with nonpolar spacers at the piperazine moiety 
 
 
Dibenzo[b,f][1,4]-oxazepines linked with polar spacers at the piperazine moiety 
 
 
Dibenzo[b,f][1,4]-oxazepines linked with polar spacers at the NH2 group in position 3 / 3’  
 
Figure 3.14. Map of the dimeric dibenzo[b,f][1,4]oxazepines linked in different 
positions of the molecule. 
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3.4.1. Dibenzo[b,f][1,4]oxazepines linked by nonpolar alkyl spacers at the 
piperazine moiety 
The pharmacologically most promising “ring-closed” VUF 6884 derivatives bearing a 
di-Cl substitution in either position 3 and 7 (159) or 3 and 8 (158) were developed 
further by transferring them into dimeric molecules. Therefore, two different strategies 
were pursued to link the molecules at the piperazine moiety: the spacer was linked to 
the piperazine moiety before (figure 3.15) and after it was added to the tricyclic core 
(figure 3.16). 
The first strategy, however, at least did not successfully lead to the desired 
compounds. Piperazine was protected by a BOC-group giving tert-butyl-piperazine-1-
carboxylate (Sengmany et al., 2007) that was sufficiently pure to be used in the next 
step without further purification and was linked by a di-halide substituted alkyl spacer 
(Zhang et al., 2011) to give dimeric molecules. Di-chloro-substituted reagents did not 
lead to the desired compounds in a satisfying amount and were thus replaced by di-
bromo or di-iodo derivatives.  
De-protection of the BOC-protected dimeric piperazine derivatives was carried out as 
usual adding TFA and DCM while being stirred for 2 hours at room temperature (Wang 
et al., 2007). However, after partitioning the reaction mixture between a solution of 
Na2CO3 in water and EtOAc, the dimeric de-protected piperazine molecules were not 
able to be removed from the aqueous layer und could thus not be linked to the tricyclic 
core (figure 3.15). 
 
i: DCM, 0°C, 1.5 h; ii: di-halide substituted alkyl spacer, K2CO3, EtOH, reflux 12 h; iii: TFA, DCM, 2 h RT 
Figure 3.15. Failed synthetic attempt on the way to dimeric VUF 6884 derivatives. 
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In the second and more successful strategy, the piperazine bearing counterparts of 
158 and 159 (i.e. 196 and 193) were linked by nucleophilic displacement with alkyl 
halides of different length (n = 6 – 8, 10) (figure 3.16) (Tanaka et al., 2011).  
 
i: TOL / ACN, 4 h reflux; ii: K2CO3, MeCN, 12 h reflux 
Figure 3.16. Synthesis of the dimeric “ring-closed” VUF 6884 derivatives linked by 
nonpolar alkyl spacers. 
 
For the nucleophilic displacement reaction at the free secondary amine of the 
piperazine moiety, different alkyl halides were used: for n = 6 or 8, di-iodo- and for n = 
7 or 10, di-bromo-substituted derivatives were applied.  
All synthesized dimeric compounds linked by nonpolar alkyl spacers were purified by 
column chromatography over silica gel (EtOAc / HX (3 : 2); EtOAc; EtOAc / NH3 (7 N 
in MeOH) (9 : 1)) and were obtained as colorless to light brown solids. Classified in 
relation to the substitution pattern, they are summarized in tables 3.8 and 3.9. 
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n 6 7 8 10 
Cpd. 212 205 208 207 
 
Table 3.8. Dimeric dibenzo[b,f][1,4]oxazepines derived from 158 linked by nonpolar 
alkyl spacers at the piperazine moiety. 
 
 
n 6 7 8 10 
Cpd. 213 206 210 209 
 
Table 3.9. Dimeric dibenzo[b,f][1,4]oxazepines derived from 159 linked by nonpolar 
alkyl spacers at the piperazine moiety. 
 
 
3.4.2. Dibenzo[b,f][1,4]oxazepines linked by polar spacers at the piperazine 
moiety 
A further series of dimeric compounds was prepared based on all the above mentioned 
piperazine bearing “ring-closed” VUF 6884 derivatives 193, 196, 232 – 235 that were 
linked at the piperazine moiety by polar di-carboxylic acid spacers. The spacers were 
prepared from either succinic or glutaric anhydride and piperazine or homopiperazine 
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according to the synthesis pathway described in figure 3.17 (Liu et al., 2002, McRobb 
et al., 2012). After re-crystallization from EtOH they were obtained as colorless solids 
and used in the next reaction steps without further purification. 
 
i: dioxane, 24 h reflux 
 
Figure 3.17. Synthesis pathway of the polar spacers containing either piperazine or 
homopiperazine. 
 
Before use, the spacers were converted into the corresponding reactive di-acid 
chlorides by treatment with oxalyl chloride in DCM (figure 3.18) 
 
i: oxalyl chloride, DMF, DCM, 2 h RT 
 
Figure 3.18. Conversion of the polar spacers into the reactive acid chlorides. 
 
The reactive di-acid chloride spacers were then added dropwisely to the piperazine 
bearing “ring-closed” VUF 6884 derivatives with intent to interact with the free 
secondary amine of the piperazine moiety by amide coupling (figure 3.19). All reactions 
were carried out in the presence of 0.2 equivalents of pyridine. 
The resulting compounds were purified by column chromatography over silica gel 
(EtOAc / HX (3 : 2); EtOAc; MeOH) and obtained as colorless solids. 
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i: DIPEA, pyridine, DCM, 6 h RT 
Figure 3.19. Synthesis pathway of the amide coupling between the reactive di-acid 
chloride spacers and the piperazine bearing “ring closed” VUF 6884 derivatives. 
 
An overview of the dimeric compounds linked by polar spacers at the piperazine moiety 
is provided in table 3.10. 
 
R / R’ H / H 
H / H 
8 / 8’–Cl 
H / H 
7 / 7’–Cl 
H / H 
H / H 
3 / 3’-Cl 
8 / 8’–Cl 
3 / 3’–Cl 
7 / 7’–Cl 
3 / 3’–Cl 
7 / 7’–Cl 
3 / 3’–Cl 
m 1 1 1 1 1 1 2 
n 2 2 2 2 2 2 3 
Cpd. 240 241 242 238 225 239 244 
 
Table 3.10. Dimeric dibenzo[b,f][1,4]oxazepines linked by polar spacers at the 
piperazine moiety. 
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3.4.3. Dibenzo[b,f][1,4]oxazepines linked by at the NH2 group in position 3 / 3’ 
Derived from the “ring-closed” VUF 6884 derivatives bearing an NH2-group in position 
3 (128, 129, 136), a series of dimeric compounds was prepared that were linked by 
differently constituted spacers. Spacers containing piperazine or homopiperazine were 
prepared according to the procedure described above (figures 3.17, 3.18) (Liu et al., 
2002, McRobb et al., 2012). The spacer in compound 215 was easily accessible by 
converting the commercially available 1,8-octanedioic acid to the corresponding di-acid 
chloride using oxalyl chloride (figure 3.20). 
 
i: oxalyl chloride, DMF, DCM, 2 h RT 
Figure 3.20. Conversion of the 1,8-octanedioic acid spacer into the reactive acid 
chloride. 
The addition of the reactive acid chloride spacers to the free amine in position 3 was 
carried out by amide coupling (figure 3.21). All reactions were performed in the 
presence of 0.2 equivalents of pyridine.  
With regard to the reaction time, a dependence on the spacer type could be observed: 
whereas spacers consisting of either a linear or a piperazine bearing dicarboxylic acid 
were less reactive (reaction time 3 – 6 hours), spacers bearing a homopiperazine 
component revealed a higher reactivity and thus a shorter reaction time (1 – 1.5 hours). 
i: DIPEA, pyridine, DCM, 1 – 6 h RT 
Figure 3.21. Synthesis pathway of the amide coupling between the reactive di-acid 
chloride spacers and the NH2 group in position 3 of the “ring-closed” VUF 6884 
derivatives. 
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The compounds were purified by column chromatography over silica gel (MeOH; NH3 
(7 N in MeOH)) and obtained as colorless solids. 
A summary of the resulting compounds linked at the NH2 group in position 3 / 3’ is 
provided in table 3.11.  
 
R / R’ spacer Cpd. 
7 / 7’–Cl 
 
215 
7 / 7’–Cl 
 
227 
7 / 7’–Cl 
 
231 
8 / 8’–Cl 
 
229 
8 / 8’–Cl 
 
230 
H / H 
 
221 
H / H 
 
243 
Table 3.11. Dimeric dibenzo[b,f][1,4]oxazepines linked at the free NH2 group in 
position 3 / 3’. 
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4. Pharmacological section 
 
4.1. Pharmacological parameters 
All previously described compounds were characterized in several different 
pharmacological testing systems at hH1, hH4, gpH1, pD1 / hD1, hD2short, hD2long, hD3, 
hD4.4, p5-HT1A, p5-HT2, hM1, hM2 and hM3 receptors. Both competition binding and 
functional assays were performed at in-vitro testing systems (organ bath experiments 
as well as receptor binding studies based on Sf9 / CHO / HEK293 membranes). The 
respective equations that were used to determine the reported pharmacological 
parameters of the compounds are explained in the following.  
 
4.1.1. Schild equation 
The Schild equation provides an established method to characterize antagonists in 
functional assays as, e.g., the organ bath experiments at the isolated guinea pig ileum 
(Arunlakshana and Schild, 1959, Jenkinson et al., 1995): 
log KB = log c(B) – log (r-1) 
or: 
pA2 = -log c(B) + log (r-1) 
KB  dissociation constant (of antagonist to receptor) 
c(B)   concentration of the antagonist* 
r   10ΔpEC50 
ΔpEC50 pEC50 (His) – pEC50 (His/B) 
EC50  concentration of agonist producing 50 % of the maximal effect 
pA2  -log of the dissociation constant (antagonist to receptor) at a 
concentration evoking a rightward shift of the concentration effect curve 
of the agonist 
(* = with pEC50(His) measured in the absence and pEC50(His/B) in the presence of a defined 
concentration c of antagonist B) 
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The Schild equation holds true in case of a strictly competitive and reversible 
antagonism that can be determined by conducting the experiments in a wide 
concentration range. As long as the slope in the Schild plot is close to unity (slope = 1) 
and the maximal effect of the dose response curve is not significantly depressed, a 
competitive and reversible antagonism can be assumed. 
Nevertheless, in some cases the slope in the Schild plot is significantly different from 
1 or – prevalent in a huge number of experiments – the dose response curve shows 
depression at higher antagonist concentrations. In these cases, no distinct conclusion 
regarding the antagonism mode can be drawn and as a consequence, the Schild 
equation is not suitable to calculate the pA2 values. If so, pA2 values have to be 
estimated for every concentration range (described in section 4.4.2.4 and 4.4.2.5). 
 
4.1.2. Cheng-Prusoff equation 
The radioligand competition binding assays were analyzed based on the Cheng-
Prusoff equation derived from the law of mass action. (Cheng and Prusoff (1973) 
𝐾𝑖 =  
𝐼𝐶50
1 +  
[𝐴]
𝐾𝐷
 
 
Ki   dissociation constant of a competitive inhibitor and a receptor, expressed 
in Sf9 membrane fragments in competition to a radioligand 
KD    dissociation constant of a radioligand 
IC50  concentration of inhibitor producing 50 % of inhibition 
[A]    concentration of the applied radioligand 
 
This equation is valid for the following assumptions: firstly, both the ligand and the 
radioligand bind to the same binding site in a reversible competitive mode. Secondly, 
an equilibrium reaction is postulated and the concentration of free ligand and free 
radioligand is known and remains on a constant level during the experiment.  
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The KD values of the pertinent radioligands were determined in saturation binding 
experiments and were reported recently (KD = 4.49 ± 0.35 nM for [3H]Mepyramine at 
hH1R (Seifert et al. 2003); KD = 9.7 ± 1.7 nM for [3H]Histamine at hH4R (Schneider et 
al. 2009)). 
 
4.1.3. GTPase activity 
For selected compounds, steady state GTPase assays for the hH1R were performed 
as described in 4.3.5. GTPase activities (as pmol Pi released per mg of protein per 
minute) of membranes were calculated according to the following equation: 
 
𝐺𝑇𝑃𝑎𝑠𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
(𝑐𝑝𝑚 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 − 𝑐𝑝𝑚 𝑏𝑙𝑎𝑛𝑘) ∙ 𝑝𝑚𝑜𝑙 𝑢𝑛𝑙𝑎𝑏𝑒𝑙𝑒𝑑 𝐺𝑇𝑃 ∙ 1.67
𝑐𝑝𝑚 𝑡𝑜𝑡𝑎𝑙 ∙ 𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ∙ min 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛
  [
𝑝𝑚𝑜𝑙
𝑚𝑔 ∙ 𝑚𝑖𝑛
] 
 
cpm reaction radioactivity counted in 600 µl of samples except those with 
1 mM unlabeled GTP 
cpm blank radioactivity counted in 600 µl of samples containing 1 mM 
unlabeled GTP; spontaneous hydrolysis of [γ-33P]-GTP 
pmol unlabeled GTP absolute amount of GTP present in the assay tubes (10 
pmol) 
1.67 factor accounting for the fact that only 600 µl of the 1000 µl 
samples were counted 
cpm total counts resulting from total added to each tube (no charcoal 
addition) 
mg protein amount of membrane protein present in each tube (10 µg) 
min incubation incubation period (20 min) 
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4.2. Antagonist binding on a molecular level 
The aim of this work was to develop new compounds that evoke an antagonistic effect 
at both the histamine hH1R and hH4R. To characterize the range of evoked 
pharmacological effects, several pharmacological testing systems were performed that 
will be described closely in section 4.3. However, before discussing the detected 
pharmacological effects, it is necessary to define the term “antagonistic effect” on a 
molecular level. 
More than half a century ago, a first differentiation between competitive and non-
competitive antagonism was made (Gaddum et al., 1955). However, these terms can 
only be used in case of co-incubation of antagonist and agonist. As soon as the 
antagonist is pre-incubated before the agonist comes to operation (e.g. in organ bath 
experiments at the isolated guinea pig ileum), further definitions have to be taken into 
consideration: surmountable antagonism occurs, if the alteration of the maximal 
agonist dose-response curve is not affected, by contrast, insurmountable antagonism 
occurs, if the maximal effect of the dose-response curve is depressed. (Vauquelin et 
al., 2002) 
The Schild-equation mentioned in 4.1.1 provides an established method to determine 
the pharmacological potency of strictly competitive, surmountable and reversibly 
bound antagonists. For insurmountable antagonists, further pharmacological effects 
have to be considered, as, e.g., the longevity of the antagonist-receptor complex, 
allosteric binding sites or receptor internalization. (Vauquelin et al., 2002) Above all the 
allosteric binding represents an intriguing expression of insurmountable antagonism, 
as the antagonist interacts with a site of the receptor that is distinct from the agonist 
binding site. Explained on a molecular level, the antagonist binding, be it reversible or 
irreversible, evokes a change in the receptor conformation, to which the agonist is no 
more capable to bind to. 
In pre-incubating organ bath experiments, the longevity of the antagonist-receptor 
complex poses a challenge for the determination of surmountable or insurmountable 
antagonism. In some cases the dissociation of the antagonist-receptor complex may 
take place so slowly, that the dose-response curve of the agonist is depressed. As a 
consequence, surmountable antagonists can misleadingly be identified as 
insurmountable antagonists, because no proper equilibrium between antagonist, 
agonist and receptor could be established during the time of the experiment (hemi-
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equilibrium conditions). (Kenakin et al., 2006) The extent of the depression is 
dependent on the “receptor reserve” that is directly linked to the receptor density of the 
tissue, the intrinsic activity of the agonist and the coupling of the receptor to the 
respective effector proteins. Thus, in tissues with a high receptor reserve, the alteration 
of the agonist dose-response curve will only be affected in case of higher antagonist 
concentrations. (Kenakin et al., 2006) 
 
4.3. Pharmacological materials and methods 
4.3.1. The Sf9 / Baculovirus expression system (Schneider and Seifert, 2010) 
The Sf9 cell/baculovirus expression system is prevalently used for high-level protein 
expression and provides several advantages compared to mammalian cells. 
(Schneider and Seifert, 2010) The viruses used in the baculovirus expression system 
(Autographa californica) are not infectious to vertebrates and their promotors are 
inactive in mammalian cells (Carbonell et al., 1985, Carbonell and Miller, 1987). 
Insect cells derived from Spodoptera frugiperda (American fall army worm) pupal 
ovarian tissue grown in suspension culture are infected with genetically modified 
baculoviruses carrying the genes of interest. GPCRs herein can freely be combined 
with different G-proteins: for example, co-infections with up to four different types of 
baculoviruses have been reported for the histamine H4R (Schneider and Seifert, 2009). 
As a consequence, in the Sf9 cell environment interactions between the respective 
GPCRs and G-proteins can be investigated without the influence of other interfering 
GPCRs and G-proteins like in mammalian cells (e.g., receptor cross talk, receptor-
hetero-dimerization).  
Additionally, the Sf9 cell environment provides the possibility to investigate G-protein 
selectivity: only very few endogenous G-proteins are expressed in Sf9 cells. G-protein-
like forms of Gαq and Gαs were reported to appear in Sf9 cells as well as one isoform 
of Gαi, however, coupling to mammalian GPCRs could be observed only meagrely. 
(Kühn et al., 1996, Houston et al., 2002, Knight and Grigliatti, 2004, Dolby et al., 2004) 
Fusion proteins, added to the Sf9 cells at infection, can amplify the coupling between 
a GPCR and the respective G-protein. For example, to obtain Sf9 cell membranes for 
use in a steady state [33P]GTPase assay at hH1R, the RGS4-protein (regulator of G-
protein signaling) has to be coexpressed to ensure the coupling of the endogenous 
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Gαq-like protein to the GPCR. By contrast, for the preparation of membranes 
expressing the hH4R, it is necessary to coexpress Gαi2 as well as Gβ1γ2, as the 
endogenous Gαi-like protein does not couple to the mammalian GPCRs. (Schneider et 
al., 2009) 
Further advantages of the Sf9 / baculovirus expression system are the expression of 
a much higher level of both recombinant GPCRs and G-proteins in Sf9 cells than in 
mammalian cells as well as the absence of constitutively active receptors, leading to 
an excellent signal-to-noise ratio in functional assays (as, e.g., steady state 
[33P]GTPase- or [35S]GTPγS-binding assays). As Sf9 cells provide a variety of 
endogenous signal transduction components that are similar to pathways in 
mammalian cells, the gain of comparable results can be performed more easily. 
(Schneider and Seifert, 2010)  
 
4.3.2. Generation of recombinant baculoviruses (Seifert et al., 2003, Seifert and 
Wieland, 2005, Schneider et al., 2009, Schnell et al., 2011)  
Sf9 cells were cultured in 250 or 500 ml disposable Erlenmeyer flasks at 28 °C under 
rotation at 150 rpm in Insect Xpress medium supplemented with 5% (v/v) fetal calf 
serum and 0.1 mg/ml gentamicin without CO2 supplementation. Cells were maintained 
at a density of 0.5-6.0 × 106 cells/ml.  
Recombinant baculoviruses encoding the hH1R+RGS4, hH2R-GsαS, hH3R+Gαi2+Gβ1γ2 
or hH4R+Gαi2+Gβ1γ2 were generated in Sf9 cells using the BaculoGOLD transfection kit 
(BDPharmingen, San Diego, CA) according to the manufacturer’s instructions. (Seifert 
and Wieland, 2005) After initial transfection, high-titer virus stocks were generated by 
two sequential virus amplifications. In the first amplification, cells were seeded at 2.0 × 
106 cells/ml and infected with a 1:100 dilution of the supernatant fluid from the initial 
transfection. Cells were cultured for 7 days, resulting in death of virtually the entire cell 
population. The supernatant of this infection was harvested and stored under light 
protection at 4 °C. In a second amplification, cells were seeded at 3.0 x 106 cells/ml 
and infected with a 1:20 dilution of the supernatant fluid from the first amplification. 
Cells were cultured for 48 hours and afterwards, the supernatant fluid was harvested. 
After the 48 hours culture period, the most of cells showed signs of infection (e.g., 
altered morphology, viral inclusion bodies), but the majority of cells was still intact. The 
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supernatant fluid from the second amplification was stored under light protection at 4 
°C and used as routine virus stock for membrane preparations.  
Before infection, Sf9 cells were sedimented by centrifugation and suspended in fresh 
medium. Cells were seeded at 3.0 x 106 cells/ml and infected with a 1:100 dilution of 
the respective high-titer baculovirus stocks encoding hH1R and RGS4 (hH1R+RGS4 
membranes), hH2R-GsαS (hH2R-GsαS membranes), hH3R, Gαi2 and Gβ1γ2 
(hH3R+Gαi2+Gβ1γ2 membranes),  or hH4R, Gαi2 and Gβ1γ2 (hH4R+Gαi2+Gβ1γ2 
membranes) (1 mL of baculovirus stock  to 100 mL of cell suspension). Cells were 
cultured for 48h at 28 °C under constant rotation (150 rpm) before membrane 
preparation. Sf9 membranes were prepared as described in the following.  
 
4.3.3. Membrane preparation out of Sf9 cells (Seifert et al., 1998) 
In a 250 ml flask, cells were seeded at a density of 3.0 × 106 cells / ml in 200 ml fresh 
medium and infected with high titer baculovirus stock carrying the genes encoding the 
desired GPCRs and G-proteins described above. After the infection, the cells were 
incubated for 48 h at 28 °C under constant rotation (150 rpm) without CO2 
supplementation (Schnell et al., 2011). 
After 48 h, the membrane preparation was performed as described at 4 °C (Seifert et 
al., 1998). Therefore, the infected Sf9-cells were partitioned in Falcon tubes of 100 ml 
and sedimented by centrifugation (1000 rpm, 10 min) after which the supernatant was 
discarded. The remaining pellet was re-suspended in 50 ml of PBS-Buffer (100 mM 
NaCl, 80 mM Na2HPO4, 20 mM NaH2PO4; pH = 7.4) and again sedimented by 
centrifugation (1000 rpm, 10 min). The supernatant was discarded as previously 
described and to the remaining pellet of infected Sf9 cells 30 ml of Lysis-Buffer (10 mM 
Tris/HCl, 1 mM EDTA, containing 0.2 mM phenylmethylsulfonyl fluoride, 10 μg/mL 
benzamidine and 10 μg/ml leupeptine as protease inhibitors; pH = 7.4) were added. 
The solution was homogenized in a Dounce homogenizer with 25 strokes on ice and 
afterwards again sedimented by centrifugation (500 rpm, 5 min). The supernatant 
(containing the desired membrane fragments) was carefully separated from the pellet 
(containing nuclei and non-broken cells), added to a plastic tube and sedimented by 
centrifugation using a Sorvall centrifuge (18000 rpm, 20 min). As high G was applied, 
the tubes had to be carefully tared before use. The supernatant was discarded and the 
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pellet was re-suspended in 20 ml of Lysis-Buffer and one last time sedimented by 
centrifugation in the Sorvall centrifuge (18000 rpm, 20 min). To the remaining pellet 25 
ml of Binding-Buffer (12.5 mM MgCl2, 1 mM EDTA, 75 mM Tris/HCl; pH = 7.4) were 
added, after which the solution was homogenized on ice by a syringe (0.4 mm) with 20 
strokes. Aliquots (1 ml) were separated in Eppendorf Cups and stored at -80 °C until 
use. 
To determine the protein concentration of the obtained membranes, a DC-Protein 
Assay of Bio Rad was performed (Hercules, CA). 
 
4.3.4. 3[H]MEP-/3[H]HIS-competition-binding experiments at hH1R and hH4R 
(Seifert et al., 2003, Schneider et al., 2010) 
All [3H]Mepyramine ([3H]MEP) and [3H]Histamine ([3H]HIS) competition-binding 
experiments at hH1R and hH4R were carried out in disposable 6 ml vials. For 
competition binding experiments, 6 cups (6 ml) of the previously prepared Sf9 cell-
membranes of each type (hH1R + RGS4, hH4R + Gαi2 + Gβ1γ2, containing 1 – 2 mg/ml 
of protein) were thawed, homogenized and sedimented by centrifugation (10 min, 
13000 rpm, 4 °C). Afterwards, the resulting membrane pellet was re-suspended in 1.5 
ml (hH1R-assay) or 3 ml (hH4R assay) of binding buffer (12.5 mM MgCl2, 1 mM EDTA 
and 75 mM Tris/HCl, pH 7.4) and kept at 4 °C until being added to the prepared 
competition binding assay in the last step.  
For the preparation of the assay, binding buffer was added to the vials (hH1R assay: 
400 µl binding buffer; hH4R assay: 350 µl binding buffer containing 6.7 % BSA). In a 
second step, increasing concentrations (1 nM – 1 mM final concentration, doublets) of 
the respective unlabeled ligands (hH1R assay: 25 µl; hH4R assay: 50 µl) were added 
as well as reference cups for the determination of the unspecific binding and solvent 
cups as blank values for each ligand (depending on the solubility of the ligand, H2O : 
DMSO proportionately 3 : 1 or 1 : 1).  
All competition binding experiments were performed in the presence of 5 nM ([3H]MEP) 
(hH1R) or 10 nM ([3H]HIS) (hH4R). In a last step, the prepared and carefully 
homogenized membranes were added to the assay mixture (hH1R: 25 µl, hH4R: 50 µl) 
and the completed assay mixture (475 µl for hH1R, consisting of 400 µl binding buffer, 
25 µl unlabeled ligand, 25 µl [3H]Mepyramine (stock solution, 100 nM), 25 µl 
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membrane; 500 µl for hH4R, consisting of 350 µl binding buffer, 50 µl unlabeled ligand, 
50 µl [3H]Histamine (stock solution, 100 nM) and 50 µl membrane) was incubated at 
room temperature for 90 min at 250 rpm. 
Bound radioligand was separated from free radioligand by filtration through GF/C filters 
using a Brandel Harvester. In case of the hH4R assay the GF/C filter was pre-treated 
with 0.3 % polyethyleneimine. After harvesting the assay mixture, two washes with 2 
ml of cold binding buffer (4 °C) were performed and the filter-bound radioactivity was 
determined after an equilibration phase of at least 4 h by liquid scintillation counting 
using a β-counter. 
Every ligand was characterized at each receptor in at least three different assays using 
different membranes in each case.  
 
4.3.5. Steady-state [33P]GTPase activity assay at hH1R (Preuss et al., 2007) 
All steady-state [33P]GTPase activity assays at hH1R were carried out in disposable 
1.5 ml Eppendorf cups. Sf9 membranes expressing hH1R + RGS4 were thawed, 
sedimented by centrifugation (4 °C, 13000 rpm, 10 min) and re-suspended in a defined 
volume of 10 mM Tris/HCl (pH 7.4) with intent to obtain a concentration of membrane 
protein of 0.5 µg/ml. The reaction vials contained 10 µl of hH1R ligands at increasing 
concentrations (1 nM – 10 µM final concentration, triplicates) as well as 50 µl of REA-
Mix (final concentration after the addition of [γ-33P]GTP: 1.0 mM MgCl2, 0.1 mM EDTA, 
0.1 mM ATP, 100 nM GTP, 0.1 mM adenylyl imidodiphosphate, 5 mM creatine 
phosphate, 40 μg of creatine kinase, and 0.2% (w/v) bovine serum albumin in 50 mM 
Tris/HCl, pH 7.4) and 20 µl of the earlier prepared Sf9 membrane (10 μg of 
protein/tube). For the determination of KB values (antagonist mode of the [33P]GTPase 
activity assay) histamine was added to the reaction mixture (final concentration 200 
nM).  
Reaction mixtures (80 μl) were pre-incubated at 25 °C for 2 minutes before 20 μl of [γ-
33P]GTP (0.1 μCi/tube) were added. All stock and work dilutions of [γ-33P]GTP were 
prepared in 20 mM Tris/HCl, pH 7.4 as solutions in H2O (millipore) turned out to be 
instable due to hydrolysis. Reactions were conducted for 20 min at 25 °C and were 
afterwards terminated by adding 900 μl of slurry consisting of 5% (w/v) activated 
charcoal and 50 mM NaH2PO4 (pH 2.0). Charcoal absorbs nucleotides but not Pi. 
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Charcoal-quenched reaction mixtures were centrifuged for 7 min at room temperature 
at 15000 rpm. After the centrifugation was completed, 600 µl of the supernatant fluid 
of reaction mixtures were removed, and 33Pi was determined by liquid scintillation 
counting. Spontaneous [γ-33P]GTP degradation was determined in tubes containing all 
components listed above and in addition to that a high concentration of unlabeled GTP 
(1 mM) that prevents [γ-33P]GTP hydrolysis by enzymatic activities present in Sf9 
membranes due to competition with [γ-33P]GTP. Spontaneous [γ-33P]GTP degradation 
was < 1% of the total amount of radioactivity added. The experimental conditions 
chosen ensured that not more than 10% of the total amount of [γ-33P]GTP added was 
converted to 33Pi. All experimental data were analyzed by non-linear regression with 
PRISM 5.0. (GraphPad Software, San Diego, CA). 
 
4.3.6. [35S]GTPγS-binding assay at hH4R (Schneider et al., 2009) 
All [35S]GTPγS-binding experiments at hH4R were carried out in disposable 96 well 
plates. Before the experiments, Sf9 membranes expressing hH4R + Gαi2 + Gβ1γ2 were 
thawed and sedimented by centrifugation (4 °C, 13000 rpm, 10 min). Membranes were 
re-suspended in 1060 µl REA-Mix (Binding Buffer plus 1.25 μM GDP, 125 mM NaCl, 
and 0.063 % (w/v) bovine serum albumin (BSA)) and stored at 4 °C until use. 
Every reaction well contained 70 µl of REA-Mix, 10 µl of the respective ligands at 
increasing concentrations (1 nM – 1 mM final concentration, triplicates), 10 µl of 
radioligand ([35S]GTPγS, 2 nM final concentration) and 10 µl of the before carefully 
homogenized Sf9 membrane suspension. Furthermore, histamine was used as 
reference ligand (final concentration 10 µM, triplicates) as well as cold GTPγS (final 
concentration 10 µM) to determine the unspecific binding. The plates were incubated 
at room temperature for 120 min (450 rpm). Afterwards, bound radioligand was 
separated from free radioligand by filtration through a GF/C-filter and washed 5 times 
with cold binding buffer (4 °C) using a Brandel Harvester. Filter-bound radioactivity was 
determined after an equilibration phase of at least 12 h by liquid scintillation counting 
using a β-counter. 
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4.3.7. [35S]GTPγS-binding assays at hH2R and hH3R (Schneider et al., 2009) 
With intent to determine the receptor selectivity of some selected compounds, 
[35S]GTPγS-binding assays were performed at hH2R and hH3R using disposable 6 ml 
vials. Therefore, membranes carrying hH2R-GsαS and hH3R + Gαi2 + Gβ1γ2 were used.  
Before the experiments, the respective Sf9 membranes were thawed and sedimented 
by centrifugation (4 °C, 13000 rpm, 10 min). Membranes were re-suspended in 1400 
µl REA-Mix (Binding Buffer plus 1.25 μM GDP, 125 mM NaCl, and 0.063 % (w/v) 
bovine serum albumin (BSA)) and stored at 4 °C until use. 
Every reaction vial contained 175 µl of REA-Mix, 25 µl of the ligands at increasing 
concentrations (100 nM – 1 mM final concentration, triplicates), 25 µl of radio ligand 
([35S]GTPγS, 2 nM final concentration) and 25 µl of the earlier carefully homogenized 
Sf9 membrane suspension. Furthermore, histamine was used as reference ligand 
(final concentration 10 µM, triplicate) and one vial containing cold GTPγS was 
measured to determine the unspecific binding. The protein content of the samples was 
15 µg/ml of membrane protein per 250 μL. The vials were incubated at room 
temperature for 240 min (250 rpm). Afterwards, bound radioligand was separated from 
free radioligand by filtration through a GF/C-filter and washed with 2 ml of cold binding 
buffer (4 °C) using a Brandel Harvester. Filter-bound radioactivity was determined after 
an equilibration phase of at least 12 h by liquid scintillation counting using a β-counter. 
 
4.3.8. Organ bath experiments at the isolated guinea pig ileum (Elz et al., 2000) 
For the preparation of the guinea pig ileum segments, guinea pigs of either sex (250 – 
500 g) were stunned by a blow on the head and exsanguinated by cutting the carotid 
artery. After slicing the abdominal wall, the ileum was removed, rinsed and cut into 
segments of 1.5 – 2.5 cm length. The ileum segments were mounted isotonically in 20 
ml organ baths containing aqueous Tyrode's solution (NaCl 137 mM, KCl 2.7 mM, 
CaCl2 1.8 mM, MgCl2 1.0 mM, NaH2PO4 0.4 mM, NaHCO3 11.9 mM and glucose 5.0 
mM) (Pertz and Elz, 1995) and were connected to a Transducer (Type TIT 1100, FMI 
GmbH, Seeheim, preload 5 mN). The contraction was measured by means of an 
amplifier (Transducer coupler 4711, FMI GmbH, Seeheim) and recorded by a 6-
channel-x/t-writer (Kompensograph C 1015, Siemens). The solution was aerated with 
carbogen (95% O2, 5% CO2) and warmed to a constant temperature of 37 °C. After an 
Chapter 4 
___________________________________________________________________ 
91 
 
equilibration period of about 30 min, the tissues were pre-stimulated three times with 
histamine (1 μM, then 10 μM) followed by washout (8 minutes) and recovery (10 
minutes), during which atropine at a concentration not affecting H1 receptors (0.05 μM) 
was added in order to block cholinergic M receptors (Leschke et al., 1995).  
For every tissue, a cumulative concentration-response curve of histamine (0.01 – 30 
µM) was recorded, followed by at most three cumulative concentration-response 
curves of histamine (0.01 – up to 1000 or 2000 µM) in the presence of increasing 
concentrations of antagonist (incubation time 15 minutes). (Elz et al., 2000) 
 
4.3.9. Pharmacological characterization of selected compounds at dopamine, 
serotonin and muscarine receptors 
4.3.9.1. Determination of the binding affinity to dopamine and serotonin 
receptors 
Receptor binding studies were carried out as described previously (Hübner et al., 
2000). In brief, the dopamine D1 receptor assay was done with porcine and human 
striatal membranes at a final protein concentration of 20 µg/assay tube and the 
radioligand [3H]SCH 23390 (specific activity = 60 Ci/mmol, Biotrend, Cologne, 
Germany) at 0.50 nM (KD =  0.67 nM, Bmax = 625 fmol/mg protein). For competition 
binding experiments with human D2long, D2short (Hayes et al. 1992), D3 (Sokoloff et al., 
1992) and D4.4 (Asghari et al., 1995) receptors, preparations of membranes from CHO 
cells stably expressing the corresponding receptor were used together with 
[3H]spiperone (specific activity = 81 Ci/mmol, PerkinElmer, Rodgau, Germany) at a 
final concentration of 0.20-0.30 nM. The assays were carried out at a protein 
concentration of 2-10 µg/assay tube, KD values of 0.12-0.15 nM, 0.092-0.12 nM, 0.14-
0.18 nM, and 0.17-0.23 nM and corresponding Bmax values of 510 fmol/mg, 2600-4800 
fmol/mg, 2300-4200 fmol/mg, and 1300-2600 fmol/mg for the D2long, D2short, D3 and D4.4 
receptors, respectively. Binding studies with the porcine serotonin receptors were 
carried out as described (Hübner et al., 2000, Bettinetti et al., 2002). Homogenates 
from porcine cerebral cortex were prepared and assays were run with membranes at 
a protein concentration per each assay tube of 60 and 80-100 µg/mL for 5-HT1A and 
5-HT2, respectively, in the presence of the radioligands [3H]WAY100635 (specific 
activity = 80 Ci/mmol, Biotrend, Cologne, Germany) (0.15 nM final concentration, KD = 
0.062-0.088 nM, Bmax = 80 fmol/mg) and [3H]ketanserin (specific activity = 53 Ci/mmol, 
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PerkinElmer, Rodgau, Germany) (0.50 nM final concentration, KD = 1.8 nM, Bmax = 100-
200 fmol/mg). Protein concentration was established by the method of Lowry using 
bovine serum albumin as standard (Lowry et al., 1951). 
 
4.3.9.2. Binding studies with muscarine receptors 
Receptor binding studies with the human muscarine receptor subtypes M1, M2 and M3 
were carried out utilizing homogenates of membranes from HEK293 cells which were 
transiently transfected with the pcDNA3.1 vector containing the human M1, M2 or M3 
receptor (all purchased from Missouri S&T cDNA Resource Center, Rolla, MO), 
respectively, by the calcium phosphate method (Jordan et al., 1996). The binding 
assays were run according to the protocol described above when membranes were 
incubated at a final concentration of 4-20 μg/well together with 0.10-0.20 nM of [3H]N-
methylscopolamine (specific activity = 80 Ci/mmol, Biotrend, Cologne, Germany) at KD 
values of 0.050-0.095 nM, 0.087-0.20 nM, and 0.080 nM and Bmax values of 350-1100 
fmol/mg, 140-490 fmol/mg, and 1800 fmol/mg protein for M1, M2 and M3, respectively. 
For all muscarine receptor systems unspecific binding was determined in the presence 
of 10 μM atropin. 
 
4.3.9.3. Data analysis for binding studies to dopamine, serotonin and 
muscarine receptors 
The resulting competition curves of the receptor binding experiments were analyzed 
by nonlinear regression using the algorithms in PRISM 3.0 (GraphPad Software, San 
Diego, CA). The data were initially fit using a sigmoid model to provide an IC50 value, 
representing the concentration corresponding to 50% of maximal inhibition. IC50 values 
were transformed to Ki values according to the equation of Cheng and Prusoff. (Cheng 
and Prusoff, 1973) In the case of two individual measurements, Ki was calculated as 
mean value in nM with the standard deviation (SD), while analyzing more than two 
single values the standard error of mean (SEM) was calculated. 
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4.4. Pharmacological results 
4.4.1. [3H]MEP-/[3H]HIS-competition binding experiments at hH1R and hH4R 
Competition binding assays at hH1R and hH4R were routinely performed for all 
synthesized compounds. Therefore, increasing ligand concentrations of 1 nM – 1 mM 
(final) were incubated together with the respective Sf9 membrane and radioligand. The 
detailed experimental parameters were described in 4.3.4. Each compound was 
characterized at least in triplicates in the presence of three different Sf9 membrane 
charges. The standard deviation (SD) was calculated and is quoted as “± SD” in the 
tables of results. The resulting competition curves of the receptor binding experiments 
were analyzed by nonlinear regression using the algorithms in PRISM 5.0 (GraphPad 
Software, San Diego, CA) 
 
4.4.1.1. Characterization of the (E)-N-(2-aminoethyl)-N'-phenylbenzamidines: 
VUF 6884 reduced to the core 
The results of the binding assays at hH1R and hH4R revealed significant 
pharmacological differences between the (E)-N-(2-aminoethyl)-N'-phenylbenz-
amidines (22, 23, 25, 28, 52, 56, 58, 62, 64, 67, 70, 73, 76, 80, 99, 103, 110, 111, 112, 
114 – 117, 180, 181, referred to as the “open” compounds in the following) and the 
corresponding dibenzo-annulated oxazepines 88, 92, 128, 129, 136, 141, 149, 158, 
159, 193, 196, 232 – 235, as well as specific structure activity relationships (SARs) 
within both series of compounds. 
The open compounds have to be partitioned into two sections: firstly, compounds 22, 
23 and 25, that carry no substituents at the aromatic core and within which the rigid 
basic N-methylpiperazine moiety was replaced by variously alkylated ethylenediamine 
derivatives, and secondly, compounds 28, 52, 56, 58, 62, 64, 67, 70, 73, 76, 80, 99, 
103, 110, 111, 112, 114 – 117, 180, 181 bearing an unchanged rigid N-
methylpiperazine moiety as well as various modifications of the substitution pattern of 
the aromatic core. 
Compounds lacking the rigid N-methylpiperazine-moiety (22, 23, 25) showed in direct 
comparison to the corresponding N-methylpiperazine bearing counterpart 28, that 
above all the hH4R is very sensitive to changes in this area of the molecule. (Table 4.1) 
However, except compound 25, the affinity to the hH1R was not mentionably affected. 
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Interestingly, compound 25 showed compared to the other two ethylenediamine-
substituted compounds 22 and 23 a significant decrease of hH1R affinity (p (25/22, 23) 
< 0.0001) that – as described in 4.4.2 – could be reproduced at the guinea pig ileum.  
Table 4.1. Binding data of the open compounds lacking the piperazine moiety. 
 
For the open compounds with rigid basic piperazine moiety, compound 28 serves as 
reference due to the lack of influences that can be traced back to substituents. 
Differences can be made with regard to the part of the molecule at which the 
substituent is located (aniline moiety or benzoic acid moiety) or the position (p- or m- 
position). As already described in the chemical section, the terms “aniline moiety” and 
“benzoic acid moiety” are derived from the synthesis strategy that was pursued to 
obtain the described compounds and serve to provide a better orientation as to be 
seen in the molecule map (figure 4.1). 
 
Figure 4.1. Molecule map of the open compounds. 
 
Compounds are separated into mono- (52, 56, 58, 64, 67, 70, 72, 76) and di-substituted 
molecules (62, 80, 99, 103, 110 – 112, 114 – 117, 180, 181). Among the mono-
substituted compounds, those bearing Cl substituents (67, 70, 73, 76) revealed the 
 R1 R2 R3  pKi (hH1R) pKi (hH4R) 
 
H -CH3 -CH3 22 5.08 ± 0.18 3.89 ± 0.23 
H -C2H5 -C2H5 23 5.07 ± 0.13 3.30 ± 0.18 
-CH3 -CH3 -CH3 25 3.58 ± 0.12 3.91 ± 0.24 
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most pronounced pharmacological effects that could also be transferred to the 
oxazepine-derived compounds later in this section. (Table 4.2) 
With regard to the hH1R affinity, p-substitution of the aniline moiety with Cl, Br or NH2 
substituents (52, 64, 67) turned out to be detrimental compared to the reference 
compound 28, whereas the hH4R affinity could be slightly increased. For the p-
substitution at the benzoic acid moiety it is necessary to distinguish between the 
different types of substituents: whereas Cl substitution (70) revealed a significant 
increase in hH1R and hH4R affinity (p (70/28) < 0.0001), for CN and NH2 substitution 
(56, 58) a decrease of affinity to both, the hH1R and the hH4R, could be observed. 
Substitution with Cl in m-position at the aniline or the benzoic acid moiety (73, 76) 
increased the affinity to the hH1R (73/28: p < 0.0001; 76/28: p = 0.0026) as well as the 
affinity to the hH4R (p (73, 76/28)< 0.0001). The reported pharmacological effects of 
the mono-substituted compounds are summarized in table 4. 2 in which compound 28 
serves as a reference. 
  
    R 
pKi  
(hH1R) 
pKi  
(hH4R) 
 
 
H 28 5.20 ± 0.14 4.07 ± 0.07 
p-NH2 52 4.41 ± 0.21 5.25 ± 0.17 
p-Br 64 3.80 ± 0.10 5.16 ± 0.09 
p-Cl 67 4.35 ± 0.15 5.20 ± 0.18 
m-Cl 73 5.99 ± 0.19 4.91 ± 0.15 
 
p-NH2 56 4.19 ± 0.17 3.63 ± 0.11 
p-CN 58 4.28 ± 0.07 3.82 ± 0.12 
p-Cl 70 6.07 ± 0.13 4.67 ± 0.12 
m-Cl 76 5.61 ± 0.21 4.82 ± 0.14 
 
Table 4.2. Binding data of the mono-substituted open compounds at hH1R and hH4R. 
With intent to combine the SARs detected when bearing only one substituent, a series 
of compounds was prepared (62, 80, 103, 110, 111, 180, 181) that were substituted at 
both, the aniline and the benzoic acid moiety. Again, compound 28 serves as a 
reference. 
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Among the di-substituted molecules, the di-chlorinated compounds 180 and 181 
revealed by approximately 1.5 orders of magnitude a significantly higher affinity to the 
hH4R compared to 28 (p (180, 181/28) < 0.0001), whereas only minor changes in hH1R 
affinity were determined. The combination of halide substituents in favourable positions 
for hH1R and hH4R binding with a p-NH2 group at the aniline moiety (110, 111) evoked 
no increase in affinity compared to 28. A p-NH2 group at the benzoic acid moiety 
combined with a halide substituent at the aniline moiety resulted at least in a moderate 
increase of the hH4R affinity (62, 80, 103). The reported pharmacological effects of the 
di-substituted compounds are shown in table 4.3, in which compound 28 is mentioned 
as a reference. 
   
R 
 pKi 
(hH1R) 
pKi 
(hH4R) 
 
 
H 28 5.20 ± 0.14 4.07 ± 0.07 
p-Cl 180 4.74 ± 0.04 5.60 ± 0.09 
m-Cl 181 5.75 ± 0.03 5.28 ± 0.04 
 
 
p-Br 62 3.69 ± 0.23 4.60 ± 0.06 
p-Cl 80 4.07 ± 0.05 4.51 ± 0.11 
m-Cl 103 5.49 ± 0.23 4.40 ± 0.21 
 
 
m-Cl 110 3.91 ± 0.06 4.12 ± 0.17 
p-Cl 111 3.70 ± 0.24 4.02 ± 0.10 
 
 
Table 4.3. Binding data of the di-substituted “open” compounds at hH1R and hH4R. 
 
A further series derived from the di-substituted compounds 80 and 103 was prepared 
that contained various acylamino groups in p-position of the benzoic acid moiety as 
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well as Cl substituents in p-position (99, 112, 114, 115) or m-position (116, 117) of the 
aniline moiety. The intent was to increase the affinity to hH4R as described by Smits et 
al. for quinoxaline and quinazoline derived molecules (Smits et al., 2008a; Smits et al., 
2008b). For all compounds, the affinity to hH1R decreased compared to 28, and the 
hH4R affinity remained on the same level (99, 114 - 117) or was increased (112). A 
summary of the binding data of the acylamino-substituted compounds is shown in table 
4.4. 
  
R1 
 
R2 
 pKi 
(hH1R) 
pKi 
(hH4R) 
 
 
 
 
 
p-Cl 
 
99 
 
4.36 ± 0.19 4.54 ± 
0.11 
p-Cl 
 
112 
 
4.61 ± 0.09 5.29 ± 
0.20 
p-Cl 
 
114 
 
4.00 ± 0.09 4.38 ± 
0.18 
p-Cl 
 
115 
 
3.22 ± 0.23 4.16 ± 
0.06 
m-Cl 
 
116 
 
4.42 ± 0.05 4.29 ± 
0.16 
m-Cl 
 
117 4.34 ± 0.22 4.41 ± 
0.08 
 
Table 4.4. Binding data of the di-substituted acylamino substituted compounds at hH1R 
and hH4R. 
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4.4.1.2. Characterization of dibenzo[b,f][1,4]oxazepines: the key role of the 
closed central oxazepine ring 
A fairly minor structural modification lead to a distinct improvement of pharmacological 
affinity at both the hH1R and hH4R: according to Smits et al. (2006), for some selected 
open compounds a series of dibenzo[b,f][1,4]oxazepine-derived counterparts with 
piperazine- or N-methylpiperazine-moiety was prepared. (Figure 4.2). 
 
 
Figure 4.2. Molecule map of the dibenzo[b,f][1,4]oxazepine-derived counterparts: the 
fusion of both phenyl moieties by an oxygen bridge results in a closed central 
oxazepine ring. 
 
In general, all synthesized dibenzo[b,f][1,4]oxazepine-derived compounds (88, 92, 
128, 129, 136, 141, 149, 158, 159, 193, 196, 232 - 235) showed very high affinity to 
the hH1R (pKi 7.66 – 9.25) and – depending on the substitution pattern and the 
piperazine-moiety – moderate to high affinity to the hH4R. For compounds synthesized 
by Smits et al. (88, 92, 141, 158) the published pKi values could not be reproduced 
and showed a difference of -0.2 to -0.8 log units. A possible reason for the detected 
deflections could be the disparity of the testing systems.  
Alike within the series of the open compounds, a reference compound 141 without any 
substituents was prepared with intent to determine the pharmacological effects of the 
core molecule. Moreover, a comparison between the two reference compounds of the 
open (28) and the closed group (141) was made: the central oxazepine ring causes a 
significant increase in hH1R and hH4R affinity (hH1R: +3 orders of magnitude, p 
(28/141) < 0.0001; hH4R: + 2 orders of magnitude, p (28/141) < 0.0001), suggesting a 
key role of this part of the molecule for interactions with hH1R and hH4R. (Figure 4.3)  
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                                                   R 
 pKi 
(hH1R) 
pKi 
(hH4R) 
 
 
 
 
H 141 8.16 ± 0.22 6.19 ± 0.231 
8-Cl 88 8.19 ± 0.13 6.64 ± 0.142 
7-Cl 92 7.76 ± 0.113 6.99 ± 0.033 
3-Cl 149 8.97 ± 0.04 6.13 ± 0.09 
3-NH2 136 7.92 ± 0.13 5.11 ± 0.06 
3-NH2, 7-Cl 129 7.66 ± 0.19 6.48 ± 0.09 
3-NH2, 8-Cl 128 8.18 ± 0.16 6.11 ± 0.13 
3-Cl, 8-Cl 158 8.52 ± 0.05 6.27 ± 0.234 
3-Cl, 7-Cl 159 9.25 ± 0.16 6.96 ± 0.16 
2-Cl LOX5 8.64 ± 0.08 5.06 ± 0.07 
 
Table 4.5. hH1R-/hH4R- binding data of the dibenzo[b,f][1,4]oxazepine-derived 
compounds bearing an N-methylpiperazine moiety. 
 
  
 
 
 
 
 
Figure 4.3. Pharmacological effect of the closed central oxazepine ring and the 
modification of the substitution pattern at hH1R and hH4R. 
                                                          
1 Smits et al. (2006): pKi (hH4R) = 6.88 ± 0.1 
2 Smits et al. (2006): pKi (hH4R) = 7.37 ± 0.1 
3 Smits et al. (2006): pKi (hH1R) = 8.11 ± 0.1; pKi (hH4R) = 7.55 ± 0.1 
4 Smits et al. (2006): pKi (hH4R) = 6.51 ± 0.1 
5 hH1R and hH4R binding data of LOX (loxapine) from Appl et al. (2012) 
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Similar effects could be detected for the pairs 67 / 92, 70 / 149 and 103 / 128. Moreover, 
for both the hH1R and the hH4R, an overview of the pKi values of all “open” and “ring-
closed” counterparts is given in figure 4.4. 
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Figure 4.4 Overview of the pKi values of all “open” and “ring-closed” counterparts at 
hH1R and hH4R. 
 
For the majority of compounds, the SARs of the substituents determined within the 
series of the open compounds could be transferred to the closed compounds. All 
results are quoted in comparison to the reference compound 141. 
The introduction of a Cl substituent in position 7 (92) turned out to be significantly 
beneficial for hH4R affinity (p (92/141) < 0.0001), whereas the introduction of a Cl 
substituent in position 3 (149) led to a significantly increased affinity to hH1R (p 
(149/141) < 0.0001). Di-substituted compounds bearing an NH2 group in position 3 and 
a Cl substituent in position 7 (129) or 8 (128) showed no remarkable change in the 
high hH1R and the moderate hH4R affinity. The introduction of only one NH2 group in 
position 3 without any further substituent led to a significant loss of affinity to hH4R 
(136) (p (136/141) < 0.0001). However, the high hH1R affinity was not affected.  
In some cases, the SARs determined at the open compounds could not be transferred 
to the closed compounds one-to-one. For example, the hH1R-beneficial effect of a Cl 
substituent in m-position of the aniline moiety (73) could not to the same extent be 
reproduced for the corresponding closed counterpart 88, as only an increase of hH4R 
affinity was revealed in comparison to the unsubstituted reference compound 141. The 
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hH1R affinity, however, was not at all influenced. A possible explanation could be that 
in the open compound 73 the lack of rigidization of the two aromatic rings (aniline and 
benzoic acid moiety) allows rotation around the single bonds adjacend the imino-bond. 
As a consequence, substituents in m-position are able to possess different positions 
in the binding pocket. Transferred to the hH4R, similar effects were observed for the 
pair 76 / LOX: m-Cl substitution of the benzoic acid moiety (76) increased the hH4R 
affinity compared to the “open” reference compound 28, whereas for the corresponding 
“ring-closed” counterpart LOX the affinity was distinctly decreased compared to the 
“ring-closed” reference compound 141.  
For the di-Cl-substituted compound 159, the beneficial effects of Cl substitution in 
position 7 (hH4R ↑) and position 3 (hH1R ↑) could be combined, resulting in a 
significantly increased affinity to both the hH1R (pKi 9.25 ± 0.16, (159/141) p < 0.0001) 
and the hH4R (pKi 6.96 ± 0.16, p (159/141) < 0.0001). The corresponding open 
counterpart 180 showed the same tendencies regarding the hH4R affinity, however, 
the pharmacological effects were not as pronounced as expected. All reported 
pharmacological effects are summarized in table 4.5.  
Figure 4.5 shows a snapshot of the molecular dynamics simulation of compound 88 
(A) and loxapine (LOX, B) in the binding pocket of hH4R. The hH4R model was 
constructed as recently described by homology modeling, using the crystal structure 
of the inactive hH1R as template. (Wagner et al., 2014) For both molecules, an 
electrostatic interaction between the protonated distal nitrogen of the N-
methylpiperazine moiety and the highly conserved Asp3.32 in TM 3 is suggested. As 88 
and LOX differ only in their substitution pattern of the aromatic tricycle, a closer focus 
on this region of the molecule is necessary to explain the differences in the affinity to 
hH4R. Embedded in a pocket between TM 3, TM 5, TM 6 and the E2-loop, the aromatic 
core is suggested to interact with several amino acids, mainly Phe168, Phe169, Tyr3.33 
and Trp6.48. Moreover, the Cl substituent in position 8 (88) is most likely to interact with 
further sub-pockets in TM 6 of the hH4R binding site, resulting in an increased hH4R 
affinity (pKi (hH4R) = 6.64 ± 0.14) By contrast, due to the Cl substituent in position 2 it 
is speculated that a sterical clash with Trp6.48 in TM 7 prevents the ligand from optimally 
fitting into the binding pocket and thus leads to a decreased hH4R affinity of LOX (pKi 
(hH4R) = 5.06 ± 0.07). (personal communication, Strasser et al., 2014) 
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Figure 4.5. Interaction of 88 (A) and LOX (B) with amino acids in the binding pocket 
of hH4R (snapshot of MD simulation, Strasser et al., 2014) 
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Among the dibenzo[b,f][1,4]oxazepine-derived compounds, a small series was 
prepared, in which the N-methylpiperazine moiety was replaced by piperazine (193, 
196, 232 – 235). For all compounds, the high affinity to hH1R was not remarkably 
influenced, however, the hH4R affinity was in all cases significantly decreased (0.5 – 1 
orders of magnitude, p < 0.0001) compared to their “ring closed” N-methylpiperazine 
counterparts (figure 4.6). This phenomenon was also observed in the laboratories of 
the Leurs group (Smits et al., 2006): a reduced basicity of the distal nitrogen as in the 
piperazine-bearing compounds caused a distinctly decreased hH4R affinity. Moreover, 
as ethylated piperazine analogues also revealed a decreased hH4R affinity, an 
important role of the steric component is suggested. Regarding the aromatic core of 
the piperazine-bearing VUF 6884 derived molecules, the SARs determined for the 
substitution pattern within the group of the N-methylpiperazine bearing compounds 
could be reproduced. 
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Figure 4.6. Comparison of the hH1R-/ hH4R affinity of the corresponding N-
methylpiperazine-/ piperazine-bearing counterparts. 
All reported pharmacological effects are summarized in table 4.6. 
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                                                    R 
 pKi 
(hH1R) 
pKi 
(hH4R) 
 
 
H 233 7.96 ± 0.03 5.33 ± 0.02 
8-Cl 234 8.40 ± 0.02 6.08 ± 0.10 
7-Cl 235 8.04 ± 0.12 6.57 ± 0.02 
3-Cl 232 8.74 ± 0.08 5.35 ± 0.03 
3-Cl, 7-Cl 193 8.23 ± 0.11 5.92 ± 0.12 
3-Cl, 8-Cl 196 8.52 ± 0.03 5.62 ± 0.06 
 
Table 4.6. hH1R-/hH4R binding data of the dibenzo[b,f][1,4]oxazepine-derived 
compounds bearing a piperazine moiety. 
 
As a conclusion it is suggested, that the fusion of the central oxazepine ring causes an 
increase of hH1R affinity in a range of, in general, about 3 log units, and about 2 log 
units of hH4R affinity. These pharmacological results emphasize that not only the 
substitution pattern, but more importantly, the closed central heterocycle and above all 
the oxygen as fusion atom plays a key role in the ligand-receptor interaction at both 
the hH1R and hH4R. As previously reported crystallographic data of modified fusion 
atoms revealed, the 3D structure of the clozapine-like molecule is strongly determined 
by the nature of the atom that fuses the phenyl rings (e.g. sulfur, carbon, oxygen or 
nitrogen). (Liégeois et al., 2002) This can be traced back to the conformational 
differences due to the dihedral angle between the planes of both aromatic rings. 
(Liégeois et al., 2002, Smits et al., 2006) Furthermore, the hH4R turned out to be very 
sensitive to changes in the rigid basic N-methylpiperazine moiety: the replacement of 
the N-methylpiperazine ring by either a flexible ethylenediamine moiety or a 
piperazine-ring caused a distinct drop of hH4R affinity that can be traced back to steric 
components as well as to the loss of basicity. (Smits et al., 2006) 
 
The detected SARs are summarized in figure 4.7. 
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Figure 4.7. SARs of the open and “ring-closed” compounds at hH1R and hH4R. 
 
4.4.1.3. Characterization of dimeric dibenzo[b,f][1,4]oxazepines 
4.4.1.3.1. Dibenzo[b,f][1,4]oxazepines linked by nonpolar alkylspacers 
As compounds 158 and 159 showed the most promising pharmacological profile with 
regard to both the hH1R and the hH4R, a series of dimeric compounds derived from 
these molecules was prepared. Due to matters of synthesis, nonpolar alkyl spacers of 
different length (n = 6, 7, 8, 10) were used to link the respective piperazine bearing 
counterparts of 158 and 159 (compounds 196 and 193) at the free amine of the 
piperazine moiety. A map of the resulting molecules is shown in figure 4.8.  
 
Figure 4.8. Molecule map of the dimeric dibenzo[b,f][1,4]oxazepine derivatives linked 
by nonpolar alkyl spacers. 
 
In all cases, the affinity to hH1R and hH4R was significantly decreased compared to 
the monomeric compounds 158 or 159 (p < 0.0001). All dimeric compounds linked by 
nonpolar spacers showed very weak affinity to the hH4R (pKi < 5), which can be traced 
rigid basic amine moiety:  hH1R ↑ , hH4R ↑ 
X = -CH3: hH1R -, hH4R ↑↑ 
X =  -H:    hH1R -, hH4R ↓ 
 
X = H: hH1R -, hH4R ↓ 
2-Cl: hH1R ↑ , hH4R ↓ 
3-Cl:  hH1R ↑ , hH4R ↓ 
3-CN: hH1R ↓ , hH4R ↓ 
3-NH2:  hH1R ↓ , hH4R ↓ 
ring fusion with oxygen: 
hH1R ↑, hH4R ↑ 
8-Cl: hH1R ↑ , hH4R - 
7-Cl:  hH1R ↓ , hH4R ↑ 
7-Br: hH1R ↓ , hH4R ↓ 
7-NH2:  hH1R ↓ , hH4R ↓ 
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back to the recently described sensitivity of the hH4R to changes in the area of the rigid 
basic piperazine moiety. (Smits et al., 2006) Moreover, a decrease in hH1R affinity in 
a range of approximately 3 - 4 log units was observed compared to the respective 
monomers. However, a differentiation regarding the spacer length is necessary:  
Compounds bearing spacers with n = 6 (212, 213), n = 8 (208, 210) and n = 10 (207, 
209) showed no mentionable difference in the moderate affinity that could be related 
to modifications of the substitution pattern or the spacer length. By contrast, for 
compounds linked by a spacer with n = 7 (205, 206), a distinct difference in hH1R 
affinity depending on the position of the Cl substituents was detected: for substituents 
in position 8 / 8’ and 3 / 3’ (205), the hH1R affinity remained on the same level as 
already reported for spacer lengths n = 6, 8, 10.  For substituents in position 7 / 7’ and 
3 / 3’ (206), the hH1R affinity was significantly increased by approximately 2 orders of 
magnitude (p (205/206) < 0.0001). (Figure 4.9) These data, in combination with 
molecular modelling studies at hH1R indicate that this compound binds only at one 
hH1R, but does not address dimeric hH1Rs. The first pharmacophor binds specifically 
in the binding pocket of hH1R, whereas the second pharmacophor binds on the 
extracellular surface of hH1R. As it will be reported later in this section (4.4.2), the 
results determined for compounds 205 and 206 could be confirmed at the isolated 
guinea pig ileum.  
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Figure 4.9. Competition binding assay at hH1R: compound 206 with substitution in 
positions 3 / 3’ and 7 / 7’ clearly superior to its 3 / 3’ and 8 / 8’ substituted analogue 
205. 
The competition binding data discussed above are summarized in table 4.7. 
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R / R’ 
 
n 
 pKi 
(hH1R) 
pKi 
(hH4R) 
8 / 8’ –Cl, 3 / 3’ –Cl 6 212 5.86 ± 0.10 < 5 
8 / 8’ –Cl, 3 / 3’ –Cl 7 205 5.63 ± 0.22 < 5 
8 / 8’ –Cl, 3 / 3’ –Cl 8 208 5.42 ± 0.23 < 5 
8 / 8’ –Cl, 3 / 3’ –Cl 10 207 5.69 ± 0.10 < 5 
7 / 7’ –Cl, 3 / 3’ –Cl 6 213 5.87 ± 0.16 < 5 
7 / 7’ –Cl, 3 / 3’ –Cl 7 206 7.44 ± 0.10 < 5 
7 / 7’ –Cl, 3 / 3’ –Cl 8 210 5.02 ± 0.20 < 5 
7 / 7’ –Cl, 3 / 3’ –Cl 10 209 5.84 ± 0.09 < 5 
 
Table 4.7. hH1R / hH4R binding data of dimeric dibenzo[b,f][1,4]oxazepine derivatives 
linked by nonpolar spacers. 
 
4.4.1.3.2. Dibenzo[b,f][1,4]oxazepines linked by polar spacers of different type 
and length: compounds linked at the piperazine moiety 
Derived from the dibenzo[b,f][1,4]oxazepine compounds that carry a piperazine moiety 
(193, 196, 232 – 235) a further series of dimeric compounds was prepared that were 
linked by different types of polar spacers. The spacers, containing a piperazine- or a 
homopiperazine component, were linked to the respective monomeric compounds at 
the free secondary amine of the piperazine moiety by amide coupling. A map of the 
resulting molecules is shown in figure 4.10. 
Pharmacological section 
___________________________________________________________________ 
108 
 
 
Figure 4.10. Molecule map of the dibenzo[b,f][1,4]oxazepine derivatives linked by 
polar spacers containing piperazine or homopiperazine components. 
 
Compared to the monomeric compounds 193, 196, 232 - 235, the affinity to hH1R and 
hH4R was in all cases decreased. As the hH4R affinity of the monomers was itself low 
due to the lack of an N-methylpiperazine moiety, the resulting dimeric compounds did 
not surprise with their low hH4R affinity (pKi < 5). This can again be quoted to the 
sensitivity of the hH4R to changes at the rigid basic N-methylpiperazine moiety that 
was already observed for the compounds linked by nonpolar spacers.  
However, a different observation could be made for the hH1R: among all dimeric 
compounds linked at the piperazine moiety (be it by polar or nonpolar spacers), the 
hH1R revealed a slight preference to compounds linked by polar spacers. Although 
decreased in a range of about 2 log units in comparison to the corresponding 
monomeric counterparts, the loss of hH1R affinity was not as pronounced as reported 
for the nonpolarly linked compounds. As a consequence, based on the fact that the 
aromatic core and the proximal part of the piperazine moiety within the molecule 
remained equal, the reason for the differences in affinity arises from the spacer type 
and its connection to the monomers. The spacers within this series of compounds 
contain a piperazine- or a homopiperazine-component that is linked to the piperazine-
moiety of the respective monomers by amide coupling with a dioic acid. Due to the 
amide bond, the piperazine components lack a basic amine, what usually represents 
an important element for hH1R binding (e.g. protonated amine-components of agonists 
and antagonists interacting with Asp3.32). (Ohta et al., 1994, Wieland et al., 1999, 
Jongejan et al., 2005) However, as amide bonds reveal a polar character, interaction 
with the amino acids in the binding pocket (e.g., water bridges) of the hH1R can be 
suggested, what could be an explanation for the improved interaction with the hH1R 
Chapter 4 
___________________________________________________________________ 
109 
 
compared to the recently described compounds linked by nonpolar alkyl spacers. 
SARs that can be related to a change of the substitution pattern occur only in 
tendencies, however, they are in general congruent with the findings within the 
corresponding group of monomers: compounds bearing four Cl substituents (225, 239) 
were slightly superior to compounds bearing only two (238, 241, 242) or even no Cl 
substituent (240). (Figure 4.11) 
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Figure 4.11. Comparison of the hH1R affinity of the corresponding monomeric and 
dimeric counterparts. 
 
The reported pharmacological effects at hH1R and hH4R are summarized in table 4.8.  
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R / R’ 
 
m 
 
n 
 pKi 
(hH1R) 
pKi 
(hH4R) 
H / H 1 2 240 6.18 ± 0.09 < 5 
8 / 8’ –Cl 1 2 241 6.54 ± 0.04 < 5 
7 / 7’ –Cl 1 2 242 5.95 ± 0.06 < 5 
3 / 3’ –Cl 1 2 238 6.33 ± 0.11 < 5 
8 / 8’ –Cl, 3 / 3’ –Cl 1 2 225 6.74 ± 0.10 < 5 
7 / 7’ –Cl, 3 / 3’ –Cl 1 2 239 6.77 ± 0.09 < 5 
7 / 7’ –Cl, 3 / 3’ –Cl 2 3 244 6.12 ± 0.05 < 5 
 
Table 4.8. hH1R-/ hH4R- competition binding data of dimeric dibenzo[b,f][1,4]- 
oxazepine derivatives linked by polar spacers. 
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4.4.1.3.3. Dibenzo[b,f][1,4]oxazepines linked by polar spacers of different type 
and length: compounds linked at the NH2 group in position 3 / 3’ 
Derived from the dibenzo[b,f][1,4]oxazepine compounds that carry an NH2 group in 
position 3 (128, 129, 136), a further series of dimeric compounds was prepared that 
were linked by different types of spacers. The spacers, consisting either of an alkyl 
chain or a piperazine or homopiperazine component, were linked to the respective 
monomeric compounds at the free amine in position 3 by amide coupling. As a 
consequence, the N-methylpiperazine moiety in the resulting molecules was not 
modified, providing the possibility to interact with the hH4R.  
A map of the molecules is shown in figure 4.12. 
 
Figure 4.12. Molecule map of the dibenzo[b,f][1,4]oxazepine derivatives linked by 
spacers containing alkyl chains or piperazine or homopiperazine components. 
 
Compared to the monomeric compounds 128 and 129, the affinity of the corresponding 
dimeric compounds (215, 227 – 231) to both, the hH1R and hH4R, was in all cases 
significantly decreased in a range of 1 to 1.5 log units (p < 0.0001). Compounds derived 
from 136 (221, 243) revealed – alike the monomeric compound – a very weak hH4R 
affinity and the hH1R affinity was decreased in a range of about 1 order of magnitude 
compared to the monomer. (Figures 4.13, 4.14) 
Regarding the hH1R, a slight preference could be determined for compounds bearing 
a homopiperazine spacer (229, 231): the observed pKi-values were significanty 
increased up to 0.5 log units compared to their analogues bearing a piperazine-spacer 
(230, 227) (p ( 227/231) = 0.0011; p (229/230) = 0.0153) With regard to the hH4R, Cl 
substitution in position 7 / 7’ (227, 231) again turned out to be slightly favourable for 
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hH4R affinity. This, in combination with a homopiperazine spacer (231) revealed a 
significantly increased hH4R affinity (p (227/231) < 0.0001; p (229/231) < 0.0001).  
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Figure 4.13. Comparison of the hH1R affinity of the corresponding monomeric and 
dimeric counterparts. 
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Figure 4.14. Competition binding assays at hH1R and hH4R for the corresponding 
monomeric and dimeric counterparts 129 and 231. 
 
The pharmacological data resulting from the competition binding assays at hH1R and 
hH4R are summarized in table 4.9. 
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R / R’ 
 
spacer 
 pKi 
(hH1R) 
pKi 
(hH4R) 
7 / 7’ –Cl  
 
215 5.15 ± 0.10 5.06 ± 0.18 
7 / 7’ –Cl 
 
227 6.17 ± 0.22 5.10 ± 0.09 
7 / 7’ –Cl 
 
231 6.64 ± 0.02 5.74 ± 0.21 
8 / 8’ –Cl 
 
229 6.64 ± 0.10 4.92 ± 0.15 
8 / 8’ –Cl 
 
230 6.34 ± 0.23 4.89 ± 0.12 
H / H 
 
221 7.08 ± 0.23 4.49 ± 0.15 
H / H 
 
243 6.84 ± 0.09 4.84 ± 0.13 
 
Table 4.9. hH1R-/ hH4R competition binding data of the dibenzo[b,f][1,4]-oxazepine 
derivatives linked by polar spacers at the free NH2 group in position 3 / 3’. 
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4.4.2. Isolated guinea pig ileum 
All compounds were additionally characterized at the isolated guinea pig ileum in the 
presence of histamine. In all cases, the concentration effect curve was shifted 
rightward and at higher antagonist concentrations (concentration depending on the 
compound), the maximum of the curve was depressed. Experimental details of the 
organ bath experiments were described in section 4.3.8. 
Figure 4.15 shows a histamine concentration-effect curve described above: the first 
curve on the left represents histamine in the absence of an antagonist, all further 
curves on the right represent the histamine concentration-effect curve in the presence 
of increasing concentrations of 141 (3.16 nM – 316 nM). From 31.6 nM on, a 
depression of the concentration effect curve can be observed.  
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Figure 4.15. Concentration effect curve of histamine revealing depression at higher 
concentrations of 141. 
 
4.4.2.1. Characterization of the mono, di, and acylamino substituted open 
compounds 
With intent to compare pA2 values on the same background, all pA2 values in the 
following were calculated via Schild plot analysis suggesting slope = 1. For cases in 
which the slope significantly differs from 1, more reliable pA2 values depending on the 
concentration range of the incubated antagonist were estimated in section 4.4.2.4 
(method A) and 4.4.2.5 (method B). 
Among the unsubstituted compounds 22, 23, 25, and 28, no distinct decrease of affinity 
to gpH1R was detected by replacing the N-methylpiperazine moiety by an 
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ethylenediamine moiety (22, 23), a fact that points out a less important role of the rigid 
basic amine structure in gpH1R binding. Again, compound 25 revealed the lowest 
gpH1R affinity among the compounds with modified ethylenediamine moiety. This was 
already observed in competition binding assays at hH1R, however, in a much more 
pronounced way. 
For the open compounds bearing an N-methylpiperazine moiety, the unsubstituted 
compound 28 serves as a reference due to its lack of substituent influences. Cl 
substitution in m-position at both the aniline and the benzoic acid moiety (73, 76) turned 
out to be beneficial for gpH1R affinity (p (73/28) < 0.0001, p (76/28) = 0.0014), affirmed 
by a distinct increase of the pA2 value. Among all open compounds, 73 marks the most 
potent representative, pointing out that a Cl substituent in m-position of the aniline 
moiety plays an important role in the ligand receptor interaction at gpH1R. A 
differentiation is necessary for Cl substitution in p-position: p-Cl substitution at the 
benzoic acid moiety proved to be advantageous for the gpH1R affinity (70), whereas 
p-Cl substitution at the aniline moiety was rather detrimental (67). In general it can be 
postulated, that p-substitution at the aniline moiety has a harmful effect on the gpH1R 
affinity, independent from the kind of the substituent (52, 64, 67). At the p-position of 
the benzoic acid moiety, all other substituents except Cl had no distinct influence on 
the pharmacological effect (56, 58). 
Open compounds bearing more than one substituent (62, 80, 103, 110, 111, 180, 181) 
showed – compared to the respective mono-substituted open compounds – either no 
or a slightly decreased pharmacological effect at gpH1R. Compounds 103 and 181 
(derived from 73) represent the most potent di-substituted open compounds, again 
emphasizing the gpH1R-advantageous effect of Cl substitution in m-position of the 
aniline moiety. By contrast, substituents in p-position of the aniline moiety again turned 
out to have very negative influence on the gpH1R affinity, most significant for 110 as 
weakest representative of the open compounds (p (110/28) = 0.0006). The discussed 
pharmacological effects are summarized in table 4.10. 
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   pA2 (gp-ileum), 
slope = 1 
 
R1 = H 
R2 = R3 = -CH3 
22 5.80 ± 0.05 
R1 = H 
R2 = R3 = -C2H5 
23 5.73 ± 0.09 
R1 = R2 = R3 = -CH3 25 5.21 ± 0.14 
 
 
H 28 5.87 ± 0.08 
p-NH2 52 5.03 ± 0.11 
p-Br 64 5.08 ± 0.06 
p-Cl 67 5.22 ± 0.10 
m-Cl 73 6.89 ± 0.07 
 
p-Cl 180 5.46 ± 0.10 
m-Cl 181 6.26 ± 0.07 
 
 
p-Br 62 5.59 ± 0.18 
p-Cl 80 4.95 ± 0.13 
m-Cl 103 6.22 ± 0.07 
 
 
p-NH2 56 5.56 ± 0.07 
p-CN 58 5.38 ± 0.08 
p-Cl 70 6.58 ± 0.07 
m-Cl 76 6.46 ± 0.03 
 
m-Cl 110 4.74 ± 0.12 
p-Cl 111 5.27 ± 0.10 
 
Table 4.10. pA2 values at the isolated guinea pig ileum (mono- and di-substituted open 
compounds). 
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The series of acylamino substituted compounds (99, 112 – 117) revealed pA2 values 
of only a moderate range (table 4.11). Unlike observed at the mono-substituted 
compounds, the position of the Cl substituent at the aniline moiety turned out to have 
no distinct influence on the pharmacological behaviour at gpH1R when combined with 
a bigger acylamino group in p-position of the benzoic acid moiety. For example, 99 
represents the most potent acylamino derivative, although a Cl substituent in the 
gpH1R-detrimental p-position of the aniline moiety is contained. Furthermore, 
compounds bearing a Cl substituent in the gpH1R-advantageous m-position of the 
aniline moiety (116, 117) did not show any improved affinity to the receptor. 
  
R1 
 
R2 
 pA2 (gp-ileum), 
slope = 1 
 
 
 
p-Cl 
 
99 5.81 ± 0.09 
p-Cl 
 
112 5.10 ± 0.16 
p-Cl 
 
114 5.06 ± 0.14 
p-Cl 
 
115 4.68 ± 0.19 
m-Cl 
 
116 5.24 ± 0.09 
m-Cl 
 
117 5.13 ± 0.14 
Table 4.11. pA2 values at the isolated guinea pig ileum (acylamino substituted 
compounds). 
 
4.4.2.2. Characterization of the closed dibenzo[b,f][1,4]-oxazepine derivatives 
With regard to the pA2 values, the dibenzo[b,f][1,4]-oxazepine derivatives were clearly 
superior to the corresponding open counterparts and the dimeric derivatives. For all 
determined SARs, the unsubstituted closed compound 141 serves as a reference 
(table 4.12). The insertion of an NH2 group in position 3 had a slightly detrimental 
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influence on the affinity to the gpH1R (136). Cl substitution in position 3 had beneficial 
effects (149), resulting in the most potent “ring-closed” VUF 6884 derivative at the 
isolated guinea pig ileum (p (149/141) = 0.0034). By contrast, Cl substitution in position 
8 and above all position 7 revealed detrimental effects (88, 92). For compound 88, this 
describes a discrepancy to the corresponding open counterpart 73. As already 
described for hH1R, a possible explanation could be, that due to the lack of rigidization 
of the two aromatic rings (aniline and benzoic acid moiety) substituents in m-position 
are – other than substituents in position 8 of a closed and thus rigid dibenzo[b,f][1,4]-
oxazepine ring system – able to possess different positions in the binding pocket. Di-
substitution had no effect on the pharmacological behaviour of the respective closed 
compounds (128, 158, 159), however, the striking decrease of gpH1R affinity detected 
for compound 129 can be explained with a combination of the two detrimental 
influences of a 3-NH2 group and a 7-Cl substituent (table 4.12). Compounds in which 
the N-methylpiperazine moiety was replaced by a piperazine-moiety showed – 
independent from the substitution pattern – a slight decrease in their affinity to gpH1R 
(193, 196, 232 – 235) (table 4.13). 
  
R 
 pA2  
(gp-ileum), slope = 1 
 
 
 
H 141 8.78 ± 0.04 
8-Cl 88 8.95 ± 0.09 
7-Cl 92 7.63 ± 0.06 
3-Cl 149 9.90 ± 0.12 
3-NH2 136 8.23 ± 0.06 
3-NH2, 7-Cl 129 7.88 ± 0.10 
3-NH2, 8-Cl 128 8.88 ± 0.06 
3-Cl, 8-Cl 158 8.78 ± 0.09 
3-Cl, 7-Cl 159 8.80 ± 0.09 
 
Table 4.12. pA2 values at the isolated guinea pig ileum (“ring-closed” compounds 
bearing an N-methylpiperazine moiety). 
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8-Cl: gpH1R ↑ 
  
R 
 pA2  
(gp-ileum), slope = 1 
 
 
H 233 7.77 ± 0.06 
8-Cl 234 8.64 ± 0.06 
7-Cl 235 7.97 ± 0.08 
3-Cl 232 8.91 ± 0.08 
3-Cl, 7-Cl 193 8.04 ± 0.04 
3-Cl, 8-Cl 196 8.59 ± 0.05 
 
Table 4.13. pA2 values at the isolated guinea pig ileum (“ring-closed” compounds 
bearing a piperazine moiety). 
 
In summary, the reported SARs of the open and “ring-closed” VUF 6884 derivatives at 
the isolated guinea pig ileum are shown in figure 4.16. 
 
                                                   
 
 
 
 
 
 
Figure 4.16. SARs of the open and “ring-closed” compounds at the isolated guinea pig 
ileum. 
 
 
 
 
rigid basic amine moiety: gpH1R - 
X = -CH3: gpH1R ↑ 
X =     -H: gpH1R ↓ (slightly) 
X = H: gpH1R ↓ 
2-Cl: gpH1R ↑ 
3-Cl:  gpH1R ↑  
3-CN: gpH1R - 
3-NH2:  gpH1R - 
ring fusion with oxygen: 
gpH1R ↑↑ 
7-Cl:  gpH1R ↓  
7-Br: gpH1R ↓ 
7-NH2:  gpH1R ↓ 
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4.4.2.3. Characterization of the dimeric dibenzo[b,f][1,4]-oxazepine derivatives 
The dimeric compounds revealed pA2 values in the center span between the “open” 
and the “ring-closed” compounds, reflected in pA2 values in a range of 5.93 – 7.89. 
Although the pA2 values were in all cases decreased compared to the respective 
monomeric “ring-closed” compounds, it can be suggested that the gpH1R is less 
sensitive to modifications of the molecule size (i.e., dimerization) than to modifications 
of the central heterocycle. Specific deflections between the different compounds 
(depending on the spacer type or the linking position) are discussed in the following. 
 
4.4.2.3.1. Dimeric “ring–closed” VUF 6884 derivatives linked by nonpolar alkyl 
spacers at the piperazine moiety 
Compared to the respective monomeric “ring-closed” compounds (158 and 159), all 
derived dimeric compounds (205 – 210, 212, 213) revealed a distinct decrease of 
affinity to the gpH1R, reflected in pA2 values in a range of 5.93 – 7.16. Independent of 
the substitution pattern a slight indisposition of compounds linked by spacers with n = 
8 (208, 210) could be observed: the detected pA2 values were by approximately 0.5 
orders of magnitude lower.  
By contrast, alike already observed in the binding studies at hH1R, compounds linked 
by a spacer with n = 7 (205, 206) revealed a dependence on the position of the Cl 
substituents: again, for substituents in position 7 / 7’ and 3 / 3’ (206) the hH1R affinity 
was by approximately 2 orders of magnitude higher compared to its 8 / 8’ and 3 / 3’ 
substituted analogue (205) (table 4.14) 
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R / R’ 
 
n 
 pA2 
(gp-ileum, slope = 1) 
8 / 8’ –Cl, 3 / 3’ –Cl 6 212 6.70 ± 0.08 
8 / 8’ –Cl, 3 / 3’ –Cl 7 205 6.75 ± 0.06  
8 / 8’ –Cl, 3 / 3’ –Cl 8 208 5.93 ± 0.08 
8 / 8’ –Cl, 3 / 3’ –Cl 10 207 6.14 ± 0.06 
7 / 7’ –Cl, 3 / 3’ –Cl 6 213 6.55 ± 0.06 
7 / 7’ –Cl, 3 / 3’ –Cl 7 206 7.21 ± 0.06 
7 / 7’ –Cl, 3 / 3’ –Cl 8 210 6.20 ± 0.06 
7 / 7’ –Cl, 3 / 3’ –Cl 10 209 6.49 ± 0.05 
 
Table 4.14. pA2 values at the isolated guinea pig ileum (dimeric “ring-closed” 
compounds linked by nonpolar alkyl spacers at the piperazine moiety). 
 
4.4.2.3.2. Dimeric “ring–closed” VUF 6884 derivatives linked by polar spacers at 
the piperazine moiety 
Among the group of the dimeric “ring-closed” VUF 6884 derivatives linked by polar 
spacers at the piperazine moiety, a preference of compounds bearing a 3 / 3’-Cl 
substituent was revealed, reflected in pA2 values in a range of 7.03 – 7.37 (225, 238, 
239, 244). Moreover, their gpH1R affinity was slightly superior compared to the above 
described dimeric “ring-closed” VUF 6884 derivatives linked by nonpolar alkyl spacers. 
Nevertheless, with regard to the potency of the monomeric counterparts, a distinctly 
dropped gpH1R affinity was observed, reflected in a decrease of 1.5 – 2.5 log units. 
(Table 4.15) 
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R / R’ 
 
m 
 
n 
 pA2 
(gp-ileum, slope = 1) 
H / H 1 2 240 6.72 ± 0.06 
8 / 8’ –Cl 1 2 241 6.63 ± 0.05 
7 / 7’ –Cl 1 2 242 6.08 ± 0.08 
3 / 3’ –Cl 1 2 238 7.22 ± 0.04 
8 / 8’ –Cl, 3 / 3’ –Cl 1 2 225 7.44 ± 0.08 
7 / 7’ –Cl, 3 / 3’ –Cl 1 2 239 7.15 ± 0.08 
7 / 7’ –Cl, 3 / 3’ –Cl 2 3 244 7.12 ± 0.06 
 
Table 4.15. pA2 values at the isolated guinea pig ileum (dimeric “ring-closed” 
compounds linked by polar spacers at the piperazine moiety). 
 
4.4.2.3.3. Dimeric “ring–closed” VUF 6884 derivatives linked at the NH2 group in 
position 3 / 3’ 
Except from compound 215, the dimeric “ring-closed” VUF 6884 derivatives linked at 
the NH2 group in position 3 / 3’ revealed pA2 values in a range ≥ 6.7. Regarding the 
substitution pattern, a slight preference for compounds bearing an 8 / 8’-Cl substituent 
was observed. Moreover, in direct comparison of two compounds bearing the same 
substitution pattern that differ only in their spacer type (piperazine vs. homo-
piperazine), a preference for the homopiperazine spacer type was shown (227 / 231, 
229 / 230, 221 / 243).  
The drop of gpH1R affinity compared to the corresponding monomeric “ring-closed” 
VUF 6884 derivatives adds up to 1 – 1.5 log units. This is less distinct than described 
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for dimeric compounds linked at the piperazine moiety in comparison to their 
monomeric counterparts. (Table 4.16) 
 
 
R / R’ 
 
spacer 
 pA2 
(gp-ileum, slope = 1) 
7 / 7’ –Cl  
 
215 6.04 ± 0.11 
7 / 7’ –Cl 
 
227 6.70 ± 0.10 
7 / 7’ –Cl 
 
231 7.22 ± 0.10 
8 / 8’ –Cl 
 
229 7.99 ± 0.03 
8 / 8’ –Cl 
 
230 7.56 ± 0.08 
H / H 
 
221 7.05 ± 0.06 
H / H 
 
243 7.14 ± 0.05 
 
Table 4.16. pA2 values at the isolated guinea pig ileum (dimeric “ring-closed” 
compounds linked at the NH2 group in position 3 / 3’). 
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4.4.2.4. Estimating the pA2 values for compounds with slope significantly ≠ 1 
(method A) 
A series of compounds revealed a slope that was significantly ≠ 1 in the Schild plot. 
Thus, the Schild plot is not suitable to calculate the pA2 values. For these compounds 
pA2 values had to be estimated for every concentration range using the following 
formula: 
KB =  
c(B)
(r − 1)
 
pA2 (estimated) = log KB   
 
KB   dissociation constant (antagonist to receptor) 
c(B)   concentration of the antagonist 
r   10 ΔpEC50 
ΔpEC50  pEC50 (His) – pEC50 (His/B)* 
 
(* = with pEC50(His) measured in the absence and pEC50(His/B) in the presence of a defined 
concentration c of antagonist B) 
 
The calculations of method A do not include concentration ranges with depression (< 
95%) of the maximal effect of the histamine dose-response curve (higher 
concentrations of the incubated antagonist; concentration differs from compound to 
compound). As a consequence, the estimated and the calculated pA2 values were 
determined only for lower concentration ranges without depression of the maximal 
effect.  
In the following table, the differences between the estimated pA2 values (slope ≠ 1) of 
each single concentration and the calculated pA2 values (slope = 1) are listed (table 
4.17) 
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Cpd. no 
depression 
c(B) 
depression 
c(B) 
pA2 
(estimated) 
n pA2  
(calculated) 
slope 
52 1 µM > 100 µM 5.83 ± 0.33 6 5.19 ± 0.12 0.40 
3.16 µM 5.19 ± 0.47 4 
10 µM 5.28 ± 0.20 6 
31.6 µM 4.33 ± 0.15 3 
100 µM 4.75 ± 0.16 4 
64* 1 µM > 3.16 µM 5.77 ± 0.09 3 5.24 ± 0.33 1.65 
3.16 µM 4.44 ± 0.06 2 
73 100 nM > 3.16 µM 7.16 ± 0.29 5 7.08 ± 0.06 0.74 
316 nM 7.02 ± 0.33 5 
1 µM 7.15 ± 0.19 5 
3.16 µM 6.84 ± 0.19 5 
76* 1 µM > 3.16 µM 6.68 ± 0.10 6 6.55 ± 0.05 0.47 
3.16 µM 6.42 ± 0.14 6 
80 316 nM > 31.6 µM 6.08 ± 0.29 4 5.22 ± 0.18 0.01 
1 µM 5.78 ± 0.36 3 
3.16 µM 4.98 ± 0.52 5 
10 µM 4.80 ± 0.44 4 
31.6 µM 4.04 ± 0.06 2 
99 316 nM > 3.16 µM 6.14 ± 0.23 3 5.87 ± 0.23 -0.04 
1 µM 5.93 ± 0.00 1 
3.16 µM 5.02 ± 0.00 1 
110 1 µM > 100 µM 5.30 ± 0.35 6 4.76 ± 0.17 0.31 
3.16 µM 5.18 ± 0.16 2 
10 µM 4.89 ± 0.29 4 
31.6 µM 4.18 ± 0.26  4 
100 µM 4.39 ± 0.15 2 
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114 316 nM > 10 µM 6.19 ± 0.18 4 5.48 ± 0.17 0.19 
1 µM 5.05 ± 0.28 3 
3.16 µM 5.45 ± 0.43 4 
10 µM 4.73 ± 0.02 2 
115 1 µM > 10 µM 5.89 ± 0.07 3 5.16 ± 0.20 -0.16 
3.16 µM 4.93 ± 0.54 4 
10 µM 4.73 ± 0.46 3 
141 3.16 nM > 316 nM 8.97 ± 0.19 6 8.89 ± 0.04 0.85 
10 nM 8.98 ± 0.05 6 
31.6 nM 8.85 ± 0.07 4 
100 nM 8.91 ± 0.35 3 
316 nM 8.67 ± 0.28 3 
149 0,316 nM > 3.16 nM 9.34 ± 0.22 5 9.59 ± 0.10 1.67 
1 nM 9.70 ± 0.19 4 
3.16 nM 10.00 ± 0.09 2 
158 0.316 nM > 31.6 nM 9.26 ± 0.44 4 8.86 ± 0.12 0.48 
1 nM 9.05 ± 0.19 4 
3.16 nM 8.69 ± 0.44 6 
10 nM 8.80 ± 0.49 3 
31.6 nM 7.74 ± 0.00 1 
207 100 nM > 10 µM 6.48 ± 0.13 4 5.93 ± 0.08 0.70 
316 nM 5.77 ± 0.35 5 
1 µM 5.96 ± 0.33 5 
3.16 µM 5.73 ± 0.34 5 
10 µM 5.76 ± 0.12 3 
208 100 nM > 3.16 µM 6.58 ± 0.26 4 6.17 ± 0.07 0.61 
316 nM 6.11 ± 0.29 7 
1 µM 6.21 ± 0.22 7 
3.16 µM 5.82 ± 0.12 4 
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215 31.6 nM > 10 µM 6.90 ± 0.32 4 6.14 ± 0.12 0.50 
 100 nM 6.72 ± 0.36 4 
316 nM 5.70 ± 0.56 4 
1 µM 5.90 ± 0.22 4 
3.16 µM 5.85 ± 0.09 4 
10 µM 5.68 ± 0.02 3 
221 31.6 nM > 10 µM 7.24 ± 0.37 4 7.08 ± 0.06 0.85 
100 nM 7.21 ± 0.22 4 
316 nM 7.16 ± 0.13 4 
1 µM 6.96 ± 0.25 4 
3.16 µM 6.88 ± 0.34 4 
10 µM 6.99 ± 0.04 3 
225 10 nM > 316 nM 7.97 ± 0.27 2 7.37 ± 0.08 0.68 
31.6 nM 7.19 ± 0.02 2 
100 nM 7.26 ± 0.18 7 
316 nM 7.34 ± 0.27 6 
227 10 nM > 1 µM 7.89 ±  0.39 5 6.96 ±  0.12 0.33 
 31.6 nM 7.19 ±  0.23 4 
100 nM 6.81 ±  0.36 5 
316 nM 6.77 ±  0.16 5 
1 µM 6.32 ±  0.42 4 
235 1 nM > 316 nM 8.76 ± 0.39 6 8.11 ± 0.09 0.59 
 3.16 nM 8.54 ± 0.20 6 
10 nM 7.87 ± 0.55 4 
31.6 nM 7.91 ± 0.25 6 
100 nM 7.78 ± 0.24 6 
316 nM 7.54 ± 0.17 3 
243 31.6 nM > 10 µM 7.53 ± 0.30 4 7.23 ± 0.06 0.85 
 100 nM 7.38 ± 0.36 4 
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316 nM 7.23 ± 0.21 4 
1 µM 7.18 ± 0.10 4 
3.16 µM 6.91 ± 0.23 3 
10 µM 7.77 ± 0.07 3 
 
* as for compounds 64 and 76 no depression of the concentration – effect curve was observed only 
within two concentration ranges, a Schild plot analysis is not realizable. Within the observed 
concentration ranges, the pA2 is estimated to be < 5.0 for compound 64 and ≤ 6.5 for compound 76. 
Table 4.17. Comparison of the estimated and the calculated pA2 values (n = number 
of experiments). 
 
Depending on the concentration of the antagonist, the estimated pA2 values are settled 
in a broad range that often differ a lot from the calculated values. Moreover, due to the 
strict restriction criteria of method A, many experimental data had to be excluded and 
did not contribute to the pharmacological overall view of the characterized compounds. 
Although the estimation of pA2 values at different concentrations according to method 
A provides a more detailed insight into the pharmacological effects of the characterized 
compounds above all at lower antagonist concentrations, a further method B was 
pursued to include the pharmacological data detected within higher antagonist 
concentrations. 
 
4.4.2.5. Estimating the pA2 values for compounds with slope significantly ≠ 1 
(method B) 
The previously described method A to determine the estimated pA2 values for 
compounds with slope significantly ≠ 1 revealed some specific disadvantages. For 
example, a huge amount of pharmacologically valuable data had to be excluded from 
the calculations due to the depression of the maximal effect of the concentration – 
effect curve (Emax < 95%). Moreover, as a consequence of this limitation, for some 
compounds the actual concentration range to estimate the pA2 value comprised at 
most one log unit in the lower section. The resulting Schild plots revealed to some 
extent a negative slope and were thus not suitable to draw a significant conclusion. 
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With intent to provide more reliable estimated pA2 values, a further method B was 
pursued: therefore, the focus was set on the rightward shift of the concentration – effect 
curves. In case of a significant rightward-shift (in general ≥ 0.5 log units), all 
concentration ranges were included in the calculations regardless of a potential 
depression of the maximal effect. If at all, the lowest concentration ranges were 
excluded from the calculations due to the lack of control organs and significant 
rightward shifts of the concentration–effect curves (< 0.5 log units). Although at higher 
concentrations a significant rightward shift of the concentration–effect curve is assured, 
in some cases the highest concentration ranges had to be excluded from the 
calculations due to a huge depression of the maximal effect (Emax < 10%).  
The resulting Schild plots of the majority of compounds still revealed a slope 
significantly ≠ 1, however, the analyzed data to estimate the pA2 values are settled in 
a central and thus more reliable concentration range. The results of this alternate 
method B to estimate the pA2 value will be summarized in the following table (4.18). A 
more detailed table comprising the rightward shift of the concentration–effect curves 
and the resulting pA2 values sorted by the concentration range will be given for one 
representative compound (73) in table 4.19. Moreover, the results of the two different 
methods A and B to estimate the pA2 values including the resulting Schild plots will be 
discussed. 
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Cpd. c(B) pA2 
(estimated) 
n pA2 
(calculated) 
slope intercept 
(absc.) 
pA2 
(est.) 
52 31.6 µM 4.51 ± 0.38 4 4.52 ± 0.09 0.72 4.73 < 5.0 
100 µM 4.73 ± 0.14 6 
316 µM 4.23 ± 0.25 4 
64* 10 µM 5.00 ± 0.26 4 4.90 ± 0.09 0.62 5.00 < 5.0 
31.6 µM 4.80 ± 0.25 4 
73 316 nM 7.24 ± 0.25 3 6.90 ± 0.07 0.75 7.37 ≤ 7.0 
1 µM 7.15 ± 0.19 5 
3.16 µM 6.84 ± 0.19 5 
10 µM 7.03 ± 0.22 6 
31.6 µM 6.43 ± 0.43 5 
76 1µM 6.68 ± 0.10 6 6.47 ± 0.03 0.86 6.69 ≤ 6.5 
3.16 µM 6.42 ± 0.14 6 
10 µM 6.47 ± 0.12 6 
31.6 µM 6.38 ± 0.27 6 
100 µM 6.36 ± 0.10 6 
80 10 µM 5.14 ± 0.03 2 4.69 ± 0.12 0.83 4.74 < 5.0 
31.6 µM 4.68 ± 0.10 4 
100 µM 4.74 ± 0.33 6 
99 1 µM 6.02 ± 0.07 3 5.71 ± 0.09 0.80 5.85 < 5.5 
3.16 µM 5.46 ± 0.06 3 
10 µM 5.54 ± 0.10 3 
31.6 µM 5.80 ± 0.00 1 
110 31.6 µM 4.69 ± 0.32 4 4.62 ± 0.07 0.99 4.63 < 5.0 
100 µM 4.49 ± 0.15 4 
316 µM 4.66 ± 0.23 5 
114 10 µM 4.64 ± 0.10 4 4.55 ± 0.06 0.82 4.55 < 5.0 
31.6 µM 4.60 ± 0.35 4 
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100 µM 4.40 ± 0.02 4 
115 3.16 µM 4.48 ± 0.24 2 4.66 ± 0.12 0.96 4.65 < 5.0 
10 µM 4.87 ± 0.24 5 
31.6 µM 4.20 ± 0.31 2 
100 µM 4.74 ± 0.15 2 
141 3.16 nM 8.97 ± 0.29 6 8.78 ± 0.04 0.82 9.22 ˃ 8.5 
10 nM 8.98 ± 0.06 6 
31.6 nM 8.88 ± 0.07 6 
100 nM 8.95 ± 0.25 6 
316 nM 8.81 ± 0.25 7 
1 µM 8.77 ± 0.15 6 
3.16 µM 8.71 ± 0.22 6 
10 µM 8.17 ± 0.23 6 
149** 1 nM 9.70 ± 0.17 5 10.13 ± 0.09 
  
1.00 10.14 ˃ 10.0 
3.16 nM 9.96 ± 0.32 5 
10 nM 10.51 ± 0.55 5 
31.6 nM 10.82 ± 0.12 5 
100 nM 10.24 ± 0.10 5 
316 nM 9.69 ± 0.40 5 
1 µM 9.84 ± 0.09 3 
158 1 nM 9.05 ± 0.19 4 8.74 ± 0.09 0.72 9.12  ˃ 8.5 
3.16 nM 8.80 ± 0.33 5 
10 nM 8.93 ± 0.48 4 
31.6 nM 8.86 ± 0.19 5 
100 nM 8.61 ± 0.53 5 
316 nM 8.17 ± 0.12 2 
207 1 µM 5.96 ± 0.33 5 5.83 ± 0.08 0.84 5.89 ˃ 5.5 
3.16 µM 5.73 ± 0.34 5 
10 µM 5.81 ± 0.14 4 
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208 316 nM 6.17 ± 0.26 6 6.06 ± 0.06 0.72 6.13 ≤ 6.0 
1 µM 6.21 ± 0.22 7 
3.16 µM 5.96 ± 0.32 5 
10 µM 5.84 ±0.23 4 
215 1 µM 5.90 ± 0.22 4 5.73 ± 0.05 0.73 5.91 ˃ 5.5 
3.16 µM 5.85 ± 0.09 4 
10 µM 5.67 ± 0.03 4 
31.6 µM 5.50 ± 0.22 4 
221 100 nM 7.21 ± 0.21 4 7.04 ± 0.06 0.85 7.22 ≥ 7.0 
316 nM 7.16 ± 0.13 4 
1 µM 6.96 ± 0.25 4 
3.16 µM 6.88 ± 0.39 4 
10 µM 6.98 ± 0.04 4 
225 100 nM 7.26 ± 0.18 7 7.32 ± 0.06 1.04 7.29 ˃ 7.0 
316 nM 7.39 ± 0.25 8 
1 µM 7.26 ± 0.28 7 
3.16 µM 7.37 ± 0.28 5 
227 316 nM 6.77 ± 0.16 5 6.40 ± 0.06 0.73 6.75 ˃ 6.0 
1 µM 6.43 ± 0.23 4 
3.16 µM 6.37 ± 0.15 5 
10 µM 6.30 ± 0.04 5 
31.6 µM 6.17 ± 0.22 6 
235 31.6 nM 7.91 ± 0.25 6 7.72 ± 0.06 0.85 7.91 ˃ 7.5 
100 nM 7.78 ± 0.24 6 
316 nM 7.53 ± 0.13 6 
1 µM 7.62 ± 0.15 4 
3.16 µM 7.66 ± 0.22 4 
243 100 nM 7.45 ± 0.12 3 7.04 ± 0.05 0.84 7.36 ≥ 7.0 
316 nM 7.23 ± 0.21 4 
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1 µM 7.18 ± 0.10 4 
3.16 µM 6.93 ± 0.19 4 
10 µM 7.03 ± 0.27 5 
31.6 µM 6.89 ± 0.16 5 
 
*   As for compound 64 a significant rightward shift of the concentration – effect curve was only observed 
within two concentration ranges, a Schild plot analysis is not realizable. Within the observed 
concentration ranges, the pA2 is estimated to be < 5.0.  
** The pA2 of compound 149 is most likely ≥ 10.0. Thus, further organ bath experiments at lower 
antagonist concentrations were performed in which a longer incubation time (˃ 15 min) prior to the 
experiment was carried out in order to achieve equilibrium conditions. However, despite the prolongued 
incubation time of 1 and 1.5 h, respectively, the pA2 of compound 149 remained on the same level 
(10.16 ± 0.05, slope = 0.7196) 
Table 4.18. Comparison of the estimated and the calculated pA2 values (method B); 
intercept (absc.): calculated intercept point of the Schild plot with the axis of abscissae 
(slope ≠ 1). 
 
With intent to give a closer insight into both method A and method B, for compound 73 
a more detailed derivation of the estimated pA2 value is provided in table 4.19. Herein, 
the restriction criteria of both methods (rightward shift (ΔpEC50, method B) and 
maximal effect (Emax, method A) of the concentration – effect curves) are listed and for 
each concentration range, the resulting pA2 value is quoted. Obviously, above all lower 
concentration ranges (100 nM – 316 nM) reveal a rather weakly pronounced rightward 
shift of the concentration effect curve, whereas at higher concentrations (˃ 1 µM) the 
rightward shift turns more and more distinct. In return, within lower concentration 
ranges almost no depression of the maximal effect is observed (< 10 µM). Higher 
concentrations ≥ 10 µM are always attended by a more or less frapping drop of the 
maximal effect of the concentration–effect curve. 
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  ΔpEC50 log (r-1) Emax pA2  (pA2)  ± SD slope pA2 
(est.) 
100 nM 0.51 0.36 99 7.36 7.29 ± 0.07 0.70 ≤ 7.0 
0.50 0.33 100 7.33 
0.42 0.21 97 7.21 
0.51 0.35 101 7.35 
0.43 0.23 99 7.23 
316 nM 0.45 0.26 100 6.76 7.04 ± 0.32 
0.43 0.23 100 6.73 
0.92 0.87 96 7.37 
0.95 0.89 98 7.39 
0.58 0.45 100 6.95 
1 µM 1.08 1.04 101 7.04 7.15 ± 0.19 
0.93 0.88 102 6.88 
1.29 1.26 98 7.26 
1.28 1.26 97 7.26 
1.34 1.32 99 7.32 
3.16 µM 1.47 1.45 96 6.95 6.84 ± 0.19 
1.57 1.56 98 7.06 
1.12 1.09 97 6.59 
1.23 1.20 96 6.70 
1.40 1.38 97 6.88 
10 µM 2.38 2.38 93 7.38 7.03 ± 0.22 
1.84 1.83 92 6.83 
1.80 1.80 91 6.80 
1.92 1.91 84 6.91 
2.10 2.09 86 7.09 
2.16 2.15 86 7.15 
31.6 µM 1.92 1.91 70 6.41 6.43 ± 0.43 
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2.22 2.21 66 6.71 
1.49 1.47 74 5.97 
1.57 1.56 50 6.06 
2.50 2.50 77 7.00 
100 µM 2.32 2.32 15 6.32 6.30 ± 0.13 
2.46 2.46 1 6.46 
2.23 2.23 14 6.23 
2.17 2.17 11 6.17 
 
Table 4.19. Detailed derivation of the estimated pA2 value of compound 73. 
 
The disparity of the different methods becomes more clear by analyzing the resulting 
Schild plots shown in figure 4.17: A. represents the Schild plot comprising all 
concentration ranges (100 nM – 100 µM), B. represents the Schild plot resulting from 
method A (concentration ranges without depression of the maximal effect, 100 nM – 
3.16 µM) and C. represents the Schild plot resulting from method B (concentration 
ranges with significant rightward shift of the concentration–effect curve, 316 nM – 31.6 
µM). 
Whereas method A focuses on a fairly small region settled at the lower border of the 
whole concentration range and thus excludes the results of more than one third of the 
experiments, method B comprises a broader field of pharmacological valuable data. 
These are settled above all in the center span of the whole concentration range. With 
intent to draw reliable pharmacological conclusions regarding the pA2 values of 
compounds with slope ≠ 1 in the Schild plot, a combination of both methods A and B 
represents a suitable approach. Therefore, the calculations are based on the centrally 
located concentration ranges with significant rightward shift of the concentration–effect 
curve that reveal an Emax ≥ 10 %. 
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Figure 4.17. Comparison of the Schild plots of compounds 73 resulting from the 
different methods to determine a reasonable pA2 value. 
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4.4.2.6. Comparison of the pKi (hH1R) and the pA2 (gp-ileum) 
The SARs determined at hH1R and gpH1R are – as reported in the previous sections 
– in general very similar. Nevertheless, with regard to, e.g., the substitution pattern of 
the open compounds, the gpH1R turned out to be more permissive than hH1R. Due to 
species differences between the hH1R and the gpH1R and the disparity of the testing 
systems (competition binding assay vs. organ bath experiments), the pA2 values 
determined at gpH1R were in the majority of cases higher than the pKi values 
determined at hH1R. However, exceptions and specific deflections within the different 
series of compounds will be discussed in the following.  
 
4.4.2.6.1. “Open” VUF 6884 derivatives 
All open compounds were characterized to have pKi values at hH1R in a range of 3.22 
– 6.07, whereas the pA2 values determined at the isolated guinea pig ileum (gpH1R) 
were settled in a range of 4.76 – 7.08. In all cases, the pA2 values were higher than 
the pKi values, what is most pronounced for compounds 25, 62, 111, and 115 (Δ ≥ 1.5 
log units, p < 0.0001). In general, the difference between the determined pA2 and pKi 
values is reflected in a range of 0.5 – 1.8 log units (figure 4.18). 
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Figure 4.18. Comparison of the pKi and the pA2 values at hH1R and gpH1R; linear fit, 
R2 = 0.7437; slope = 1.19 ± 0.15; dotted line: line of identity. 
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4.4.2.6.2. “Ring–closed” VUF 6884 derivatives 
Among the series of the “ring-closed” VUF 6884 derivatives the comparison of the pKi 
and the pA2 values revealed some specific particularities: as the pKi values were 
innately very high (7.66 – 9.25), the increase of pA2 values turned out to be less distinct 
than reported above for the series of the “open” compounds, reflected in a range of 
7.59 – 9.59.  No significant difference between the pKi and the pA2 could be determined 
for compounds 88, 232, and 235. Some compounds (92, 159, 193, 196, 233) revealed 
a pA2 value even lower than the pKi value (in a range of 0.2 – 0.7 log units). This is 
most significant for compounds bearing a Cl substituent in position 7 (92, 159, 193) 
(92: p = 0.0042; 159:  p < 0.0001; 193: p = 0.0247), what was already reported to have 
a more detrimental effect on the gpH1R than on the hH1R (figure 4.19). 
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Figure 4.19. Comparison of the pKi and the pA2 values at hH1R and gpH1R; linear fit, 
R2 = 0.4566; slope = 0.56 ± 0.17; dotted line: line of identity. 
 
4.4.2.6.3. Dimeric “ring-closed” VUF 6884 derivatives linked by nonpolar alkyl 
spacers at the piperazine moiety 
Within the series of the dimeric compounds linked by nonpolar alkyl spacers at the 
piperazine moiety the determined pA2 values (5.93 – 7.16) were in the majority of cases 
higher than the pKi values (5.02 – 7.44), reflected in a difference between pA2 and pKi 
values in a range of 0.7 – 1.2 log units. However, compound 206 marks an exception 
from these findings as the extraordinarily high pKi value of compound 206 could not to 
the same extent be reproduced at the isolated guinea pig ileum. The detected pA2 
value was by approximately 0.3 orders of magnitude lower than the pKi found in the 
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binding studies at hH1R. However, in both cases this compound is characterized by a 
significantly increased affinity to either the hH1R or the gpH1R compared to the spare 
compounds of this series (p < 0.0001) (figure 4.20). 
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Figure 4.20. Comparison of the pKi and the pA2 values at hH1R and gpH1R; linear fit, 
R2 = 0.6155; slope = 1.38 ± 0.45; dotted line: line of identity. 
 
4.4.2.6.4. Dimeric “ring–closed” VUF 6884 derivatives linked by polar spacers at 
the piperazine moiety 
Among the group of the dimeric “ring-closed” VUF 6884 derivatives linked by polar 
spacers at the piperazine moiety the pA2 values (6.06 – 7.37) were in a range of 0.1 – 
1.0 orders of magnitude higher than the determined pKi values (5.95 – 6.77). Whereas 
compounds 241 and 242 showed no distinct difference in their affinity to either the 
hH1R or the gpH1R (Δ ≈ 0.1), for compounds 238 and 244 a significant difference 
between the pA2 and the pKi value in a range of Δ ≈ 1.0 orders of magnitude was 
revealed (p < 0.0001). (Figure 4.21) 
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Figure 4.21. Comparison of the pKi and the pA2 values at hH1R and gpH1R; linear fit, 
R2 = 0.3411; slope = 0.39 ± 0.24; dotted line: line of identity. 
 
4.4.2.6.5. Dimeric “ring–closed” VUF 6884 derivatives linked at the NH2 group in 
position 3 / 3’ 
The group of the dimeric “ring-closed” VUF 6884 derivatives linked at the NH2 group in 
position 3 / 3’ is characterized by the highest affinity to the gpH1R among the dimeric 
molecules (pA2 values 6.14 – 7.89). Except from compound 215, that was already 
reported to have a significantly lower pKi value than the spare compounds within this 
series ((pKi (hH1R) = 5.15); p < 0.0001), all compounds revealed pA2 values ≥ 6.7. 
Compound 221 strikes with an equal affinity to the hH1R and the gpH1R. In general, a 
difference between the pA2 values and the pKi values in a range of 0.4 – 1.2 orders of 
magnitude is revealed. (Figure 4.22) 
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Figure 4.22. Comparison of the pKi and the pA2 values at hH1R and gpH1R; linear fit, 
R2 = 0.4481; slope = 0.76 ± 0.38; dotted line: line of identity. 
Chapter 4 
___________________________________________________________________ 
141 
 
4.4.2.6.6. Discussion 
The comparison of the pKi values determined at hH1R and the pA2 values determined 
at gpH1R revealed in the majority of cases that the characterized compounds were 
more affine to gpH1R than to hH1R (exceptions mentioned above). On the one hand, 
this can be related to the discrepancy of the testing systems and thus to the different 
conditions prevalent in the binding- and the organ bath assay, respectively. On the 
other hand, the different affinities can be traced back to species differences and as a 
consequence, to significant differences in the pharmacological properties of the 
receptors: within the TM regions, the identity of the amino acid sequence identity adds 
up to about 92 %, whereas, e.g., in the extracellular loops, the amino acid sequence 
identity of hH1R and gpH1R accounts for about 70 %. (Strasser et al., 2008, Strasser 
et al., 2013) In total, they show an overall sequence identity of about 72 %. (Strasser 
et al., 2008) As transmembrane and extracellular regions are involved in ligand binding 
(Ji et al., 1998), the discrepancies of the amino acid sequences within these regions 
are suggested to cause the determined deflections of the affinity to hH1R and gpH1R. 
 
 
4.4.3. Pharmacological characterization of selected compounds at dopamine, 
serotonin and muscarine receptors 
 
As clozapine is known to show affinity to several GPCRs (Baldessarini and 
Frankenburg, 1991), for clozapine as well as for selected open (67, 70, 73, 76, 56, 80, 
103, 99, 110, 111), closed (88, 92, 128, 129, 136, 141, 149, 158, 159), and dimeric 
compounds (205 – 210, 212, 213) competition binding assays at pD1 / hD1, hD2short, 
hD2long, hD3, hD4.4, p5-HT1A, p5-HT2, hM1, hM2 and hM3 receptors were performed in 
cooperation with Prof. Dr. Peter Gmeiner and Dr. Harald Hübner of the Friedrich 
Alexander University Erlangen. The experimental details were described in 4.3.9.1 
(dopamine and serotonin receptors) and 4.3.9.2 (muscarine receptors).  
The series of compounds with the pharmacologically most interesting and pronounced 
effects was, due to the analogy to the clozapine molecule, the monomeric closed 
dibenzo[b,f][1,4]-oxazepine derived series. For all SARs determined among this series, 
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the unsubstituted compound 141 serves as a reference. Interestingly, one specific SAR 
was observed for all dopamine, serotonin and muscarine receptors: the significant 
beneficial effect of a Cl substituent in position 8 (88). As clozapine bears the same 
substitution pattern, this part of the molecule is suggested to be – among others – 
responsible for its interaction with such a broad variety of GPCRs. Furthermore it is 
suggested, that alike already observed at histamine receptors (hH1R, hH4R, gpH1R), a 
closed central oxazepine ring plays an important role and is essential above all for the 
affinity to dopamine and serotonin receptors. 
As the plenty of compounds and receptor subtypes provides a huge amount of 
pharmacological data, the detailed pharmacological results for each compound and 
receptor subtype are summarized in tables 4.20 – 4.22. However, notable specific 
preferences of the respective receptor subtypes are reported in the following. 
 
4.4.3.1. Porcine and human dopamine receptors pD1 / hD1  
With regard to the porcine D1R, only the closed compounds evoked pharmacologically 
interesting effects on a moderate to high level depending on the substitution pattern. 
Modifications in position 3, either by the insertion of an NH2 group (136) or a Cl 
substituent (149, 159) led to a decrease in affinity. Cl substitution in position 7, 
however, slightly improved the affinity to the pD1R (92). Due to its apparent structural 
similarity to clozapine, compound 88 revealed the highest affinity to the pD1R. 
The dimeric compounds were characterized at the human D1R, however, the observed 
pharmacological effects were only of a lower range (pKi ≤ 5).  
 
4.4.3.2. Human dopamine receptors hD2short, hD2long and hD3  
The determined SARs at these three human dopamine receptors were in good 
agreement. Although the group of the open compounds in general turned out to have 
a very low affinity to the respective receptors, a beneficial effect of a Cl substituent in 
p- or m-position of the benzoic acid moiety was observed (70, 76). Among the dimeric 
compounds, independent of the substitution pattern a slight preference for compounds 
linked by a spacer with chain length n = 7 was observed (205, 206). Dimeric 
compounds linked by spacers with chain length n = 6 and n = 8 showed a dependence 
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on their substitution pattern (208, 212: beneficial effect of a Cl substituent in position 8 
/ 8’). 
Regarding the monomeric closed compounds, the insertion of an NH2 group in position 
3 was detrimental (129, 136). By contrast, Cl substitution in positions 3 (149), 7 (92) or 
8 (88, 158) increased the receptor affinity. Interestingly, the combination of substituents 
in position 3 and 7 led to a dropped affinity to the hD3R (128, 159). 
 
4.4.3.3. Human dopamine receptor hD4.4a 
The hD4.4R turned out to be very sensitive regarding modifications of the molecule size 
or the substitution pattern. In the group of the open compounds, only Cl substitution in 
p-position of the benzoic acid moiety was tolerated (70). Dimeric compounds showed 
in general a very weak affinity.  
With regard to the monomeric closed compounds, the insertion of an NH2 group in 
position 3 turned again out to be detrimental to the receptor affinity (136, 129). 
Compounds bearing a Cl substituent in position 8 (88, 128, 158) revealed an increased 
affinity to the hD4.4, however, further modifications of the substitution pattern had no 
effects.  
(a: the D4R shows polymorphism (VNTR) reflected in 2 – 11 repeats of 16 amino acid long sequences 
within the IL-3. The D4.4R represents the most frequently occurring type, bearing 4 repeats) 
 
4.4.3.4. Porcine serotonin receptors p5-HT1A and p5-HT2 
All “ring-closed” and dimeric compounds showed significantly lower affinity to the p5-
HT1A than to p5-HT2 receptor. Open and dimeric compounds showed almost no 
pharmacological effects at p5-HT1A (pKi ≤ 5), and with regard to the monomeric closed 
compounds substituents other than 8-Cl were not tolerated.  
Focussing on the p5-HT2, the open compounds again revealed almost no 
pharmacological effect. The dimeric compounds, however, showed in all cases a 
significantly higher affinity than to p5-HT1A. Among them, similar tendencies as already 
observed at human dopamine receptors hD2short, hD2long and hD3 (section 4.4.3.2) were 
exhibited: compounds linked by a spacer with chain length n = 7 (205, 206) showed, 
independent of the substitution pattern, a slightly increased affinity. Compounds linked 
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by spacers with chain length n = 6 and n = 8 showed a dependence on their substitution 
pattern (208, 212: increased affinity of compounds bearing Cl substituents in position 
8 / 8’). 
The group of the closed monomeric compounds moreover revealed beneficial effects 
for Cl substitution in position 3 (149, 158, 159) and 7 (92, 159). As in the majority of 
receptor subtypes characterized in this study, the insertion of an NH2 group in position 
3 decreased the affinity to p5-HT1A and p5-HT2 (136). 
 
4.4.3.5. Human muscarine receptors hM1, hM2 and hM3 
The role of the closed central oxazepine ring observed for dopamine and serotonin 
receptors turned out to be less important with regard to human muscarine receptors, 
what is reflected in a moderate affinity of all open compounds. This is emphasized by 
a further intriguing finding concerning the nature of the fusion atom between the two 
phenyl rings: whereas compound 88 (oxygen as fusion atom) was more affine than 
clozapine (CLO) (nitrogen as fusion atom) within the group of the dopamine and 
serotonin receptors, the human muscarine receptors revealed a preference for 
clozapine. As a consequence it can be suggested that the effects of oxygen as fusion 
atom (e.g., 3D structure of the molecule, electronic and steric effects) are of a 
secondary importance for the interaction with muscarine receptors. Modifications 
regarding the size of the molecule (e.g., dimerization), however, proved to have 
detrimental effects on the affinity (pKi ≤ 5). 
Focussing on the monomeric closed compounds, an interesting effect was observed: 
while being responsible for the significant decrease of affinity to all dopamine and 
serotonin receptors, the insertion of an NH2 group in position 3 proved to be beneficial 
for the affinity to all three human muscarine receptors (136, 128, 129).  
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←  closed  → 
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Table 4.21. Pharmacological data of selected “ring-closed” compounds at dopamine, 
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4.4.4. Functional assays at human histamine receptors: pharmacological 
results of steady state [33P]GTPase activity assays and [35S]GTPγS 
binding assays 
For all closed compounds as well as for the most promising dimeric compounds 
functional assays at hH1R and hH4R were performed. Furthermore, for a small series 
among this selection, selectivity investigations were performed with regard to the four 
human histamine receptor subtypes (hH1-4R). 
 
4.4.4.1. Steady-state [33P]GTPase activity assays at hH1R 
All assays were carried out using Sf9 cell membranes co-expressing hH1R and the 
regulator of G-protein coupling RGS4. Alike the results reported for the functional 
assays at gpH1R, all characterized compounds revealed a functional antagonism at 
hH1R that was determined in the “agonist mode” of the steady-state [33P]GTPase 
activity assay (figure 4.23).  
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Figure 4.23. Agonist mode of the steady-state [33P]GTPase activity assay at hH1R 
proving functional antagonism of the tested compounds 92 (7-Cl), 141 (not 
substituted), 149 (3-Cl), 159 (3-Cl, 7-Cl). 
 
In most cases the pKB values determined in the steady-state [33P]GTPase activity 
assays were lower than the pKi values determined in the binding studies at hH1R (table 
4.23). The SARs that were detected in the binding assays in dependence of the 
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substitution pattern could be reproduced, however, in a more alleviated way. Among 
the dimeric compounds, no distinct difference of affinity between compounds linked at 
the piperazine moiety (225, 239) and compounds linked at the free NH2 group in 
position 3 / 3’ (229, 231) could be observed.  
Figure 4.24 shows the data obtained in the antagonist mode of the steady-state 
[33P]GTPase activity assay for compounds 159, 193 and 239, as they form a 
successional series within the tested compounds. Both, 159 and its marginally 
modified analogue 193 revealed an almost identical pKB value (159: 7.97 ± 0.10; 193: 
7.81 ± 0.14), emphasizing a less important role of the basic piperazine-moiety. 
However, dimerization with a polar spacer (239) led to a significant decrease of the 
pKB value (239: 6.51 ± 0.20; p (239/159, 193) < 0.0001). 
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Figure 4.24. Antagonist mode of the steady-state [33P]GTPase activity assay at hH1R 
for compounds 159 (3-Cl, 7-Cl), 193 (piperazine bearing analogue of 159) and 239 
(dimeric analogue of 159, linked by a polar spacer); 10-10 molar ligand concentration + 
200 nM histamine was set to 100 %. 
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Cpd. pKia pKBb Hill slopeb 
88 8.19 ± 0.13 8.03 ± 0.20 -1.48 ± 0.65 
92 7.76 ± 0.11 7.85 ± 0.11 -0.96 ± 0.29 
128 8.18 ± 0.16 8.24 ± 0.20 -0.94 ± 0.31 
129 7.66 ± 0.19 7.71 ± 0.26 -0.69 ± 0.39 
141 8.16 ± 0.22 8.35 ± 0.26 -0.66 ± 0.18 
149 8.97 ± 0.04 8.67 ± 0.10 -1.10 ± 0.49 
158 8.52 ± 0.05 8.27 ± 0.25 -1.40 ± 0.68 
159 9.25 ± 0.16 7.97 ± 0.10 -1.04 ± 0.47 
193 8.23 ± 0.11 7.81 ± 0.14 -1.40 ± 0.37 
196 8.52 ± 0.03 8.26 ± 0.22 -0.98 ± 0.40 
225 6.74 ± 0.10 6.50 ± 0.14 -1.15 ± 0.26 
229 6.64 ± 0.10 6.59 ± 0.21 -0.69 ± 0.67 
231 6.64 ± 0.02 6.45 ± 0.11 -1.01 ± 0.31 
232 8.74 ± 0.08 8.39 ± 0.22 -1.06 ± 0.29 
233 7.96 ± 0.03 8.03 ± 0.16 -1.66 ± 0.44 
234 8.40 ± 0.02 8.20 ± 0.23 -1.29 ± 0.14 
235 8.04 ± 0.12 7.96 ± 0.24 -1.09 ± 0.22 
239 6.77 ± 0.09 6.51 ± 0.20 -1.18 ± 0.52 
 
Table 4.23. pKB values determined for selected compounds in the steady-state 
[33P]GTPase activity assay at hH1R + RGS4 (a = data obtained from the competition binding assay 
at hH1R + RGS4; b = data obtained from the steady-state [33P]GTPase activity assay at hH1R + RGS4) 
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4.4.4.2. [35S]GTPγS binding assays at hH4R 
With intent to get a closer insight into the functional activity of some selected 
compounds at hH4R, [35S]GTPγS binding assays were carried out using Sf9 cell 
membranes co-expressing hH4R + Gαi2 + Gβ1γ2. In all cases, a partial agonism could 
be observed, what is in good agreement with the data published for clozapine (Appl et 
al., 2012) and VUF 6884 (Smits et al., 2006). The partial agonistic effects (Emax) are 
quoted in relation to histamine that was determined at a concentration of 10 µM and 
set to 1.0. All compounds revealed partial agonistic effects in a range of 0.34 – 0.68 of 
the histamine effect. The pEC50 values detected in the [35S]GTPγS binding assays at 
hH4R were either lower or equal to the pKi values determined in the competition binding 
assays at hH4R. In addition to that, the SARs in dependence of the substitution pattern 
could be reproduced, above all with regard to the known hH4R beneficial Cl substitution 
in position 7 (92, 129, 159, 235). Figure 4.25 shows the [35S]GTPγS binding assay at 
hH4R for compounds 92, 129, 159, and 231, as they are all characterized by a Cl 
substituent in position 7 and a free N-methylpiperazine moiety. The most potent 
representative within this series, compound 159 (pEC50: 6.96 ± 0.15) additionally 
carries a Cl substituent in position 3. The insertion of an NH2 group (129) or the 
dimerization by spacers linked in this position (231) led to a decreased pEC50 value 
(129: 6.40 ± 0.13; 231: 5.73 ± 0.20). As expected, the exchange of the N-
methylpiperazine moiety by piperazine (193, 196, 232 – 235) had a detrimental effect 
on the hH4R affinity, reflected in pEC50 values decreased in a range of 0.5 – 1.0 log 
units. (Table 4.24) 
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Figure 4.25. [35S]GTPγS binding assay of compounds 92 (7-Cl), 129 (3-NH2, 7-Cl), 
159 (3-Cl, 7-Cl) and 231 (dimeric analogue of 129, linked in position 3) at hH4R. 
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Cpd. pKia pEC50b Emaxb, c 
88 6.64 ± 0.14 6.20 ± 0.05 0.55 ± 0.19 
92 6.99 ± 0.03 6.58 ± 0.19 0.45 ± 0.19 
128 6.11 ± 0.13 6.11 ± 0.16 0.35 ± 0.08 
129 6.48 ± 0.09 6.40 ± 0.13 0.35 ± 0.14 
141 6.19 ± 0.23 6.16 ± 0.04 0.62 ± 0.14 
149 6.13 ± 0.09 6.08 ± 0.05 0.68 ± 0.20 
158 6.27 ± 0.23 6.20 ± 0.24 0.57 ± 0.16 
159 6.96 ± 0.16 6.96 ± 0.15 0.55 ± 0.12 
193 5.92 ± 0.12 5.87 ± 0.12 0.50 ± 0.18 
196 5.62 ± 0.06 5.39 ± 0.09 0.48 ± 0.10 
231 5.74 ± 0.21 5.73 ± 0.20 0.61 ± 0.01 
232 5.35 ± 0.03 5.35 ± 0.19 0.40 ± 0.07 
233 5.33 ± 0.16 5.21 ± 0.15 0.37 ± 0.09 
234 6.08 ± 0.06 5.76 ± 0.10 0.38 ± 0.12 
235 6.57 ± 0.16 6.11 ± 0.07 0.34 ± 0.11 
 
Table 4.24. pEC50 values and Emax data determined for selected compounds in the 
[35S]GTPγS binding assay at hH4R + Gαi2 + Gβ1γ2; (a = data obtained from the competition binding 
assay at hH4R + Gαi2 + Gβ1γ2; b = data obtained from the [35S]GTPγS binding assay at hH4R + Gαi2 + Gβ1γ2; c = the 
efficacy of histamine was determined at a concentration of 10 µM and set to 100 % (= 1.0). 
 
4.4.4.3. [35S]GTPγS binding assays at hH2R and hH3R (selectivity studies) 
With regard to the human histamine receptor subtype selectivity, [35S]GTPγS binding 
assays at hH2R and hH3R were performed. Therefore, Sf9 cell membranes co-
expressing hH2R-GsαS and hH3R + Gαi2 + Gβ1γ2 were used, respectively. All 
characterized compounds revealed an inverse agonism at both the hH2R and the 
hH3R. The determined pEC50 values at either the hH2R or the hH3R were significantly 
lower than the pKB and pEC50 values detected in the steady-state [33P]GTPase activity 
assay at hH1R and in the [35S]GTPγS binding assay at hH4R, indicating a distinct 
preference for the target receptors. The inverse agonistic efficacies (inv. eff.) are 
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quoted in relation to histamine that was determined at a concentration of 10 µM and 
set to 1.0. As a result, all compounds revealed inverse agonistic efficacies in a range 
of -0.31 to -0.15 at hH2R and -0.39 to -0.19 at hH3R. Interestingly, compound 128 
revealed the highest inverse agonistic efficacy to both the hH2R and the hH3R, whereas 
compound 136 revealed in both cases the lowest inverse agonistic efficacies. 
Moreover, compound 159 turned out to have the highest potencies at hH2R and hH3R, 
however, regarding the high hH1R and hH4R affinity (pKB (hH1R) = 7.54 ± 0.10; pEC50 
(hH4R) = 6.96 ± 0.15), a selectivity towards the target receptors is still given. (Figures 
4.26, 4.27, table 4.25) 
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Figure 4.26. [35S]GTPγS binding assay of compounds 129 (3-NH2, 7-Cl), 141 (no 
substitution), 149 (3-Cl) and 159 (3-Cl, 7-Cl) at hH2R-GsαS revealing an inverse 
agonism. 
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Figure 4.27. [35S]GTPγS binding assay of compounds 129 (3-NH2, 7-Cl), 141 (no 
substitution), 149 (3-Cl) and 159 (3-Cl, 7-Cl) at hH3R + Gαi2 + Gβ1γ2 revealing an inverse 
agonism. 
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Cpd. 
hH2R hH3R 
pEC50 Inv. eff.a pEC50 Inv. eff.a 
128 3.96 ± 0.11 -0.31 ± 0.03 3.73 ± 0.21 -0.39 ± 0.01 
129 4.37 ± 0.04 -0.24 ± 0.02 3.97 ± 0.11 -0.32 ± 0.03 
136 4.20 ± 0.05 -0.15 ± 0.03 4.42 ± 0.19 -0.19 ± 0.03 
141 3.98 ± 0.34 -0.26 ± 0.02 4.01 ± 0.08 -0.32 ± 0.03 
149 4.84 ± 0.10 -0.22 ± 0.06 4.40 ± 0.08 -0 28 ± 0.01 
158 4.74 ± 0.12 -0.21 ± 0.04 4.20 ± 0.17 -0.28 ± 0.01 
159 5.01 ± 0.06 -0.19 ± 0.02 4.46 ± 0.02 -0.26 ± 0.01 
 
Table 4.25. pEC50 values and Emax data determined for selected compounds in the 
[35S]GTPγS binding assay at hH2R-GsαS and hH3R + Gαi2 + Gβ1γ2; a the efficacy of 
histamine was determined at a concentration of 10 µM and set to 100 % (= 1.0). 
  
Chapter 4 
___________________________________________________________________ 
155 
 
4.5. Discussion 
4.5.1. Structure activity relationships of a selected core compound prevalent 
within all series: compounds bearing Cl substituents in position 3 and 7 / 
p- position of the aniline and the benzoic acid moiety (related to 159) 
The pharmacologically most promising compound 159 finds itself within all structurally 
modified series described above. In the course of the different structural conversions, 
specific structure-activity as well as structure-selectivity relationships could be 
observed that contribute to a better understanding of the interaction of VUF 6884 
derived ligands with the H1R and the H4R on a molecular level.   
As already reported in previous sections, Cl substitution in p-position of the aniline 
moiety revealed a beneficial effect on the affinity to the H4R. However, regarding the 
H1R affinity, no effect on the affinity related to the substituents could be observed. 
Moreover, the central molecule core lacks rigidization and thus the affinities remain in 
general on a moderate level (figure 4.28). 
 
180 pKi (hH1R) =         
4.74 ± 0.04 
pKi (hH4R) =          
5.60 ± 0.09 
pA2 (gpH1R) =      
5.75 ± 0.13 
 
Figure 4.28. Pharmacological data of compound 180 (“open” analogue of 159). 
The closure of the central oxazepine ring evokes an increase of affinity to the hH1R in 
a range of about 4.5 orders of magnitude and to the hH4R in a range of about 1.4 
orders of magnitude. With regard to the gpH1R, an increase of affinity of about 3 orders 
of magnitude was observed. These results point out that the part of the molecule 
marked in green (e.g., the central oxazepine ring) plays a key role in the ligand-receptor 
interaction (figure 4.29). 
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159 pKi (hH1R) =      
9.25 ± 0.16 
pKi (hH4R) = 
6.96 ± 0.16 
pA2 (gpH1R) =         
8.63 ± 0.13 
 
Figure 4.29. Pharmacological data of compound 159. 
But not only the central oxazepine ring plays an important role in the interaction with 
the target receptors, also the N-methylpiperazine moiety was found to be crucial at 
least for the affinity to the hH4R. When replaced by piperazine, the hH4R affinity drops 
down to almost the level of the “open” analogue. The affinity to the hH1R and the gpH1R 
was less affected, however, a decrease in a range of about one order of magnitude 
was observed (figure 4.30).  
 
193 pKi (hH1R) =      
8.23 ± 0.11 
pKi (hH4R) =    
5.92 ± 0.12 
pA2 (gpH1R) =       
7.97 ± 0.05 
 
Figure 4.30. Pharmacological data of compound 193 (piperazine-bearing analogue of 
159). 
With intent to address (homo- or hetero-) dimeric hH1Rs / hH4Rs and thus to increase 
the potency of compound 159, several attempts to obtain dimeric molecules were 
carried out modifying the spacer length within the molecule. However, the affinity of 
the resulting dimeric molecules to the target receptors was significantly decreased 
compared to the monomer 159. An exception marks 206, maintaining an H1R affinity 
(human and guinea pig) on a moderate high level: it is suggested that this compound 
addresses only monomeric H1Rs and additionally interacts with the extracellular 
surface of the H1R.  
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Regarding the hH4R, a complete loss of affinity was the consequence of the 
dimerization. This can be traced back to the important role of a (free) N-
methylpiperazine moiety in hH4R binding, as it is prevalent in the H4R antagonist 
JNJ7777120 (Jablonowski et al., 2003), in several 2-aminopyrimidines targeting the 
hH4R (Altenbach et al., 2008) as well as in the VUF6884 molecule (Smits et al., 2006). 
(Figure 4.31) 
 
213 n = 6 pKi (hH1R) =     
5.87 ± 0.16 
pKi (hH4R) =         
< 5 
pA2 (gpH1R) = 
6.67 ± 0.05 
206 n = 7 pKi (hH1R) =   
7.44 ± 0.16 
pKi (hH4R) =         
< 5 
pA2 (gpH1R) = 
7.16±  0.09 
210 n = 8 pKi (hH1R) =   
5.02 ± 0.20 
pKi (hH4R) =         
< 5 
pA2 (gpH1R) = 
6.22 ± 0.09 
209 n= 10 pKi (hH1R) =   
5.84 ± 0.09 
pKi (hH4R) =         
< 5 
pA2 (gpH1R) = 
6.54 ± 0.05 
 
Figure 4.31. Pharmacological data of compounds 206, 209, 210 and 213 (dimeric 
analogues of 159 linked by nonpolar alkyl-spacers). 
 
Although the H4R affinity was still on a very low level, the affinity to the H1R profited 
from the insertion of polar piperazine or homopiperazine bearing spacers. Besides, the 
hH1R revealed a slight preference for the piperazine-spacer type (239). (Figure 4.32) 
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239 
 
pKi (hH1R) =      
6.77 ± 0.09 
pKi (hH4R) =       
< 5 
pA2 (gpH1R) =       
7.03 ± 0.11 
244 
 
pKi (hH1R) =      
6.12 ± 0.05 
pKi (hH4R) =        
< 5 
pA2 (gpH1R) =       
7.12 ± 0.06 
 
Figure 4.32. Pharmacological data of compounds 239 and 244 (dimeric analogues of 
159 linked by polar spacers). 
 
The last series of dimeric compounds derived from 159 is characterized by a free N-
methylpiperazine moiety as the spacer is attached in position 3. Due to matters of 
synthesis, the 3-Cl substituent was replaced by an NH2 group that made it easier to 
create dimers linked at this position of the molecule. As expected, the H4R affinity 
returned to an at least 10 µM level. Both the H1R and the H4R revealed a preference 
for the homopiperazine spacer-type (231), reflected in an up to 0.5 orders of magnitude 
higher affinity. The use of a spacer without piperazine or homopiperazine moiety 
resulted in a significant decrease of affinity toward H1Rs irrespective of species (215) 
(p < 0.0001). (Figure 4.33) 
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215 
 
pKi (hH1R) =      
5.15 ± 0.10 
pKi (hH4R) =        
5.06 ± 0.18 
pA2 (gpH1R) =       
6.14 ± 0.12 
227 
 
pKi (hH1R) =      
6.17 ± 0.22 
pKi (hH4R) =        
5.10 ± 0.09 
pA2 (gpH1R) =       
6.96 ± 0.12 
231 
 
pKi (hH1R) =      
6.64 ± 0.02 
pKi (hH4R) =        
5.74 ± 0.21 
pA2 (gpH1R) =       
7.06 ± 0.15 
Figure 4.33. Pharmacological data of compounds 215, 227 and 231 (dimeric 
analogues of 159 linked in position 3 / 3’). 
 
4.5.2. Structure activity relationships of H1R and H4R ligands 
Within this study, some specific structure activity relationships (SARs) for VUF 6884 
derived molecules were reported for H1R and H4R. As due to the continuous progress 
in pharmacological research (e.g., molecular modelling studies, scaffold hopping 
approaches) the four histamine receptors and their ligands have been intensively 
investigated throughout the last decades, a comparison of the results found in this work 
to previously described SARs of H1R- and H4R-ligands in literature will be given in the 
following. Moreover, as both H1R- and H4R-ligands reveal some key elements 
regarding their chemical structure, the SARs of these regions will find themselves in 
the spotlight of interest. 
Aromatic rings and a side chain with a basic nitrogen were found to be the essential 
pharmacophoric requirements for H1R antagonists. (Naruto et al., 1985, Ter Laak et 
al., 1995, Shishoo et al., 2000) These structural elements find themselves, e.g., in the 
well-known first generation H1R antagonists mepyramine and doxepin, in the second 
generation antagonist cetirizine as well as in clozapine and related molecules (VUF 
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6884 and -derivatives synthesized in this work) (Naruto et al., 1985, Wieland et al., 
1999, Smits et al., 2006, Shimamura et al., 2011). (Figure 4.34) 
 
Figure 4.34. Pharmacophoric requirements of H1R antagonists. (Naruto et al., 1985, 
Wieland et al., 1999, Smits et al., 2006, Shimamura et al., 2011) 
On a molecular level, an interaction of the positively charged amine moiety with Asp3.32 
in TM 3 of the H1R as well as an interaction of the aromatic rings with aromatic amino 
acids (Trp4.56, Phe6.52 and Phe6.55) in TM 4 and TM 6 is postulated. (Ohta et al., 1994, 
Wieland et al.,1999, Strasser et al., 2008a, Strasser et al., 2013, Wagner et al., 2014) 
Focusing on tricyclic H1R antagonists like doxepine or clozapine and analogues, an 
additional interaction of the hetero atom in the central heterocycle with the H1R is 
suggested: therein, a water molecule may act as hydrogen bond mediator between 
amino acids in the binding pocket of H1R (Thr3.37) and the hetero atom in the aromatic 
core of the respective ligand, what could be a possible explanation for the higher H1R 
affinity of “ring-closed” VUF 6884 derivatives compared to the corresponding “open” 
counterparts presented in this work. However, further studies have to be performed, in 
order to support this hypothesis. 
The introduction of Cl substituents at the aromatic rings of the VUF 6884 derivatives 
revealed that the H1R shows specific preferences for Cl substitution in position 3 / p-
position of the benzoic acid moiety and m-position of the aniline moiety: the H1R affinity 
of compounds bearing Cl substituents in these positions (p-position of the benzoic acid 
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moiety / position 3: 70, 149; m-position of the aniline moiety: 73) was distinctly 
increased compared to the corresponding unsubstituted counterparts (28, 141) (figure 
4.35). It may be speculated that the lipophilic character of a Cl substituent in these 
positions provides a further possibility to interact with amino acids of the H1R binding 
pocket. This is emphasized by the finding that within the series of the “open” 
compounds, Cl substituents in m-position of the aniline moiety are able to possess 
different positions in the binding pocket of H1R and thus reveal an increase in H1R 
affinity (see section 4.4.1.2). 
 
Figure 4.35. SARs of Cl substituents introduced at the aromatic rings of the VUF 6884 
derived molecules. 
Regarding the H4R, the SARs determined within this study are in good agreement with 
previously published data in literature, e.g., by Jablonowski et al. (2003), Terzioglu et 
al. (2004), Smits et al. (2006, 2008) and Altenbach et al. (2008). The therein described 
molecules reveal some specific key elements for the interaction with the H4R: an N-
methylpiperazine moiety, a lipophilic substituent located at the left ring of the aromatic 
core structure as well as a basic nitrogen. (Figure 4.36)  
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Figure 4.36. Pharmacophoric requirements and structural analogy of H4R antagonists 
/ inverse agonists 
The N-methylpiperazine moiety turned out to be crucial for H4R affinity as neither 
replacement by ethylenediamine-/ piperazine-elements nor connection to a spacer in 
this position was tolerated. This can be related to the recently described sensitivity of 
the H4R to steric effects in this position of the molecule. (Jablonowski et al., 2003, 
Terzioglu et al., 2004, Smits et al., 2006) (Figure 4.37) 
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Figure 4.37. Modifications of the N-methylpiperazine moiety proving a sensitivity of the 
H4R to steric effects in this region of the molecule. (Jablonowski et al., 2003, Terzioglu 
et al., 2004, Smits et al., 2006) 
 
With regard to the nature and the position of the lipophilic substituent at the left 
aromatic ring, Cl substituents were found to reveal the most pronounced SAR profile 
of the characterized compounds. (Jablonowski et al., 2003, Terzioglu et al., 2004, 
Smits et al., 2006) Focusing on clozapine derived compounds, a distinct preference for 
Cl substitution in position 7 was reported in literature, what is congruent with the 
findings of our group. (Smits et al., 2006) The replacement of the Cl substituent by, 
e.g., a Br substituent, as it was carried out for two representatives within the series of 
the “open” compounds (62, 64), led to no significant change of the hH4R affinity 
compared to the Cl substituted analogues (67, 80). This phenomenon was already 
observed within a SAR study of JNJ7777120 derived molecules. (Jablonowski et al., 
2003, Terzioglu et al., 2004) 
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As a result, the SARs of the VUF 6884 derived compounds characterized within this 
study are in good agreement with the data of common ligands described in literature 
for both, the H1R and the H4R. Nevertheless, our results contribute to a better 
understanding of histamine receptors as they widen the H4R-focused scope of Smits 
et al. (2006) to the H1R. Moreover, a broader range of structural modifications within 
the synthesized compounds is comprised: not only slightly modified VUF 6884 
derivatives were prepared (88, 92, 128, 129, 136, 141, 149, 158, 159, 193, 196, 232 – 
235) but also reduced (22, 23, 25, 28, 52, 56, 58, 62, 64, 67, 70, 73, 76, 80, 99, 103, 
110, 111, 112, 114 – 117, 180, 181) and distinctly enlarged analogues (205 – 210, 
212, 213, 215, 221, 225, 227, 229 – 231, 238 – 244). The pharmacological 
characterization of these compounds at both, the H1R and the H4R provides a closer 
insight into H1R and H4R on a molecular level und represents a reasonable approach 
on the way to the development of dual action H1R- / H4R-ligands.  
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5. Summary 
 
Derived from the atypical antipsychotic drug clozapine and its structurally optimized 
derivative VUF 6884, several series of differently modified analogues were prepared 
with intent to get a closer insight into the H1R and the H4R on a molecular level as well 
as to improve the affinity to this receptors.  
The synthesized compounds can be divided into three major groups (“truncated”, “ring-
closed” and “dimeric” VUF 6884 derivatives) that in turn are subdivided into smaller 
subgroups with different characteristic modifications. An overview is given in figure 5.1. 
The group of the truncated VUF 6884 derivatives is in general characterized by a ring 
opening of the central heterocycle, resulting in an increased flexibility of the two 
aromatic rings in the core of the molecule. Modifications regarding the rigid basic N-
methylpiperazine moiety, the substitution pattern or the size of the inserted 
substituents led to three subgroups referred to as “ethylenediamine“, “open” or 
“acylamino” group. All truncated VUF 6884 derivatives revealed a decreased affinity to 
both the H1R and the H4R compared to clozapine or VUF 6884. However, when 
substituted with chlorine, special positions in the molecule turned out to have specific 
beneficial effects on either the affinity to the H1R or the H4R: p-Cl substitution of the 
left aromatic ring (the “aniline moiety”) was found to improve H4R affinity, whereas p-
Cl substitution of the right aromatic ring (the “benzoic acid moiety”) revealed 
advantageous effects on the H1R affinity. Although all compounds among the 
“acylamino” group revealed rather weak affinity to the target receptors, the loss of 
affinity was more pronounced with regard to the H1R. This emphasizes the influence 
of substituents in p-position of the benzoic acid moiety on the interaction with the H1R. 
By contrast, among the “ethylenediamine” group, the dropped affinity toward the H4R 
is particularly striking. As a consequence, a dependence of the H4R affinity on the rigid 
basic N-methylpiperazine moiety is postulated. The group of the VUF derivatives is 
characterized by a closed central oxazepine ring, resulting in distinctly improved affinity 
to both the H1R and the H4R. The direct comparison to the corresponding “open” 
counterparts points out a key role of the closed central heterocycle in the ligand-
receptor interaction.  
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Figure 5.1. Overview of the structurally different clozapine derivatives synthesized in 
this work. 
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Two subgroups of “ring-closed” VUF 6884 derivatives were prepared differing in their 
piperazine moiety (referred to as piperazine and N-methylpiperazine group). Again, a 
dependence of the H4R affinity on the rigid basic N-methylpiperazine moiety was 
revealed: in all cases, the “ring-closed” VUF 6884 derivatives of the piperazine group 
showed a reduced H4R affinity compared to their “ring-closed” VUF 6884 derived 
counterparts of the N-methylpiperazine group. Moreover, the substituent-dependent 
structure-activity relationships (SARs) determined at the “open” counterparts could be 
proved: Cl substitution in position 3 improved the affinity to the H1R, whereas Cl 
substitution in position 7 improved the affinity to the H4R. A combination of Cl 
substituents in these two H1R- and H4R beneficial positions resulted in a new lead 
compound with distinctly improved affinity to both target receptors (compound 159, pKi 
(hH1R) = 9.25 ± 0.16, pKi (hH4R) = 6.96 ± 0.16)). With intent to address homo- and 
heterodimeric H1R- and H4Rs or extracellular binding sites of monomeric H1Rs and 
H4Rs and hence to evoke a further increase of affinity, based on this compound and 
derivatives thereof a third group of molecules was prepared, referred to as “dimeric” 
VUF 6884 derivatives. The resulting compounds are linked with different spacers (polar 
or nonpolar) in different positions of the molecule (piperazine moiety or NH2 group in 
position 3 / 3’). However, as the spacers turned out to be not of a sufficient length, an 
interaction with homo- or heterodimeric H1Rs / H4Rs was not achieved. 
The dimeric compounds linked at the piperazine moiety either by nonpolar or polar 
spacers are characterized by a distinct decrease of affinity to the H4R (pKi (hH4R) ≤ 5). 
This can again be traced back to the key role of the N-methylpiperazine moiety in H4R 
interaction: the spacers either bloc the methyl group or decrease the basicity of the 
nitrogen and thus reduce the affinity to the H4R. Moreover, as the H4R was found to be 
sensitive to steric effects at the N-methylpiperazine moiety, a negative influence on the 
H4R affinity is suggested. Regarding their H1R affinity, compounds linked by polar 
spacers are slightly superior, however, compared to their monomeric counterparts, a 
distinct decrease was revealed in all cases. Among the “dimeric” VUF 6884 derivatives 
linked at the NH2 group in position 3 / 3’ at least some showed a H4R affinity of a 
moderate range (pKi (hH4R) = 5 – 6) due to the free basic N-methylpiperazine moiety. 
The H1R affinity in turn is decreased in comparison to the monomeric counterparts and 
showed almost no dependence on the substitution pattern (compounds without Cl 
substitution as most H1R-potent representatives of this group). All compounds were 
additionally characterized at the isolated guinea pig ileum, however, the observed 
Chapter 6 
___________________________________________________________________ 
173 
 
SARs were comparatively equal to the findings in the hH1R binding assays. Due to 
species differences and the disparity of the testing systems, the pA2 values resulting 
from the organ bath experiments were mostly higher than the pKi values detected in 
the binding assays. Moreover, some selected compounds were characterized at 
dopamine, serotonin and muscarine receptors, as clozapine as so called “dirty drug” 
shows affinity to a broad variety of GPCRs, dopamine, serotonin, muscarine and 
histamine receptors included. As a result, the Cl substituent in position 8 was found to 
play an important role in the interaction with GPCRs other than histamine receptors. 
Taken together, due to the various structure modifications of the synthesized 
compounds, a detailed structure-activity relationship map of clozapine and its 
derivatives was set up in this work that contributes to a better understanding of the 
pharmacological profile on a molecular level. (Figure 5.2) Possible future investigations 
on this topic could start from further modifications of the aromatic core (e.g., insertion 
of heteroaromatic rings in the aniline or benzoic acid moiety) or from pursuing the 
dimerization strategy with optimized spacer length and type (e.g., inserting a further 
basic center in the spacer). 
 
 
                                                
 
 
 
Figure 5.2. SARs of VUF 6884 derived compounds (truncated, “ring-closed” and 
dimeric) at hH1R and hH4R 
 
rigid basic amine moiety:  hH1R ↑ , hH4R ↑ 
X = -CH3: hH1R -, hH4R ↑↑ 
X =   H:    hH1R -, hH4R ↓ 
dimerization: 
nonpolar spacers:    hH1R ↓↓, hH4R ↓↓↓ 
polar spacers:          hH1R ↓,   hH4R ↓↓↓ 
 
 
X = H: hH1R -, hH4R ↓ 
2-Cl: hH1R ↑ , hH4R ↓ 
3-Cl:  hH1R ↑ , hH4R ↓ 
3-CN: hH1R ↓ , hH4R ↓ 
3-NH2:  hH1R ↓ , hH4R ↓ 
dimerization: 
polar spacers: hH1R ↓,   hH4R ↓↓ 
ring fusion with oxygen: 
hH1R ↑, hH4R ↑ 
8-Cl: hH1R ↑ , hH4R - 
7-Cl:  hH1R ↓ , hH4R ↑ 
7-Br: hH1R ↓ , hH4R ↓ 
7-NH2:  hH1R ↓ , hH4R ↓ 
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6. Experimental section 
 
6.1. General chemical procedures 
Commercially available reagents were purchased from Acros Organics (Geel, 
Belgium), Sigma-Aldrich Chemie GmbH (München, Germany), TCI Europe GmbH 
(Eschborn, Germany), Activate Scientific GmbH (Prien, Germany) or Merck KGaA 
(Darmstadt, Germany) and used as received. Column chromatography was carried out 
using Merck silica gel Geduran 60 (0.063-0.200). Reactions were monitored by thin 
layer chromatography (TLC) on Merck silica gel 60 F254 aluminium sheets and spots 
were visualized with UV light at 254 nm. Nuclear Magnetic Resonance (1H-NMR and 
13C-NMR) spectra were recorded on a Bruker Avance 300 spectrometer using per-
deuterated solvents (CDCl3, DMSO-d6, CD3OD) (Deutero GmbH, Kastellaun, 
Germany). Nuclear Magnetic Resonance 2D spectra (HSQC, HMBC and COSY) were 
recorded using a Bruker Avance 400 spectrometer. The chemical shift δ is given in 
parts per million (ppm) with reference to the chemical shift of the residual protic solvent 
compared to tetramethylsilane (δ = 0 ppm). Multiplicities were specified with the 
following abbreviations: s (singlet), bs (broad singlet), d (doublet), t (triplet), q (quartet) 
and m (multiplet) as well as combinations thereof. The multiplicity of carbon atoms 
(13C-NMR) was determined by DEPT 135 and DEPT 90 (distortionless enhancement 
by polarization transfer): “+” primary and tertiary carbon atom (positive DEPT 135 
signal), “-“ secondary carbon atom (negative DEPT 135 signal), “quat” quaternary 
carbon atom. Mass spectrometry analysis (MS) was performed on a Finnigan MAT 95, 
a Finnigan SSY 710A and on a Finnigan ThermoQuest TSQ 7000 spectrometer. 
Melting points (mp) were measured on a BÜCHI B-545 melting point apparatus using 
an open capillary and are uncorrected. The elementary analysis (CHN) was performed 
with a Heraeus CHN Rapid. Chemical names were generated using ChemBioDraw 
Ultra 12.0. (Cambridgesoft). Purification of compounds 243 and 244 by preparative 
HPLC was performed by Dr. Rudolf Vasold and Simone Strauss (Institute of Organic 
Chemistry, Chair Prof. Dr. Burkhard König, University of Regensburg, Germany). 
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6.2. General procedure A: 
Preparation of compounds 22, 23, 25 
To a solution of N-phenylbenzamide in benzene, one equivalent of PCl5 was added 
and heated at reflux for 2 h. After cooling to room temperature the solvent and formed 
POCl3 was removed under reduced pressure. The residue was re-dissolved in 
benzene and a 2-fold excess of substituted ethylenediamine was added dropwise. 
After stirring for 2 h at room temperature the solution was left over night without stirring. 
The precipitated solid was filtered and washed with acetone and the combined washing 
solutions were concentrated and dried in vacuo over night. The residue was purified 
by chromatography over silica gel (EtOAc / 7 N NH3 in methanol (9 : 1)) to give 
compounds 22, 23 and 25 as colorless solids. 
 
(E)–N-(2-(Dimethylamino)ethyl)-N’-phenylbenzimidamide (22) 
 
C17H21N3 (M = 267.37 g/mol) 
22 was prepared according to general procedure A using N-phenylbenzamide (2.00 g, 
10.10 mmol) in 10 ml benzene and N,N-dimethylethylenediamine (1.80 g, 20.20 mmol) 
and was obtained as a colorless solid (0.35 g, 1.31 mmol, 12.9 % yield).  
C17H21N3 (M = 267.37 g/mol), mp 53.2 °C. 1H-NMR (300 MHz, CDCl3) δ 7.23 (s, 5H), 
δ 7.04 (t, 2H, J = 7.3Hz), δ 6.79 (t, 1H, J = 7.0Hz), δ 6.63 (d, 2H, J = 7.1Hz), δ 5.26 (s, 
1H), δ 3.57 (bs, 2H), δ 2.58 (bs, 2H), δ 2.26 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ 
157.80 (Cquat), 129.06 (+, 2 Ar-CH), 128.69 (+, 2 Ar-CH), 128.31 (+, Ar-CH), 128.18 (+, 
Ar-CH), 123.16 (+, 2 Ar-CH), 121.17 (+, 2 Ar-CH), 57.73 (-, CH2), 45.18 (+, 2 CH3), 
39.14 (-, CH2). ESI-MS m/z 268 [MH+]. CHN (C17H21N3) calc.: C 76.37; H 7.92; N 15.72; 
exp.: C 76.13; H 7.91; N 15.70. 
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(E)-N-(2-(Diethylamino)ethyl)-N’-phenylbenzimidamide (23) 
   
C19H25N3 (M = 295.42 g/mol) 
23 was prepared according to general procedure A using N-phenylbenzamide (4.00 g, 
20.28 mmol) in 16 ml benzene and N,N-diethylethylenediamine (4.71 g, 40.56 mmol) 
and was obtained as a colorless solid (0.38 g, 1.29 mmol, 6.4 % yield).  
C19H25N3 (M = 295.42 g/mol), mp 55.2 °C. 1H-NMR (300 MHz, CDCl3) δ 7.24 (s, 5H), 
δ 7.05 (s, 2H), δ 6.81 (s, 1H), δ 6.64 (s, 2H), δ 5.45 (s, 1H), 3.57 (bs, 2H), δ 2.75 (bs, 
2H), δ 2.59 (t, J = 5.1Hz, 4H), δ 1.05 (d, J = 5.8Hz, 6H). 13C-NMR (75 MHz, CDCl3) δ 
129.15 (Cquat), 128.67 (+, 2 Ar-CH), 128.36 (+, Ar-CH), 128.21 (+, Ar-CH), 123.12 (+, 
4 Ar-CH), 121.21 (+, 2 Ar-CH), 46.72 (-, 4 CH2), 11.75 (+, 2 CH3). ESI-MS m/z 296.1 
[MH+]. CHN (C19H25N3 ∙ 71  H2O) calc.: C 76.58; H 8.55; N 14.10; exp.: C 76.20; H 8.16; 
N 14.03. 
 
(E)-N-(2-(Dimethylamino)ethyl)-N-methyl-N’-phenylbenzimidamide (25) 
 
C18H23N3 (M = 281.40 g/mol) 
25 was prepared according to general procedure A using N-phenylbenzamide (2.50 g, 
12.68 mmol) in 10 ml benzene and N,N,N’-trimethylethylenediamine (2.59 g, 25.36 
mmol) and was obtained as a colorless solid (1.60 g, 5.69 mmol, 44.9 % yield).  
C18H23N3 (M = 281.40 g/mol), mp 58.1 °C. 1H-NMR (300 MHz, CDCl3) δ 7.20 (t, J = 
5.0Hz, 3H), δ 7.10 (d, J = 7.7Hz, 2H), δ 6.97 (m, 2H), δ 6.70 (t, J = 7.3Hz, 3H), δ 3.21 
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(s, 3H), δ 3.05 (bs, 2H), δ 2.48 (bs, 2H), δ 2.14 (m, 6H). 13C-NMR (75 MHz, CDCl3) δ 
151.40 (3 Cquat), 133.91 (+, 2 Ar-CH), 128.85 (+, 2 Ar-CH), 128.38 (+, Ar-CH), 128.01 
(+, Ar-CH), 122.99 (+, 2 Ar-CH), 120.77 (+, 2 Ar-CH), 59.37 (-, 2 CH2), 45.70 (+, 3 
CH3). ESI-MS m/z 282 [MH+]. CHN (C18H23N3) calc.: C 76.83; H 8.24; N 14.93; exp.: C 
76.64; H 8.09; N 15.17. 
 
6.3. General procedure B: 
Preparation of compounds 4, 45 – 47, 53, 59, 65, 68, 71, 74, 77, 100, 104, 
105, 176, 177 
To a solution of substituted aniline (10 mmol) and triethylamine (15 mmol) in 200 ml 
DCM, substituted benzoylchloride (12 mmol) was added under nitrogen atmosphere 
and vigorous stirring. After stirring at room temperature for 6 h the mixture was heated 
at reflux over night. The next day the mixture was cooled to room temperature, the 
solvent was removed under reduced pressure und the resulting solid was washed with 
3 M HCl. All compounds were re-crystallized from acetone and obtained as crystalline 
solids of different colours. 
N-Phenylbenzamide (4) 
 
C13H11NO (M = 197.23 g/mol) 
4 was prepared according to general procedure B using aniline (0.93 g, 10 mmol) and 
benzoylchloride (1.69 g, 12 mmol) and was obtained as colorless crystalline solid (1.20 
g, 6.08 mmol, 60.8 % yield).  
C13H11NO (M = 197.23 g/mol), mp 166.7 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.25 (s, 
1H), δ 7.96 (d, J = 6.7Hz, 2H), δ 7.78 (d, J = 8.4Hz, 2H), δ 7.56 (t, J = 6.9Hz, 3H), δ 
7.36 (m, 2H), δ 7.10 (t, J = 7.4Hz, 1H). EI–MS (m/z) 197.1 [M+•˙]. CHN (C13H11NO) 
calc.: C 79.16; H 5.62; N 7.10; exp.: C 78.90; H 5.50; N 7.14. 
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4-Cyano-N-phenylbenzamide (47) 
   
C14H10N2O (M = 222.24 g/mol) 
47 was prepared according to general procedure B using aniline (0.93 g, 10 mmol) and 
4-cyanobenzoylchloride (1.99 g, 12 mmol) and was obtained as a colorless crystalline 
solid (1.35 g, 6.07 mmol, 60.8 % yield).  
C14H10N2O (M = 222.24 g/mol), mp 180.4 °C. 1H-NMR (300 MHz, CDCl3) δ 7.98 (d, J 
= 8.5Hz, 2H), δ 7.80 (m, 3H), δ 7.63 (d, J = 7.8Hz, 2H), δ 7.40 (m, 2H), δ 7.20 (t, J = 
7.4Hz, 1H). ESI-MS m/z 223 [MH+]. CHN (C14H10N2O · 71  H2O) calc.: C 74.79; H 4.61; 
N 12.46; exp.: C 74.89; H 4.31; N 12.50. 
 
N-(4-Bromophenyl)benzamide (59) 
  
C13H10BrNO (M = 276.13 g/mol) 
59 was prepared according to general procedure B using 4-bromoaniline (1.72 g, 10 
mmol) and benzoylchloride (1.69 g, 12 mmol) and was obtained as a light rose 
crystalline solid (2.09 g, 7.57 mmol, 75.7 % yield).  
C13H10BrNO (M= 276.13 g/mol), mp 205.9 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.37 
(s, 1H), 7.95 (d, J = 6.8Hz, 2H), 7.77 (d, J = 8.9Hz, 2H), 7.56 (m, 5H). EI-MS m/z 51 
(8), 63 (3), 77 (39), 91 (3), 105 (100), 145 (1), 167 (1), 195 (1), 275 (22) M+•, 277 (21). 
CHN (C13H10BrNO) calc.: C 56.55; H 3.65; N 5.07; exp.: C 56.77; H 3.51; N 4.79. 
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N-(4-Chlorophenyl)benzamide (65) 
  
C13H10ClNO (M = 231.68 g/mol) 
65 was prepared according to general procedure B using 4-chloroaniline (1.27 g, 10 
mmol) and benzoylchloride (1.69 g, 12 mmol) and was obtained as a colorless 
crystalline solid (1.46 g, 6.30 mmol, 63.0 % yield).  
C13H10ClNO (M= 231.68 g/mol), mp 197.7 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.37 
(s, 1H), δ 7.95 (d, J = 6.8Hz, 2H), δ 7.82 (d, J = 8.9Hz, 2H), δ 7.57 (m, 3H), δ 7.41 (d, 
J = 8.9Hz, 2H). EI-MS m/z 94 (1), 105 (5), 139 (1), 231 (77) M+•, 249 (100) MNH4+, 251 
(32). CHN (C13H10ClNO) calc.: C 67.39; H 4.35; N 6.05; exp.: C 67.49; H 4.41; N 5.94. 
 
4-Chloro-N-phenylbenzamide (68) 
  
C13H10ClNO (M = 231.68 g/mol) 
68 was prepared according to general procedure B using aniline (0.93 g, 10 mmol) and 
4-chlorobenzoylchloride (2.10 g, 12 mmol) and was obtained as a colorless crystalline 
solid (1.57 g, 6.78 mmol, 67.8 % yield).  
C13H10ClNO (M = 231.68 g/mol), mp 200.9 °C. 1H-NMR (300 MHz, CDCl3) δ 7.82 (d, J 
= 8.6Hz, 2H), δ 7.74 (s, 1H), δ 7.62 (d, J = 7.6Hz, 2H), δ 7.47 (d, J = 8.7 Hz, 2H), δ 
7.43 – 7.34 (m, 2H), δ 7.17 (t, J = 7.4Hz, 1H). EI-MS m/z 94 (1), 105 (5), 139 (1), 231 
(77) M+•, 249 (100) MNH4+, 251 (32). CHN C13H10ClNO calc.: C 67.39; H 4.35; N 6.05; 
exp.: C 67.30; H 4.26; N 5.85. 
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N-(3-Chlorophenyl)benzamide (71) 
  
C13H10ClNO (M = 231.68 g/mol) 
71 was prepared according to general procedure B using 3-chloroaniline (2.56 g, 20 
mmol) and benzoylchloride (3.38 g, 24 mmol) and was obtained as a colorless 
crystalline solid (2.56 g, 11.0 mmol, 45.8 % yield).  
C13H10ClNO (M = 231.68 g/mol), mp 128.1 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.42 
(s, 1H), δ 7.96 (d, J = 10.1Hz, 3H), δ 7.72 (d, J = 9.3Hz, 1H), δ 7.57 (m, 3H), δ 7.39 (t, 
J = 8.1Hz, 1H) δ 7.16 (d, J = 8.0Hz, 1H). CI-MS m/z 105 (8) Ph-CO+, 232 (80) MH+, 
249 (100) MNH4+. CHN (C13H10ClNO) calc.: C 67.39; H 4.35; N 6.05; exp.: C 67.25; H 
4.40; N 5.88. 
 
3-Chloro-N-phenylbenzamide (74) 
    
C13H10ClNO (M = 231.68 g/mol) 
74 was prepared according to general procedure B using aniline (0.93 g, 10 mmol) and 
3-chlorobenzoylchloride (2.10 g, 12 mmol) and was obtained as a colorless crystalline 
solid (1.77 g, 7.64 mmol, 76.4 % yield).  
C13H10ClNO (M = 231.68 g/mol), mp 137.7 °C. 1H-NMR (300 MHz, CDCl3) δ 7.85 (t, J 
= 1.9Hz, 1H), δ 7.81 (s, 1H), δ 7.74 (d, J = 7.7Hz, 1H), δ 7.63 (d, J = 7.6Hz, 2H), δ 7.52 
(d, J = 8.9Hz, 1H), δ 7.40 (m, 3H), δ 7.17 (t, J = 7.4Hz, 1H). CI-MS m/z 139 (1), 215 
(1), 231 (4), 232 (33, MH+), 233 (6), 234 (10), 235 (1), 249 (100, MNH4+), 250 (14), 251 
(33), 252 (5), 266 (2). CHN (C13H10ClNO) calc.: C 67.39; H 4.35; N 6.05; exp.: C 67.46; 
H 4.40; N 6.05. 
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N-(4-Nitrophenyl)benzamide (45) 
   
C13H10N2O3 (M = 242.23 g/mol) 
45 was prepared according to general procedure B using 4-nitroaniline (1.38 g, 10 
mmol) and benzoylchloride (1.69 g, 12 mmol) and was obtained as a light brown 
crystalline solid. (1.41 g, 5.82 mmol, 58.2 % yield).  
C13H10N2O3 (M = 242.23 g/mol), mp 201.9 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.82 
(s, 1H), δ 8.28 (d, J = 9.3Hz, 2H), δ 8.07 (d, J = 9.3Hz, 2H), δ 7.98 (d, J = 6.9Hz, 2H), 
δ 7.60 (m, 3H). ESI-MS m/z 240.9 [(M-H)-]. CHN (C13H10N2O3) calc.: C 64.46; H 4.16; 
N 11.56; exp.: C 64.69; H 4.34; N 11.89. 
 
4-Nitro-N-phenylbenzamide (53) 
     
C13H10N2O3 (M = 242.23 g/mol) 
53 was prepared according to general procedure B using aniline (0.93 g, 10 mmol) and 
4-nitrobenzoylchloride (2.23 g, 12 mmol) and was obtained as a yellow crystalline solid 
(1.75 g, 7.22 mmol, 72.3 % yield).  
C13H10N2O3 (M = 242.23 g/mol), mp 218.8 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.57 
(s, 1H), δ 8.38 (d, J = 8.9Hz, 2H), δ 8.18 (d, J = 8.9Hz, 2H), δ 7.78 (d, J = 7.6Hz, 2H), 
δ 7.38 (t, J = 6.9Hz, 2H), δ 7.14 (t, J = 7.4Hz, 1H). ESI-MS m/z 242.9 [MH+]. CHN 
(C13H10N2O3) calc.: C 64.46; H 4.16; N 11.56; exp.: C 64.41; H 3.83; N 11.65. 
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N-(4-Bromophenyl)-4-nitrobenzamide (46) 
   
C13H9BrN2O3 (M = 321.13 g/mol) 
46 was prepared according to general procedure B using 4-bromoaniline (1.72 g, 10 
mmol) and 4-nitrobenzoylchloride (2.23 g, 12 mmol) and was obtained as a yellow 
crystalline solid. (0.93 g, 2.90 mmol, 29.0 % yield).  
C13H9BrN2O3 (M = 321.13 g/mol), mp 248.9 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.69 
(s, 1H), δ 8.38 (d, J = 8.9Hz, 2H), δ 8.18 (d, J = 8.9Hz, 2H), δ 7.77 (d, J = 8.9Hz, 2H), 
δ 7.57 (d, J = 8.9Hz, 2H). ESI-MS m/z 320.9 [(MH)-]. CHN (C13H9BrN2O3) calc.: C 
48.62; H 2.82; N 8.72; exp.: C 48.77; H 2.76; N 8.90. 
 
N-(4-Chlorophenyl)-4-nitrobenzamide (77) 
   
C13H9ClN2O3 (M = 276.68 g/mol) 
77 was prepared according to general procedure B using 4-chloroaniline (1.28 g, 10 
mmol) and 4-nitrobenzoylchloride (2.23 g, 12 mmol) and was obtained as a yellow 
crystalline solid (1.55 g, 5.60 mmol, 56.0 % yield).  
C13H9ClN2O3 (M = 276.68 g/mol), mp 231.0 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.69 
(s, 1H), δ 8.38 (d, 2H, J = 8.9Hz), δ 8.18 (d, 2H, J = 8.9Hz), δ 7.82 (d, 2H, J = 8.9Hz), 
δ 7.45 (d, 2H, J = 8.9Hz). CI-MS m/z 120 (3), 247 (57), 248 (9), 249 (20), 250 (3), 264 
(36), 265 (5), 266 (11), 276 (9), 277 (16, MH+), 278 (6), 279 (5), 294 (100, MNH4+), 295 
(14), 296 (33), 297 (4), 311 (4). CHN (C13H9ClN2O3) calc.: C 56.43; H 3.28; N 10.13; 
exp.: C 56.42; H 3.34; N 10.11. 
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N-(3-Chlorophenyl)-4-nitrobenzamide (100) 
   
C13H9ClN2O3 (M = 276.68 g/mol) 
100 was prepared according to general procedure B using 3-chloroaniline (6.38 g, 50 
mmol) and 4-nitrobenzoylchloride (11.13 g, 60 mmol) and was obtained as a light 
yellow crystalline solid (6.74 g, 24.36 mmol, 40.6 % yield).  
C13H9ClN2O3 (M = 276.68 g/mol), mp 105.9 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.76 
(s, 1H), δ 8.38 (d, J = 8.9Hz, 2H), δ 8.19 (d, J = 8.9Hz, 2H), δ 7.98 (t, J = 2.0Hz, 1H), 
δ 7.72 (d, J = 9.3Hz, 1H) δ 7.42 (t, J = 8.1Hz, 1H) δ 7.21 (d, J = 8.0Hz, 1H). EI-MS m/z 
50 (5), 75 (7), 76 (19), 92 (12), 104 (33), 120 (9), 134 (2), 150 (100), 276 (25) M+•, 278 
(8). CHN (C13H9ClN2O3) calc.: C 56.43; H 3.28; N 10.13; exp.: C 56.28; H 3.50; N 
10.13. 
 
3-Chloro-N-(4-nitrophenyl)benzamide (105) 
    
C13H9ClN2O3 (M = 276.68 g/mol) 
105 was prepared according to general procedure B using 4-nitroaniline (6.91 g, 50 
mmol) and 3-chlorobenzoylchloride (10.50 g, 60 mmol) and was obtained as light green 
crystalline solid (10.49 g, 37.91 mmol, 75.8 %).  
C13H9ClN2O3 (M = 276.68 g/mol), mp 195.3°C. 1H-NMR (300 MHz, DMSO-d6) δ 10.89 
(s, 1H), δ 8.28 (d, J = 9.3Hz, 2H), δ 8.06 (d, J = 9.3Hz, 3H), δ 7.94 (d, J = 7.8Hz, 1H), 
δ 7.72 (d, J = 9.0Hz, 1H), δ 7.60 (t, J = 7.9Hz, 1H). EI-MS m/z 75 (11), 76 (4), 111 (38), 
113 (12), 139 (100), 140 (7), 141 (30), 276 (9, M+•). CHN (C13H9ClN2O3) calc.: C 56.43; 
H 3.28; N 10.13; exp.: C 56.52; H 3.41; N 10.10. 
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4-Chloro-N-(4-nitrophenyl)benzamide (104) 
  
C13H9ClN2O3 (M = 276.68 g/mol) 
104 was prepared according to general procedure B using 4-nitroaniline (6.91 g, 50 
mmol) and 4-chlorobenzoylchloride (10.50 g, 60 mmol) and was obtained as green 
crystalline solid (12.11 g, 43.74 mmol, 87.5 % yield).  
C13H9ClN2O3 (M = 276.68 g/mol), mp 214.9 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.87 
(s, 1H), δ 8.28 (d, J = 9.3Hz, 2H), δ 8.04 (m, 4H), δ 7.65 (d, J = 8.6Hz, 2H). EI-MS m/z 
40 (23), 44 (100), 75 (10), 111 (33), 113 (11), 139 (96), 140 (8), 141 (31), 276 (6) M+˙. 
CHN (C13H9ClN2O3) calc.: C 56.43; H 3.28; N 10.13; exp.: C 56.47; H 3.47; N 9.98. 
 
4-Chloro-N-(4-chlorophenyl)benzamide (176) 
   
C13H9Cl2NO (M = 266.12 g/mol) 
176 was prepared according to general procedure B using 4-chloroaniline (2.55 g, 20 
mmol) and 4-chlorobenzoylchloride (4.20 g, 24 mmol) and was obtained as colorless 
crystalline solid (4.2 g, 15.78 mmol, 78.9 % yield).  
C13H9Cl2NO (M = 266.12 g/mol), mp 212.6 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.44 
(s, 1H), δ 7.98 (d, J = 8.6Hz, 2H), δ 7.81 (d, J = 8.9Hz, 2H), δ 7.62 (d, J = 8.6Hz, 2H), 
δ 7.42 (d, J = 8.9Hz, 2H). EI-MS m/z 265.0 [M+•]. CHN (C13H9Cl2NO) calc.: C 58.67; H 
3.41; N 5.26; exp.: C 58.52; H 3.50; N 5.11. 
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4-Chloro-N-(3-chlorophenyl)benzamide (177) 
  
C13H9Cl2NO (M = 266.12 g/mol) 
177 was prepared according to general procedure B using 3-chloroaniline (2.55 g, 20 
mmol) and 4-chlorobenzoylchloride (4.20 g, 24 mmol) and was obtained as colorless 
crystalline solid (1.89 g, 7.1 mmol, 35.5 % yield).  
C13H9Cl2NO (M = 266.12 g/mol), mp 114.6 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.48 
(s, 1H), δ 8.16 (d, J = 8.6Hz, 1H), δ 7.98 (m, 2H), δ 7.72 (d, J = 8.6Hz, 2H), δ 7.63 (d, 
J = 8.6Hz, 1H), δ 7.39 (t, J = 8.1Hz, 1H), δ 7.18 (d, J = 8.0Hz, 1H). EI-MS m/z 265.0 
[M+•]. CHN (C13H9Cl2NO) calc.: C 58.67; H 3.41; N 5.26; exp.: C 58.86; H 3.55; N 5.12. 
 
6.4. General procedure C:  
Preparation of compounds 28, 50, 55, 58, 61, 64, 67, 70, 73, 76, 79, 102, 
108, 109, 180, 181 
To a solution of N-phenylbenzamide (4, 45 – 47, 53, 59, 65, 68, 71, 74, 77, 100, 104, 
105, 176, 177) in acetonitrile and benzene (2 : 1) one equivalent of PCl5 was added 
and the mixture was heated at reflux for 2 h. After the completion of the reaction the 
solvent was removed under reduced pressure and the resulting very reactive 
imidchloride was used in the next step without further purification.  
To a solution of the imidchloride (1.5 mmol) and triethylamine (2.5 mmol) in acetonitrile 
and benzene (2:1), N-methylpiperazine (2.0 mmol) was added dropwise under 
vigorous stirring. The mixture was heated at reflux over night and the next day the 
solvent was removed under reduced pressure. The resulting solid was purified by 
column chromatography (ethyl acetate / methanol 1:1) and compounds 28, 50, 55, 58, 
61, 64, 67, 70, 73, 76, 79, 102, 108, 109, 180, 181 were obtained as solids of different 
colours. 
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(E)-N-((4-Methylpiperazin-1-yl)(phenyl)methylen)aniline (28) 
  
C18H21N3 (M = 279.38 g/mol) 
28 was prepared according to general procedure C from 4 (2.00 g, 10.14 mmol) in 
acetonitrile / benzene (90 ml) giving intermediate (E)-N-phenylbenzimidoyl chloride 
(2.18 g, 10.14 mmol) to which triethylamine (1.71 g, 16.9 mmol), N-methylpiperazine 
(1.35 g, 13.50 mmol) and acetonitrile / benzene (90 ml) were added to give 28 as 
colorless solid (1.33 g, 4.76 mmol, 46.9 % yield).  
C18H21N3 (M = 279.38 g/mol), mp 83.1 °C. 1H-NMR (300 MHz, CDCl3) δ 7.22 (m, 3H), 
δ 7.11 (m, 2H), δ 6.99 (m, 2H), δ 6.74 (t, J = 7.4Hz, 1H), δ 6.55 (d, J = 8.2Hz, 2H), δ 
3.47 (bs, 4H), δ 2.47 (bs, 4H), δ 2.35 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 160.48 
(Cquat), 150.97 (Cquat), 133.42 (Cquat), 129.08 (+, 2 Ar-CH), 128.63 (+, 2 Ar-CH), 128.18 
(+, Ar-CH), 128.13 (+, Ar-CH), 122.82 (+, 2 Ar-CH), 121.07 (+, 2 Ar-CH), 55.00 (-, 2 
Pip-CH2), 47.38 (-, 2 Pip-CH2), 46.21(+, CH3). ESI-MS m/z 280 [MH+]. CHN (C18H21N3) 
calc.: C 77.38; H 7.58; N 15.04; exp.: 77.12; H 7.84; N 14.86. 
 
(E)-4-((4-Methylpiperazin-1-yl)(phenylimino)methyl)benzonitrile (58) 
  
C19H20N4 (M = 304.39 g/mol) 
58 was prepared according to general procedure C from 47 (1.33 g, 6.00 mmol) in 
acetonitrile / benzene (60 ml) giving intermediate (E)-4-cyano-N-phenylbenzimidoyl 
chloride (1.44 g, 6.00 mmol) to which triethylamine (0.76 g, 7.50 mmol), N-
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methylpiperazine (0.60 g, 6.00 mmol) and acetonitrile / benzene (60 ml) were added 
to give 58 as a colorless foam (0.69 g, 2.27 mmol, 37.8 % yield).  
C19H20N4 (M = 304.39 g/mol), mp 131.4 °C. 1H-NMR (300 MHz, CDCl3) δ 7.53 (d, J = 
8.4Hz, 2H), δ 7.23 (d, J = 8.3Hz, 2H), δ 7.01 (t, J = 7.8 Hz, 2H), δ 6.77 (t, J = 7.4Hz, 
1H), δ 6.50 (d, J = 7.3Hz, 2H), δ 3.41 (bs, 4H), δ 2.46 (bs, 4H), δ 2.35 (s, 3H). 13C-
NMR (75 MHz, CDCl3) δ 158.28 (Cquat), 150.08 (Cquat), 138.25 (Cquat), 132.05 (+, 2 Ar-
CH), 129.76 (+, 2 Ar-CH), 128.45 (+, Ar-CH), 122.50 (+, 2 Ar-CH), 121.72 (+, 2 Ar-CH), 
118.16 (Cquat), 112.55 (Cquat, C≡N), 54.78 (-,2 Pip-CH2), 46.12 (+, CH3), 45.09 (-, 2 Pip-
CH2). ESI-MS m/z 304.9 [MH+]. CHN (C19H20N4 · ½ H2O) calc.: C 72.82; H 6.75; N 
17.88; exp.: C 72.51; H 6.47; N 17.78. 
 
(E)-4-Bromo-N-((4-methylpiperazin-1-yl)(phenyl)methylene)aniline (64) 
  
C18H20BrN3 (M = 358.28 g/mol) 
64 was prepared according to general procedure C from 59 (2.02 g, 7.32 mmol) in 
acetonitrile / benzene (60 ml) giving intermediate (E)-N-(4-bromophenyl)benzimidoyl 
chloride (2.15 g, 7.32 mmol) to which triethylamine (0.51 mmol, 5.00 mmol), N-
methylpiperazine (0.73 g, 7.32 mmol) and acetonitrile / benzene (60 ml) were added 
to give 64 as a colorless solid (0.62 g, 1.73 mmol, 23.7 % yield).  
C18H20BrN3 (M = 358.28 g/mol), mp 80.3 °C. 1H-NMR (300 MHz, CDCl3) δ 7.40 (s, 1H), 
δ 7.24 (d, J = 3.6Hz, 2H), δ 7.08 (d, J = 8.5Hz, 4H), δ 6.42 (d, J = 8.6Hz, 2H), δ 3.44 
(bs, 4H), δ 2.44 (bs, 4H), δ 2.34 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 160.68 (Cquat), 
150.09 (Cquat), 132.96 (Cquat), 131.07 (+, 2 Ar-CH), 128.95 (+, 2 Ar-CH), 128.41 (+, Ar-
CH), 127.04 (+, 2 Ar-CH), 124.55 (+, 2 Ar-CH), 113.88 (Cquat), 54.88 (-, 2 Pip-CH2), 
46.36 (-, 2 Pip-CH2), 46.07 (+, CH3). ESI-MS m/z 357.8 [MH+], 359.8. CHN (C18H20BrN3 
· ¾ H2O) calc.: C 58.15; H 5.83; N 11.30; exp.: C 58.29; H 5.54; N 11.11. 
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(E)-4-Chloro-N-((4-methylpiperazin-1-yl)(phenyl)methylene)aniline (67) 
  
C18H20ClN3 (M = 313.82 g/mol) 
67 was prepared according to general procedure C from 65 (1.39 g, 6.00 mmol) in 
acetonitrile / benzene (60 ml) giving intermediate (E)-N-(4-chlorophenyl)benzimidoyl 
chloride (1.50 g, 6.00 mmol) to which triethylamine (0.71 mmol, 7.00 mmol), N-
methylpiperazine (0.60 g, 6.00 mmol) and acetonitrile / benzene (60 ml) were added 
to give 67 according to general procedure as a colorless solid (0.61 g, 1.95 mmol, 32.6 
% yield).  
C18H20ClN3 (M = 313.82 g/mol), mp 74.1 °C. 1H-NMR (300 MHz, CDCl3) δ 7.24 (d, J = 
3.4Hz, 3H), δ 7.08 (d, J = 9.6Hz, 2H), δ 6.94 (d, J = 8.7Hz, 2H), δ 6.46 (d, J = 8.7Hz, 
2H), δ 3.43 (bs, 4H), δ 2.45 (bs, 4H), δ 2.34 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 
160.77 (Cquat), 149.67 (Cquat), 133.07 (Cquat), 128.96 (+, 2 Ar-CH), 128.85 (+, 2 Ar-CH), 
128.37 (+, Ar-CH), 128.15 (+, Ar-CH), 127.05 (+, 2 Ar-CH), 126.14 (Cquat), 124.04 (+, 
Ar-CH), 54.90 (-, 2 Pip-CH2), 46.10 (+, CH3), 45.88 (-, 2 Pip-CH2). ESI-MS m/z 313.9 
[MH+]. CHN (C18H20ClN3 · 101  H2O) calc.: C 68.45; H 6.45; N 13.30; exp.: C 68.45; H 
6.78; N 13.47. 
 
(E)-N-((4-Chlorophenyl)(4-methylpiperazin-1-yl)methylene)aniline (70) 
  
C18H20ClN3 (M = 313.82 g/mol) 
70 was prepared according to general procedure C from 68 (1.39 g, 6.00 mmol) in 
acetonitrile / benzene (60 ml) giving intermediate (E)-4-chloro-N-phenylbenzimidoyl 
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chloride (1.50 g, 6.00 mmol) to which triethylamine (0.71 mmol, 7.00 mmol), N-
methylpiperazine (0.60 g, 6.00 mmol) and acetonitrile / benzene (60 ml) were added 
to give 70 as a colorless solid (0.42 g, 1.33 mmol, 22.2 % yield).  
C18H20ClN3 (M = 313.82 g/mol), mp 68.1 °C. 1H-NMR (300 MHz, CDCl3) δ 7.21 (d, J = 
8.4Hz, 2H), δ 7.03 (m, 4H), δ 6.77 (t, J = 7.4Hz, 1H), δ 6.53 (d, J = 7.3Hz, 2H), δ 3.42 
(bs, 4H), δ 2.45 (bs, 4H), δ 2.34 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 159.32 (Cquat), 
150.67 (Cquat), 134.63 (Cquat), 131.83 (Cquat), 130.46 (+, 2 Ar-CH), 128.57 (+, 2 Ar-CH), 
128.33 (+, Ar-CH), 122.67 (+, 2 Ar-CH), 121.31 (+, 2 Ar-CH), 54.91 (-, 2 Pip-CH2), 
46.18 (+, CH3), 45.92 (-, 2 Pip-CH2). ESI-MS m/z 313.9 [MH+]. CHN (C18H20ClN3 · 101  
H2O) calc.: C 68.45; H 6.45; N 13.30; exp.: C 68.40; H 6.34; N 13.15. 
 
(E)-3-Chloro-N-((4-methylpiperazin-1-yl)(phenyl)methylene)aniline (73) 
  
C18H20ClN3 (M = 313.82 g/mol) 
73 was prepared according to general procedure C from 71 (0.30 g, 1.30 mmol) in 
acetonitrile / benzene (30 ml) giving intermediate (E)-N-(3-chlorophenyl)benzimidoyl 
chloride (0.33 g, 1.30 mmol) to which triethylamine (0.20 g, 2.00 mmol), N-
methylpiperazine (0.13 g, 1.30 mmol) and acetonitrile / benzene (30 ml) were added 
to give 73 according to general procedure as a colorless solid (0.08 g, 0.24 mmol, 18.5 
% yield).  
C18H20ClN3 (M = 313.82 g/mol), mp 156.2 °C. 1H-NMR (300 MHz, CDCl3) δ 7.26 (m, 
3H), δ 7.10 (d, J = 9.6Hz, 2H), δ 6.89 (t, J = 7.9Hz, 1H), δ 6.71 (d, J = 7.9Hz, 1H), δ 
6.59 (t, J = 2.0Hz, 1H), δ 6.39 (d, J = 8.6Hz, 1H), δ 3.50 (bs, 4H), δ 2.52 (bs, 4H), δ 
2.40 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 160.78 (Cquat), 152.40 (Cquat), 133.57 (Cquat), 
132.84 (Cquat), 129.06 (+, 2 Ar-CH), 128.89 (+, 2 Ar-CH), 128.40 (+, Ar-CH), 123.00 (+, 
2 Ar-CH), 121.06 (+, 2 Ar-CH), 54.84 (-, 2 Pip-CH2), 46.03 (+, CH3), 45.71 (-, 2 Pip-
CH2). ESI-MS m/z 313.9 [MH+]. CHN (C18H20ClN3 · ½ H2O) calc.: C 66.97; H 6.56; N 
13.02; exp.: C 66.99; H 6.48; N 12.94. 
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(E)-N-((3-Chlorophenyl)(4-methylpiperazin-1-yl)methylene)aniline (76) 
  
C18H20ClN3 (M = 313.82 g/mol) 
76 was prepared according to general procedure C from 74 (1.39 g, 6.00 mmol) in 
acetonitrile / benzene (60 ml) giving intermediate (E)-3-chloro-N-phenylbenzimidoyl 
chloride (1.50 g, 6.00 mmol) to which triethylamine (0.71 g, 7.00 mmol), N-
methylpiperazine (0.60 g, 6.00 mmol) and acetonitrile / benzene (60 ml) were added 
to give 76 as a colorless solid (0.87 g, 2.76 mmol, 45.9 % yield).  
C18H20ClN3 (M = 313.82 g/mol), mp 93.0 °C. 1H-NMR (300 MHz, CDCl3) δ 7.17 (m, 
3H), δ 7.00 (m, 3H), δ 6.77 (t, J = 7.4Hz, 1H), δ 6.54 (d, J = 8.1Hz, 2H), δ 3.45 (bs, 
4H), δ 2.48 (bs, 4H), δ 2.36 (s, 3 H). 13C-NMR (75 MHz, CDCl3) δ 158.74 (Cquat), 150.44 
(Cquat), 135.21 (Cquat), 134.34 (Cquat), 129.55 (+, 2 Ar-CH), 128.89 (+, 2 Ar-CH), 128.31 
(+, Ar-CH), 127.27 (+, 2 Ar-CH), 122.62 (+, Ar-CH), 121.45 (+, Ar-CH), 54.86 (-, 2 Pip-
CH2), 46.12 (+, CH3), 45.69 (-, 2 Pip-CH2). ESI-MS m/z 313.9 [MH+]. CHN (C18H20ClN3) 
calc.: C 68.89; H 6.42; N 13.39; exp.: C 68.56; H 6.44; N 13.37. 
 
(E)-N-((4-Methylpiperazin-1-yl)(phenyl)methylene)-4-nitroaniline (50) 
  
C18H20N4O2 (M = 324.38 g/mol) 
50 was prepared according to general procedure C from 45 (0.36 g, 1.50 mmol) in 
acetonitrile / benzene (30 ml) giving intermediate (E)-N-(4-nitrophenyl)benzimidoyl 
chloride (0.39 g, 1.50 mmol) to which triethylamine (0.25 g, 2.50 mmol), N-
methylpiperazine (0.20 g, 2.00 mmol) and acetonitrile / benzene (30 ml) were added 
to give 50 as a yellow hygroscopic foam (0.26 g, 0.79 mmol, 52.6 % yield).  
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C18H20N4O2 (M = 324.38 g/mol), mp 216.7 °C. 1H-NMR (300 MHz, CDCl3) δ 7.88 (d, J 
= 9.1Hz, 2H), δ 7.28 (m, 3H), δ 7.10 (d, J = 6.5Hz, 2H), δ 6.57 (d, J = 9.1Hz, 2H), δ 
3.49 (bs, 4H), δ 2.47 (bs, 4H), δ 2.35 (s, 3H). ESI-MS m/z 325 [MH+]. CHN (C18H20N4O2 
· ½ H2O) calc.: C 64.85; H 6.35; N 16.81; exp.: C 64.59; H 6.12; N 16.83. 
 
(E)-N-((4-Methylpiperazin-1-yl)(4-nitrophenyl)methylene)aniline (55) 
  
C18H20N4O2 (M = 324.38 g/mol) 
55 was prepared according to general procedure C from 53 (1.69 g, 7.00 mmol) in 
acetonitrile / benzene (60 ml) giving intermediate (E)-4-nitro-N-phenylbenzimidoyl 
chloride (1.82 g, 7.00 mmol) to which triethylamine (0.89 g, 8.75 mmol), N-
methylpiperazine (0.70 g, 7.00 mmol) and acetonitrile / benzene (60 ml) were added 
to give 55 according to general procedure as a yellow hygroscopic foam (1.51 g, 4.66 
mmol, 66.5 % yield).  
C18H20N4O2 (M = 324.38 g/mol), mp 146.5 °C. 1H-NMR (300 MHz, CDCl3) δ 8.09 (d, J 
= 8.8Hz, 2H), δ 7.30 (d, J = 8.7Hz, 2H), δ 7.01 (t, J = 7.8Hz, 2H), δ 6.77 (t, J = 7.4Hz, 
1H), δ 6.52 (d, J = 7.3Hz, 2H), δ 3.43 (bs, 4H), δ 2.48 (bs, 4H), δ 2.36 (s, 3H). ESI-MS 
m/z 324.9 [MH+]. CHN (C18H20N4O2 · ½ H2O) calc.: C 64.85; H 6.35; N 16.81; exp.: C 
64.69; H 6.29; N 17.03. 
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(E)-4-Bromo-N-((4-methylpiperazin-1-yl)(4-nitrophenyl)methylene)aniline (61) 
 
C18H19BrN4O2 (M = 403.27 g/mol) 
61 was prepared according to general procedure C from 46 (0.64 g, 2.00 mmol) in 
acetonitrile / benzene (30 ml) giving intermediate (E)-N-(4-bromophenyl)-4-
nitrobenzimidoyl chloride (0.68 g, 2.00 mmol) to which triethylamine (0.15 g, 1.50 
mmol), N-methylpiperazine (0.20 g, 2.00 mmol) and acetonitrile / benzene (30 ml) were 
added to give 61 as a yellow solid (0.38 g, 0.94 mmol, 47.1 % yield). 
C18H19BrN4O2 (M = 403.27 g/mol), mp 156.8 °C. 1H-NMR (300 MHz, CDCl3) δ 8.13 (d, 
J = 8.8Hz, 2H), δ 7.29 (d, J = 8.8Hz, 2H), δ 7.11 (d, J = 8.6Hz, 2H), δ 6.39 (d, J = 
8.6Hz, 2H), δ 3.40 (bs, 4H), δ 2.45 (bs, 4H), δ 2.34 (s, 3H). ESI-MS m/z 404.8 [MH+]. 
CHN (C18H19BrN4O2 · H2O) calc.: C 51.32; H 5.02; N 13.30; exp.: C 51.33; H 4.77; N 
13.14. 
 
(E)-4-Chloro-N-((4-methylpiperazin-1-yl)(4-nitrophenyl)methylene)aniline (79) 
  
C18H19ClN4O2 (M = 358.2 g/mol) 
79 was prepared according to general procedure C from 77 (16.42 g, 59.35 mmol) in 
acetonitrile / benzene (300 ml) giving intermediate (E)-N-(4-chlorophenyl)-4-
nitrobenzimidoyl chloride (17.50 g, 59.30 mmol) to which triethylamine (7.10 g, 70.00 
mmol), N-methylpiperazine (5.94 g, 59.3 mmol) and acetonitrile / benzene (300 ml) 
were added to give 79 according to general procedure as a yellow hygroscopic foam 
(11.40 g, 31.77 mmol, 53.6 % yield).  
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C18H19ClN4O2 (M = 358.82 g/mol), mp 133.0 °C. 1H-NMR (300 MHz, CDCl3) δ 8.13 (d, 
J = 8.8Hz, 2H), 7.29 (d, J = 8.8Hz, 2H), 6.96 (d, J = 8.7Hz, 2H), 6.44 (d, J = 8.7Hz, 
2H), 3.45 (bs, 4H), 2.47 (bs, 4H), 2.36 (s, 3H). ESI-MS m/z 358.9 [MH+]. CHN 
(C18H19ClN4O2) calc.: C 60.25; H 5.34; N 15.61; exp.: C 60.33; H 5.51; N 15.61. 
 
(E)-3-Chloro-N-((4-methylpiperazin-1-yl)(4-nitrophenyl)methylene)aniline (102) 
  
C18H19ClN4O2 (M = 358.82 g/mol) 
102 was prepared according to general procedure C from 100 (6.00 g, 21.69 mmol) in 
acetonitrile / benzene (150 ml) giving intermediate (E)-N-(3-chlorophenyl)-4-
nitrobenzimidoyl chloride (6.40 g, 21.69 mmol) to which triethylamine (2.74 g, 27.11 
mmol), N-methylpiperazine (2.17 g, 21.69 mmol) and acetonitrile / benzene (150 ml) 
were added to give 102 as a yellow hygroscopic foam (2.97 g, 8.28 mmol, 38.2 % 
yield).  
C18H19ClN4O2 (M = 358.82 g/mol), mp 113.6 °C. 1H-NMR (300 MHz, CDCl3) δ 8.15 (d, 
J = 8.8Hz, 2H), δ 7.31 (d, J = 8.7Hz, 2H), δ 6.92 (t, J = 7.9Hz, 1H), δ 6.76 (d, J = 6.0Hz, 
1H), δ 6.58 (t, J = 2.0Hz, 1H), δ 6.35 (d, J = 8.9Hz, 1H), δ 3.49 (bs, 4H), δ 2.61 (bs, 
4H), δ 2.45 (s, 3H). ESI-MS m/z 358.9 [MH+]. CHN (C18H19ClN4O2 · H2O) calc.: C 
59.26; H 5.43; N 15.36; exp.: C 59.21; H 5.68; N 15.28. 
 
(E)-N-((3-Chlorophenyl)(4-methylpiperazin-1-yl)methylene)-4-nitroaniline (109) 
  
C18H19ClN4O2 (M = 358.82 g/mol) 
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109 was prepared according to general procedure C from 105 (8.48 g, 30.65 mmol) in 
acetonitrile / benzene (150 ml) giving intermediate (E)-3-chloro-N-(4-
nitrophenyl)benzimidoyl chloride (9.05 g, 30.65 mmol) to which triethylamine (3.88 g, 
38.31 mmol), N-methylpiperazine (3.07 g, 30.65 mmol) and acetonitrile / benzene (150 
ml) were added to give 109 as a yellow hygroscopic foam (4.47 g, 12.46 mmol, 40.7 
% yield).  
C18H19ClN4O2 (M = 358.82 g/mol), mp 107.9 °C. 1H-NMR (300 MHz, CDCl3) δ 7.92 (d, 
J = 9.0Hz, 2H), δ 7.23 (m, 2H), δ 7.14 (t, J = 1.7Hz, 1H), δ 6.96 (d, J = 7.4Hz, 1H), δ 
6.58 (d, J = 9.0Hz, 2H), δ 3.49 (bs, 4H), δ 2.53 (bs, 4H), δ 2.40 (s, 3H). ESI-MS m/z 
358.9 [MH+]. CHN (C18H19ClN4O2 · 31  H2O) calc.: C 59.26; C 5.43; N 15.36; exp.: C 
59.18; H 5.59; N 15.16. 
 
(E)-N-((4-Chlorophenyl)(4-methylpiperazin-1-yl)methylene)-4-nitroaniline (108) 
  
C18H19ClN4O2 (M = 358.82 g/mol) 
108 was prepared according to general procedure C from 104 (8.31 g, 30.03 mmol) in 
acetonitrile / benzene (150 ml) giving intermediate (E)-4-chloro-N-(4-
nitrophenyl)benzimidoyl chloride (8.86 g, 30.03 mmol) to which triethylamine (3.80 g, 
37.54 mmol), N-methylpiperazine (3.01 g, 30.03 g mmol) and acetonitrile / benzene 
(150 ml) were added to give 108 as a yellow hygroscopic foam (2.97 g, 8.27 mmol, 
27.5 % yield).  
C18H19ClN4O2 (M = 358.82 g/mol), mp 113.1 °C. 1H-NMR (300 MHz, CDCl3) δ 7.91 (d, 
J = 9.0Hz, 2H), δ 7.26 (t, J = 4.3Hz, 2H), δ 7.05 (d, J = 8.5Hz, 2H), δ 6.56 (d, J = 9.1Hz, 
2H), δ 3.50 (bs, 4H), δ 2.51 (bs, 4H), δ 2.38 (s, 3H). ESI-MS m/z 358.9 [MH+]. CHN 
(C18H19ClN4O2 · 31 H2O) calc.: C 59.26; H 5.43; N 15.63; exp.: C 59.24; H 5.51; N 15.33. 
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(E)-4-Chloro-N-((4-chlorophenyl)(4-methylpiperazin-1-yl)methylene)aniline (180) 
  
C18H19Cl2N3 (M = 348.27 g/mol) 
180 was prepared according to general procedure C from 176 (4.00 g, 15.03 mmol) in 
acetonitrile / benzene (105 ml) giving intermediate (E)-4-chloro-N-(4-
chlorophenyl)benzimidoyl chloride (4.28 g, 15.03 mmol) to which triethylamine (1.90 g, 
18.79 mmol), N-methylpiperazine (1.51 g, 15.03 g mmol) and acetonitrile / benzene 
(120 ml) were added to give 180 as a colorless solid (1.03 g, 3.07 mmol, 20.4 % yield).  
C18H19Cl2N3 (M = 348.27 g/mol), mp 293.2 °C (decomposition). 1H-NMR (300 MHz, 
CDCl3) δ 7.26 (d, J = 8.4Hz, 2H), δ 7.01 (m, 4H), δ 6.45 (d, J = 8.6Hz, 2H), δ 3.68 (bs, 
4H), δ 2.82 (bs, 4H), δ 2.59 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 159.65 (Cquat), 149.36 
(Cquat), 134.91 (Cquat), 131.44 (Cquat), 130.35 (+, 2 Ar-CH), 128.77 (+, 2 Ar-CH), 128.35 
(+, 2 Ar-CH), 126.41 (Cquat), 123.91 (+, 2 Ar-CH), 54.86 (-, 2 Pip-CH2), 46.15 (+, CH3), 
45.77 (-, 2 Pip-CH2). ESI–MS m/z 348.1 [MH+]. CHN (C18H19Cl2N3 ∙ ⅔ H2O) calc.: C 
60.01; H 5.69; N 11.66; exp.: C 59.91; H 5.33; N 11.55. 
 
(E)-3-Chloro-N-((4-chlorophenyl)(4-methylpiperazin-1-yl)methylene)aniline (181) 
  
C18H19Cl2N3 (M = 348.27 g/mol) 
181 was prepared according to general procedure C from 177 (1.60 g, 6.01 mmol) in 
acetonitrile / benzene (90 ml) giving intermediate (E)-4-chloro-N-(3-
chlorophenyl)benzimidoyl chloride (1.71 g, 6.01 mmol) to which triethylamine (0.76 g, 
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7.51 mmol), N-methylpiperazine (0.60 g, 6.01 mmol) and acetonitrile / benzene (75 ml) 
were added to give 181 as a colorless solid (470 mg, 1.35 mmol, 22.5 % yield).  
C18H19Cl2N3 (M = 348.27 g/mol), mp 97.1 °C 1H-NMR (300 MHz, CDCl3) δ 7.25 (d, J = 
7.4Hz, 2H), δ 7.05 (d, J = 8.5Hz, 2H), δ 6.92 (t, J = 7.9Hz, 1H), δ 6.75 (d, J = 8.0Hz, 
1H), δ 6.59 (t,  J = 2.0Hz, 1H), δ 6.36 (d, J = 8.9Hz, 1H), δ 3.50 (bs, 4H), δ 2.55 (bs, 
4H), δ 2.41 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 159.59 (Cquat), 152.09 (Cquat), 135.03 
(Cquat), 133.76 (Cquat), 131.23 (Cquat), 130.28 (+, 2 Ar-CH), 129.28 (+, 2 Ar-CH), 128.80 
(+, Ar-CH), 122.86 (+, Ar-CH), 121.39 (+, Ar-CH), 120.86 (+, Ar-CH), 54.77 (-, 2 Pip-
CH2), 46.03 (+, CH3), 45.81 (-, 2 Pip-CH2). ESI–MS m/z 348.1 [MH+]. CHN 
(C18H19Cl2N3 ∙ 4 3⁄  H2O) calc.: C 58.07; H 5.87; N 11.29; exp.: C 58.28; H 5.48; N 10.94. 
 
6.5. General procedure D:  
Preparation of compounds 52, 56, 62, 80, 103, 110, 111 
To a solution of 50, 55, 61, 79, 102, 108, or 109 in ethanol the 5-fold excess of SnCl2 
· 2 H2O was added and the mixture was heated at reflux over night. The next day the 
mixture was cooled to room temperature and the solvent was evaporated under 
reduced pressure. Water and DCM (1 : 3) were added to the resulting solid and the pH 
was adjusted to 7 using a saturated solution of Na2CO3. The aqueous layer was 
extracted with DCM and the combined organic layers were dried over Na2SO4. 
Evaporation of the solvent yielded the crude product, which was purified by column 
chromatography (EtOAc / methanol (1 : 1)) to give the title compounds 52, 56, 62, 80, 
103, 110, 111. 
 
(E)-N-((4-Aminophenyl)(4-methylpiperazin-1-yl)methylene)aniline (56) 
  
C18H22N4 (M = 294.39 g/mol) 
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56 was prepared according to general procedure D from 55 (0.50 g, 1.54 mmol) in 60 
ml ethanol and was obtained as a light yellow foam (0.19 g, 0.64 mmol, 41.7 % yield).  
C18H22N4 (M = 294.39 g/mol), mp 140.0 °C. 1H-NMR (300 MHz, CDCl3) δ 7.02 (t, J = 
7.8Hz, 2H), δ 6.90 (d, J = 8.4Hz, 2H), δ 6.75 (t, J = 7.3Hz, 1H), δ 6.57 (d, J = 7.3Hz, 
2H), δ 6.49 (d, J = 8.5Hz, 2H), δ 4.52 (s, 2H), δ 3.45 (bs, 4H), δ 2.48 (bs, 4H), δ 2.35 
(s, 3H). 13C-NMR (75 MHz, CDCl3) δ 161.23 (Cquat), 151.08 (Cquat), 146.90 (2 Cquat), 
130.72 (+, 2 Ar-CH), 128.18 (+, Ar-CH), 122.93 (+, 2 Ar-CH), 120.94 (+, 2 Ar-CH), 
114.38 (+, 2 Ar-CH), 54.85 (-, 2 Pip-CH2), 46.07 (-, 2 Pip-CH2), 45.93 (+, CH3). ESI-
MS m/z 295.0 [MH+]. CHN (C18H22N4 · H2O) calc.: C 69.20; H 7.74; N 17.93; exp.: C 
69.09; H 7.86; N 17.78. 
 
(E)-N-((4-Aminophenyl)(4-methylpiperazin-1-yl)methylene)-4-bromoaniline (62) 
  
C18H21BrN4 (M = 373.29 g/mol) 
62 was prepared according to general procedure D from 61 (0.81 g, 2.00 mmol) in 60 
ml ethanol and was obtained as a light yellow foam (0.20 g, 0.53 mmol, 37.9 % yield). 
C18H21BrN4 (M = 373.29 g/mol), mp 162.2 °C. 1H-NMR (300 MHz, CDCl3) δ 7.10 (d, J 
= 8.6Hz, 2H), δ 6.87 (d, J = 8.4Hz, 2H), δ 6.51 (d, J = 8.5Hz, 2H), δ 6.43 (d, J = 8.6Hz, 
2H), δ 3.73 (s, 2H), δ 3.44 (bs, 4H), δ 2.44 (bs, 4H), δ 2.33 (s, 3H). 13C-NMR (75 MHz, 
CDCl3) δ 161.45 (Cquat), 150.71 (Cquat), 146.98 (Cquat), 131.06 (+, 2 Ar-CH), 130.62 (+, 
2 Ar-CH), 124.64 (+, 2 Ar-CH), 122.44 (Cquat), 114.47 (+, 2 Ar-CH), 113.47 (Cquat), 
55.01 (-, 2 Pip-CH2), 46.16 (+, CH3), 45.80 (-, 2 Pip-CH2). ESI-MS m/z 372.8 [MH+], 
374.8. CHN (C18H21BrN4 ·⅓ H2O) calc.: C 57.35; H 5.86; N 14.59; exp.: C 57.48; H 
5.60; N 14.40. 
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(E)-N-((4-Aminophenyl)(4-methylpiperazin-1-yl)methylene)-4-chloroaniline (80) 
  
C18H21ClN4 (M = 328.84 g/mol) 
80 was prepared according to general procedure D from 79 (2.18 g, 6.08 mmol) in 80 
ml ethanol and was obtained as a very light yellow foam (0.76 g, 2.32 mmol, 38.1 % 
yield).  
C18H21ClN4 (M = 328.84 g/mol), mp 158.3 °C. 1H-NMR (300 MHz, CDCl3) δ 6.96 (d, J 
= 8.6Hz, 2H), δ 6.87 (d, J = 8.4Hz, 2H), δ 6.49 (t, J = 8.9Hz, 4H), δ 3.73 (s, 2H), δ 3.44 
(bs, 4H), δ 2.44 (bs, 4H), δ 2.34 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 161.51 (Cquat), 
150.05 (Cquat), 147.02 (Cquat), 130.64 (+, 2 Ar-CH), 128.15 (+, 2 Ar-CH), 125.83 (Cquat), 
124.13 (+, 2 Ar-CH), 122.37 (Cquat), 114.45 (+, 2 Ar-CH), 55.03 (-, 2 Pip-CH2), 46.17 
(+, CH3), 45.79 (-, 2 Pip-CH2). ESI-MS m/z 328.9 [MH+]. CHN (C18H21ClN4) calc.: C 
65.74; H 6.44; N 17.04; exp.: C 65.38; H 6.29; N 17.03. 
 
(E)-N-((4-Aminophenyl)(4-methylpiperazin-1-yl)methylene)-3-chloroaniline (103) 
  
C18H21ClN4 (M = 328.84 g/mol) 
103 was prepared according to general procedure D from 102 (1.50 g, 4.18 mmol) in 
60 ml ethanol and was obtained as a very light yellow foam (0.43 g, 1.31 mmol, 31.3 % 
yield).  
C18H21ClN4 (M = 328.84 g/mol), mp 152.4°C. 1H-NMR (300 MHz, CDCl3) δ 6.90 (m, 
3H), δ 6.72 (d, J = 9.0Hz, 1H), δ 6.60 (t, J = 2.0Hz, 1H), δ 6.52 (d, J = 8.5Hz, 2H), δ 
Chapter 6 
___________________________________________________________________ 
201 
 
6.41 (d, J = 8.9Hz, 1H), δ 3.73 (s, 2H), δ 3.46 (bs, 4H), δ 2.46 (bs, 4H), δ 2.34 (s, 3H). 
13C-NMR (75 MHz, CDCl3) δ 161.53 (Cquat), 153.06 (Cquat), 147.04 (Cquat), 133.53 
(Cquat), 130.58 (+, 2 Ar-CH), 129.05 (+, 2 Ar-CH), 123.05 (+, Ar-CH), 122.38 (Cquat), 
121.14 (+, Ar-CH), 120.69 (+, Ar-CH), 114.47 (+, Ar-CH), 54.99 (-, 2 Pip-CH2), 46.15 
(+, CH3), 45.74 (-, 2 Pip-CH2). ESI-MS m/z 328.9 [MH+]. CHN (C18H21ClN4 · 32  CH3OH) 
calc.: C 64.02; H 6.67; N 16.16; exp.: C 63.97; H 6.75; N 16.24. 
 
(E)-N1-((4-Methylpiperazin-1-yl)(phenyl)methylen)benzene-1,4-diamine (52) 
  
C18H22N4 (M = 294.39 g/mol) 
52 was prepared according to general procedure D from 50 (0.43 g, 1.33 mmol) in 60 
ml ethanol and was obtained as a light yellow foam (0.19 g, 0.64 mmol, 47.8 % yield).  
C18H22N4 (M = 294.39 g/mol), mp 140.3 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J = 
9.0Hz, 2H), δ 7.25 (m, 3H), δ 7.08 (d, J = 6.4Hz, 2H), δ 6.55 (d, J = 9.0Hz, 2H), δ 3.71 
(s, 2H), δ 3.49 (bs, 4H), δ 2.47 (bs, 4H), δ 2.35 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 
160.66 (Cquat), 142.79 (Cquat), 140.14 (Cquat), 133.83 (Cquat), 129.16 (+, 2 Ar-CH), 
128.43 (+, 2 Ar-CH), 128.17 (+, Ar-CH), 123.52 (+, 2 Ar-CH), 115.55 (+, 2 Ar-CH), 
55.02 (-, 2 Pip-CH2), 46.19 (+, CH3), 45.89 (-, 2 Pip-CH2). ESI-MS m/z 280 [MH+]. CHN 
(C18H21N3 · ⅓ H2O) calc.: C 71.97; H 7.61; N 18.65; exp.: C 72.05; H 7.52; N 18.42. 
 
(E)-N1-((3-Chlorophenyl)(4-methylpiperazin-1-yl)methylene)benzene-1,4-diamine 
(110) 
  
C18H21ClN4 (M = 328.84 g/mol) 
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110 was prepared according to general procedure D from 109 (2.30 g, 6.41 mmol) in 
60 ml ethanol and was obtained as a light yellow foam (0.16 g, 0.48 mmol, 3.6 % yield).  
C18H21ClN4 (M = 328.84 g/mol), mp 128.4 °C. 1H-NMR (300 MHz, CDCl3) δ 7.90 (d, J 
= 9.1Hz, 2H), δ 7.22 (m, 2H), δ 7.13 (t, J = 1.5Hz, 1H), δ 6.94 (d, J = 7.2Hz, 1H), δ 
6.56 (d, J = 9.1Hz, 2H), δ 3.79 (s, 2H), δ 3.49 (bs, 4H), δ 2.53 (bs, 4H), δ 2.40 (s, 3H). 
13C-NMR (75 MHz, CDCl3) δ 159.01 (Cquat), 142.29 (Cquat), 140.41 (Cquat), 135.71 
(Cquat), 134.30 (Cquat), 129.54 (+, 2 Ar-CH), 128.95 (+, 2 Ar-CH), 128.69 (+, Ar-CH), 
127.39 (+, Ar-CH), 123.38 (+, Ar-CH), 115.67 (+, Ar-CH), 54.89 (-, 2 Pip-CH2), 46.14 
(+, CH3), 46.02 (-, 2 Pip-CH2). ESI-MS m/z 328.9 [MH+]. CHN (C18H21ClN4 · 43  CH3OH) 
calc.: C 62.49; H 7.14; N 15.08; exp.: C 62.31; H 6.73; N 15.11. 
 
(E)-N1-((4-Chlorophenyl)(4-methylpiperazin-1-yl)methylene)benzene-1,4-diamine 
(111) 
  
C18H21ClN4 (M = 328.84 g/mol) 
111 was prepared according to general procedure D from 108 (1.08 g, 3.01 mmol) in 
60 ml ethanol and was obtained as a light yellow solid (0.13 g, 0.40 mmol, 4.4 % yield).  
C18H21ClN4 (M = 328.84 g/mol), mp 126.4 °C. 1H-NMR (300 MHz, CDCl3) δ 7.21 (d, J 
= 8.5Hz, 2H), δ 7.04 (d, J = 8.4Hz, 2H), δ 6.38 (m, 4H), δ 3.40 (s, 2H), δ 2.68 (bs, 4H), 
δ 2.45 (bs, 4H), δ 2.34 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 159.54 (Cquat), 142.48 
(Cquat), 140.36 (Cquat), 134.41 (Cquat), 132.25 (Cquat), 130.55 (+, 2 Ar-CH), 128.54 (+, 2 
Ar-CH), 123.40 (+, 2 Ar-CH), 115.66 (+, 2 Ar-CH), 54.93 (-, 2 Pip-CH2), 46.16 (+, CH3), 
46.06 (-, 2 Pip-CH2). ESI-MS m/z 328.9 [MH+]. CHN (C18H21ClN4 · 54  CH3OH) calc.: C 
63.70; H 6.88; N 15.81; exp.: C 63.74; H 6.75; N 15.93. 
 
Chapter 6 
___________________________________________________________________ 
203 
 
6.6. General procedure E:  
Preparation of compounds 99, 112, 114 - 117 
To a solution of 80 or 103 (2.0 mmol) and triethylamine (3.0 mmol) in 100 ml DCM a 
substituted acid chloride (2.4 mmol) was added under nitrogen atmosphere and 
vigorous stirring. After stirring at room temperature for 6 h the mixture was heated at 
reflux over night. The next day the solution was cooled to room temperature, 
concentrated and purified by column chromatography (ethyl acetate / methanol 1 : 1) 
to give the title compounds 99, 112, 114 - 117. 
 
(E)-N-(4-((4-Chlorophenylimino)(4-methylpiperazin-1-yl)methyl)phenyl)benz-
amide (99) 
 
C25H25ClN4O (M = 432.95 g/mol) 
99 was prepared according to general procedure E from 30 (2.00 g, 6.10 mmol) and 
benzoylchloride (1.03 g, 7.32 mmol) and was obtained as a light yellow foam (1.19 g, 
2.75 mmol, 45.0 % yield).  
C25H25ClN4O (M = 432.95 g/mol), mp 95.9 °C. 1H-NMR (300 MHz, CDCl3) δ 7.84 (d, J 
= 7.0Hz, 3H), δ 7.52 (m, 5H), δ 7.10 (d, J = 8.5Hz, 2H), δ 6.97 (d, J = 8.6Hz, 2H), δ 
6.49 (d, J = 8.6Hz, 2H), δ 3.48 (bs, 4H), δ 2.49 (bs, 4H), δ 2.37 (s, 3H). 13C-NMR (75 
MHz, CDCl3) δ 165.90 (Cquat, C=O), 160.36 (Cquat), 149.53 (Cquat), 138.55 (Cquat), 
134.60 (Cquat), 132.11 (+, 2 Ar-CH), 129.99 (+, 2 Ar-CH), 128.85 (+, 2 Ar-CH), 128.74 
(Cquat), 128.28 (+, Ar-CH), 127.06 (+, 2 Ar-CH), 126.27 (Cquat), 124.07 (+, 2 Ar-CH), 
119.85 (+, 2 Ar-CH), 54.84 (-, 2 Pip-CH2), 46.00 (+, CH3), 45.90 (-, 2 Pip-CH2). ESI-
MS m/z 433.0 [MH+]. CHN (C25H25ClN4O · ½ H2O) calc.: C 67.94; H 5.93; N 12.68; 
exp.: C 67.67; H 6.18; N 12.43. 
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(E)-4-Chloro-N-(4-((4-chlorophenylimino)(4-methylpiperazin-1-yl)methyl)-
phenyl)-benzamide (112) 
  
C25H24Cl2N4O (M = 467.39 g/mol) 
112 was prepared according to general procedure E from 80 (0.72 g, 2.19 mmol) and 
4-chlorobenzoylchloride (0.46 g, 2.63 mmol) and was obtained as a light yellow solid 
(0.41 g, 0.88 mmol, 40.2 % yield).  
C25H24Cl2N4O (M = 467.39 g/mol), mp 75.0 °C. 1H-NMR (300 MHz, CDCl3) δ 7.78 (d, 
J=8.6Hz, 3H), δ 7.49 (m, 4H), δ 7.10 (d, J=8.5Hz, 2H), δ 6.96 (d, J=8.6Hz, 2H), δ 6.48 
(d, J=8.6Hz, 2H), δ 3.46 (bs, 4H), δ 2.47 (bs, 4H), δ 2.35 (s, 3H). 13C-NMR (75 MHz, 
CDCl3) δ 164.83 (Cquat, C=O), 160.33 (Cquat), 149.74 (Cquat), 138.41 (Cquat), 138.18 
(Cquat), 132.96 (Cquat), 130.00 (+, 2 Ar-CH), 129.20 (Cquat), 129.11 (+, 2 Ar-CH), 128.49 
(+, 2 Ar-CH), 128.25 (+, 2 Ar-CH), 126.17 (Cquat), 124.05 (+, 2 Ar-CH), 119.88 (+, 2 Ar-
CH), 54.89 (-, 2 Pip-CH2), 46.19 (-, 2 Pip-CH2), 46.13 (+, CH3). ESI-MS m/z 466.9 
[MH+]. CHN (C25H24Cl2N4O · 32 H2O) calc.: C 62.63; H 5.33; N 11.69; exp.: C 62.59; H 
5.59; N 11.40. 
 
(E)-N-(4-((4-Chlorophenylimino)(4-methylpiperazin-1-yl)methyl)phenyl)acet-
amide (114) 
  
C20H23ClN4O (M = 370.88 g/mol) 
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114 was prepared according to general procedure E from 80 (0.95 g, 2.89 mmol) and 
acetylchloride (0.27 g, 3.47 mmol) and was obtained as colorless foam (0.59 g, 1.59 
mmol, 55.0 % yield).  
C20H23ClN4O (M = 370.88 g/mol), mp 82.1 °C. 1H-NMR (300 MHz, CDCl3) δ 7.40 (d, J 
= 8.4Hz, 2H), δ 7.20 (s, 1H), δ 7.04 (d, J = 8.5Hz, 2H), δ 6.94 (d, J = 8.6Hz, 2H), δ 6.46 
(d, J = 8.6Hz, 2H), δ 3.44 (bs, 4H), δ 2.46 (bs, 4H), δ 2.34 (s, 3H), δ 2.15 (s, 3H). 13C-
NMR (75 MHz, CDCl3) δ 168.53 (Cquat, C=O), 160.50 (Cquat), 149.76 (Cquat), 138.43 
(Cquat), 129.89 (+, 2 Ar-CH), 128.60 (Cquat), 128.21 (+, 2 Ar-CH), 126.10 (Cquat), 124.06 
(+, 2 Ar-CH), 119.31 (+, 2 Ar-CH), 54.91 (-, 2 Pip-CH2), 46.13 (+, CH3), 46.07 (-, 2 Pip-
CH2), 24.58 (+, CH3). ESI-MS m/z 370.9 [MH+]. CHN (C20H23ClN4O · ¾ H2O) calc.: C 
62.49; H 6.42; N 14.58; exp.: C 62.22; H 6.51; N 14.23. 
 
(E)-N-(4-((4-Chlorophenylimino)(4-methylpiperazin-1-yl)methyl)phenyl)propion-
amide (115) 
  
C21H25ClN4O (M = 384.90 g/mol) 
115 was prepared according to general procedure E from 80 (0.88 g, 2.68 mmol) and 
propionylchloride (0.28 g, 3.21 mmol) and was obtained as colorless foam (0.25 g, 0.64 
mmol, 23.9 % yield).  
C21H25ClN4O (M = 384.90 g/mol), mp 94.1 °C. 1H-NMR (300 MHz, CDCl3) δ 7.42 (d, J 
= 8.4Hz, 2H), δ 7.15 (s, 1H), δ 7.04 (d, J = 8.6Hz, 2H), δ 6.95 (d, J = 8.6Hz, 2H), δ 6.46 
(d, J = 8.6Hz, 2H), δ 3.46 (bs, 4H), δ 2.49 (bs, 4H), δ 2.36 (m, 5H), δ 1.23 (t, 3H, J = 
7.5Hz). 13C-NMR (75 MHz, CDCl3) δ 172.18 (Cquat, C=O), 160.49 (Cquat), 149.76 (Cquat), 
138.47 (Cquat), 129.90 (+, 2 Ar-CH), 128.47 (Cquat), 128.21 (+, 2 Ar-CH), 126.10 (Cquat), 
124.05 (+, 2 Ar-CH), 119.25 (+, 2 Ar-CH), 54.84 (-, 2 Pip-CH2), 46.19 (-, 2 Pip-CH2), 
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46.06 (+, CH3), 30.74 (-, CH2), 9.58 (+, CH3). ESI-MS m/z 385.0 [MH+]. CHN 
(C21H25ClN4O · H2O) calc.: C 63.60; H 6.75; N 13.91; exp.: C 63.93; H 6.58; N 13.64. 
 
(E)-N-(4-((3-Chlorophenylimino)(4-methylpiperazin-1-yl)methyl)phenyl)acet-
amide (116) 
  
C20H23ClN4O (M = 370.88 g/mol) 
116 was prepared according to general procedure E from 103 (1.54 g, 4.68 mmol) and 
acetylchloride (0.44 g, 5.62 mmol) and was obtained as colorless foam (0.16 g, 0.44 
mmol, 9.4 % yield).  
C20H23ClN4O (M = 370.88 g/mol), mp 179.6 °C. 1H-NMR (300 MHz, CDCl3) δ 7.42 (d, 
J = 8.4Hz, 2H), δ 7.28 (s, 1H), δ 7.06 (d, J = 8.5Hz, 2H), δ 6.90 (t, J = 7.9Hz, 1H), δ 
6.72 (d, J = 7.9Hz, 1H), δ 6.58 (t, J = 1.9Hz, 1H), δ 6.39 (d, J = 8.1Hz, 1H), δ 3.49 (bs, 
4H), δ 2.53 (bs, 4H), δ 2.39 (s, 3H), δ 2.15 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 168.50 
(Cquat, C=O), 160.44 (Cquat), 152.58 (Cquat), 138.44 (Cquat), 133.59 (Cquat), 129.86 (+, 2 
Ar-CH), 129.16 (+, 2 Ar-CH), 128.51 (Cquat), 122.94 (+, Ar-CH), 121.09 (+, Ar-CH), 
121.03 (+, Ar-CH), 119.33 (+, Ar-CH), 54.92 (-, 2 Pip-CH2), 46.15 (+, CH3), 45.99 (-, 2 
Pip-CH2), 24.60 (+, CH3). ESI-MS m/z 371.2 [MH+]. CHN (C20H23ClN4O · 54 H2O) calc.: 
C 62.35; H 6.44; N 14.54; exp.: C 62.60; H 6.10; N 14.25. 
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(E)-N-(4-((3-Chlorophenylimino)(4-methylpiperazin-1-yl)methyl)phenyl)benz-
amide (117) 
    
C25H25ClN4O (M = 432.95 g/mol) 
117 was prepared according to general procedure E from 103 (0.97 g, 2.95 mmol) and 
benzoylchloride (0.50 g, 3.54 mmol) and was obtained as colorless foam (0.26 g, 0.61 
mmol, 20.7 % yield).  
C25H25ClN4O (M = 432.95 g/mol), mp 91.9 °C. 1H-NMR (300 MHz, CDCl3) δ 7.83 (d, J 
= 8.6Hz, 3H), δ 7.51 (m, 5H), δ 7.13 (d, J = 8.5Hz, 2H), δ 6.92 (t, J = 7.9Hz, 1H), δ 
6.73 (d, J = 7.1Hz, 1H), δ 6.62 (t, J = 2.0Hz, 1H), δ 6.41 (d, J = 8.9Hz, 1H), δ 3.48 (bs, 
4H), δ 2.52 (bs, 4H), δ 2.39 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 165.80 (Cquat, C=O), 
160.33 (Cquat), 152.52 (Cquat), 138.45 (Cquat), 134.62 (Cquat), 133.66 (Cquat), 132.12 (+, 
2 Ar-CH), 129.97 (+, 2 Ar-CH), 129.19 (+, 2 Ar-CH), 128.89 (+, 2 Ar-CH), 128.82 (Cquat), 
127.00 (+, Ar-CH), 122.98 (+, Ar-CH), 121.12 (+, Ar-CH), 121.06 (+, Ar-CH), 119.78 
(+, Ar-CH), 54.86 (-, 2 Pip-CH2), 46.17 (-, 2 Pip-CH2), 46.07 (+, CH3). ESI-MS m/z 
433.0 [MH+]. CHN (C25H25ClN4O · 2 H2O) calc.: C 67.48; H 5.97; N 12.59; exp.: C 
67.34; H 6.16; N 12.25. 
 
6.7. General procedure F:  
Preparation of compounds 84, 118, 145 
To a solution of substituted 2-fluorobenzoic acid in THF, one equivalent of 
thionylchloride was added dropwise and heated at reflux for 2 h. After cooling to room 
temperature, the solvent as well as excess thionylchloride were removed under 
reduced pressure yielding the crude product. Compounds 84, 118, and 145 were used 
in the next step without further purification. 
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2-Fluorobenzoyl chloride (84) 
   
C7H4ClFO (M = 158.56 g/mol) 
84 was prepared according to general procedure F using 2-fluorobenzoic acid (1.40 g, 
10 mmol) in 30 ml THF yielding a light yellow solid (1.59 g, 10 mmol, 100 % yield).  
 
2-Fluoro-4-nitrobenzoyl chloride (118) 
   
C7H3ClFNO3 (M = 203.56 g/mol) 
118 was prepared according to general procedure F using 2-fluoro-4-nitrobenzoic acid 
(6.66 g, 36 mmol) in 75 ml THF yielding a light yellow solid (7.33 g, 36 mmol, 100 % 
yield).  
 
4-Chloro-2-fluorobenzoyl chloride (145) 
    
C7H3Cl2FO (M = 193.00 g/mol) 
145 was prepared according to general procedure F using 4-chloro-2-fluorobenzoic 
acid (5.16 g, 29.55 mmol) in 50 ml THF yielding a light yellow solid (5.70 g, 29.55 mmol, 
100 % yield).  
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6.8. General procedure G:  
Preparation of compounds 85, 89, 119, 120, 132, 138, 146, 152, 153 
To a solution of substituted 2-aminophenol (50 mmol) and triethylamine (100 mmol) in 
100 ml dry THF, substituted 2-fluorobenzoyl chloride (50 mmol) was added dropwise 
at 0 °C. After the complete adding of the acid chloride, the mixture was allowed to 
warm to room temperature while stirring under a nitrogen atmosphere over night. The 
next day the mixture was diluted with 400 ml water and adjusted with HCl (w = 4 %) to 
pH 7. The precipitated solid was then filtered over a glass filter and washed with HCl 
(w = 4 %) and water and was afterwards dried in vacuo over night to give the title 
compounds 85, 89, 119, 120, 132, 138, 146, 152, 153 as solids of different colour that 
were used in the next step without further purification. 
 
N-(5-Chloro-2-hydroxyphenyl)-2-fluorobenzamide (85) 
 
C13H9ClFNO2 (M = 265.67 g/mol) 
85 was prepared according to general procedure G using 2-amino-4-chlorophenol 
(7.18 g, 50.00 mmol) and 2-fluorobenzoyl chloride (8.00 g, 50.00 mmol) and was 
obtained as a light brown solid (12.54 g, 47.20 mmol, 94.4 % yield).  
C13H9ClFNO2 (M = 265.67 g/mol), mp 235.3 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.47 
(s, 1H), δ 9.48 (d, J = 9.2Hz, 1H), δ 8.21 (s, 1H), δ 7.90 (t, J = 7.8Hz, 1H), δ 7.64 (m, 
1H), δ 7.39 (m, 2H), δ 7.05 (d, J = 8.6Hz, 1H), δ 6.92 (d, J = 8.6Hz, 1H). CI-MS m/z 
123 (7), 140 (2), 157 (2), 180 (2), 248 (2), 266 (89, MH+), 267 (14), 268 (27), 269 (4), 
283 (100, MNH4+), 284 (14), 285 (31), 286 (4), 300 (1). CHN (C13H9ClFNO2) calc.: C 
58.77; H 3.41; N 5.27; exp.: C 58.66; H 3.47; N 5.13. 
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N-(4-Chloro-2-hydroxyphenyl)-2-fluorobenzamide (89) 
 
C13H9ClFNO2 (M = 265.67 g/mol) 
89 was prepared according to general procedure G using 2-amino-5-chlorophenol 
(3.62 g, 25.20 mmol) and 2-fluorobenzoyl chloride (4.00 g, 25.20 mmol) and was 
obtained as a red-brown solid (3.45 g, 12.99 mmol, 51.6 % yield).  
C13H9ClFNO2 (M = 265.67 g/mol), mp 142.7 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.63 
(s, 1H), δ 9.45 (d, J = 8.3Hz, 1H), δ 8.07 (d, J = 8.5Hz, 1H), δ 7.88 (t, J = 7.3Hz, 1H), 
δ 7.63 (m, 1H), δ 7.38 (m, 2H), δ 6.91 (d, J = 12.4Hz, 2H). GC-MS m/z 123 (3), 180.1 
(4), 265.9 (82, MH+), 267.1 (12), 268 (25), 269.1 (3), 283 (100), 284.1 (14), 285 (33), 
286.1 (4). CHN (C13H9ClFNO2) calc.: C 58.77; H 3.41; N 5.27; exp.: C 58.89; H 3.46; 
N 5.02. 
 
2-Fluoro-N-(2-hydroxyphenyl)benzamide (138) 
   
C13H10FNO2 (M = 231.22 g/mol) 
138 was prepared according to general procedure G using 2-aminophenol (3.93 g, 
36.00 mmol) and 2-fluorbenzoylchloride (5.71 g, 36.00 mmol) and was obtained as a 
colorless solid after re-crystallization from acetone (7.98 g, 34.51 mmol, 95.9 % yield). 
 C13H10FNO2 (M = 231.22 g/mol), mp 166.8 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.06 
(s, 1H), 9.44 (d, J = 9.0Hz, 1H), 8.12 (d, J = 12.4Hz, 1H), 7.97 (m, 2H), 7.48 (m, 3H), 
6.73 (m, 2H). ESI-MS m/z 232.0 [MH+]. CHN (C13H10FNO2) calc.: C 67.53; H 4.36; N 
6.06; exp.: C 67.47; H 4.38; N 5.86. 
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5-Chloro-2-fluoro-N-(2-hydroxyphenyl)benzamide (146) 
  
C13H9ClFNO2 (M = 265.67 g/mol) 
146 was prepared according to general procedure G using 2-aminophenol (3.22 g, 
29.55 mmol) and 145 (5.70 g, 29.55 mmol) and was obtained as a colorless solid after 
re-crystallization from acetone (5.03 g, 18.93 mmol, 64.1 % yield).  
C13H9ClFNO2 (M = 265.67 g/mol), mp 191.6 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.05 
(s, 1H), δ 9.49 (d, J = 7.6Hz, 1H), δ 8.02 (d, J = 7.4Hz, 1H), δ 7.89 (t, J = 8.3Hz, 1H), 
δ 7.65 (d, J = 12.9Hz, 1H), δ 7.47 (d, J = 8.4Hz, 1H), δ 6.92 (m, 3H). GC-MS m/z 266 
[MH+]. CHN (C13H9ClFNO2) calc.: C 58.77; H 3.41; N 5.27; exp.: C 58.72; H 3.52; N 
5.11.  
 
4-Chloro-N-(5-chloro-2-hydroxyphenyl)-2-fluorobenzamide (152) 
  
C13H8Cl2FNO2 (M = 300.11 g/mol) 
152 was prepared according to general procedure G using 2-amino-4-chlorophenol 
(4.47 g, 31.11 mmol) and 145 (6.00 g, 31.11 mmol) and was obtained as a colorless 
crystalline solid after re-crystallization from acetone (2.09 g, 6.96 mmol, 22.4 % yield). 
C13H8Cl2FNO2 (M = 300.11 g/mol), mp 208.5 °C. 1H-NMR (300 MHz, DMSO-d6) δ 
10.63 (s, 1H), δ 9.48 (d, J = 7.0Hz, 1H), δ 8.01 (d, J = 8.2Hz, 1H), δ 7.77 (t, J = 8.1Hz, 
1H), δ 7.64 (d, J = 10.8Hz, 1H), δ 7.46 (d, J = 10.1Hz, 1H), δ 6.89 (m, 2H). ESI-MS 
m/z 300.0 [MH+]. CHN (C13H8Cl2FNO2) calc.: C 52.03; H 2.69; N 4.67; exp.: C 52.18; 
H 2.76; N 4.57. 
 
Experimental section 
___________________________________________________________________ 
212 
 
4-Chloro-N-(4-chloro-2-hydroxyphenyl)-2-fluorobenzamide (153) 
  
C13H8Cl2FNO2 (M = 300.11 g/mol) 
153 was prepared according to general procedure G using 2-amino-5-chlorophenol 
4.25 g, 29.62 mmol) and 145 (5.72 g, 29.62 mmol) and was obtained as a light purple 
crystalline solid after re-crystallization from acetone (7.47 g, 24.89 mmol, 84.0 % yield).  
C13H8Cl2FNO2 (M = 300.11 g/mol), mp 230.9 °C. 1H-NMR (300 MHz, DMSO-d6) δ 
10.61 (s, 1H), δ 9.51 (d, J = 7.1Hz, 1H), δ 8.03 (d, J = 8.5Hz, 1H), δ 7.86 (t, J = 8.3Hz, 
1H), δ 7.64 (d, J = 11.0Hz, 1H), δ 7.46 (d, J = 10.2Hz, 1H), δ 6.91 (m, 2H). ESI-MS 
m/z 300.0 [MH+]. CHN (C13H8Cl2FNO2) calc.: C 52.03; H 2.69; N 4.67; exp.: C 51.98; 
H 2.82; N 4.38. 
 
N-(5-Chloro-2-hydroxyphenyl)-2-fluoro-4-nitrobenzamide (119) 
  
C13H8ClFN2O4 (M = 310.67 g/mol) 
119 was prepared according to general procedure G using 2-amino-4-chlorophenol 
(5.17 g, 36.00 mmol) and 118 (7.33 g, 36.00 mmol) and was obtained as a light yellow 
crystalline solid after re-crystallization from acetone (1.74 g, 5.60 mmol, 15.5 % yield).  
C13H8ClFN2O4 (M = 310.67 g/mol), mp 273.5 °C. 1H-NMR (300 MHz, DMSO-d6) δ 
10.41 (s, 1H), δ 9.90 (d, J = 8.9Hz, 1H), δ 8.28 (d, J = 12.3Hz, 1H), δ 8.19 (d, J = 
10.6Hz, 1H), δ 8.10 (d, J = 2.5Hz, 1H), δ 8.03 (m, 1H), δ 7.08 (d, J = 11.3Hz, 1H), δ 
6.93 (d, J = 8.6Hz, 1H). ESI-MS m/z 309.0 [(M-H)-]. CHN (C13H8ClFN2O4) calc.: C 
50.26; H 2.60; N 9.02; exp.: C 50.24; H 2.70; N 9.03. 
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N-(4-Chloro-2-hydroxyphenyl)-2-fluoro-4-nitrobenzamide (120) 
  
C13H8ClFN2O4 (M = 310.67 g/mol) 
120 was prepared according to general procedure G using 2-amino-5-chlorophenol 
(5.17 g, 36.00 mmol) and 118 (7.33 g, 36.00 mmol) and was obtained as a brown solid 
(3.30 g, 10.60 mmol, 29.5 % yield).  
C13H8ClFN2O4 (M = 310.67 g/mol), mp 247.7 °C. 1H-NMR (300 MHz, DMSO-d6) δ 
10.57 (s, 1H), δ 9.86 (d, J = 8.6Hz, 1H), δ 8.23 (d, J = 5.1Hz, 2H), δ 8.00 (m, 2H), δ 
6.92 (d, J = 13.7Hz, 2H). ESI-MS m/z 309.0 [(M-H)-]. CHN (C13H8ClFN2O4) calc.: C 
50.26; H 2.60; N 9.02; exp.: C 50.37; H 2.78; N 8.82. 
 
2-Fluoro-N-(2-hydroxyphenyl)-4-nitrobenzamide (132) 
  
C13H9FN2O4 (M = 276.22 g/mol) 
132 was prepared according to general procedure G using 2-aminophenol (3.15 g, 
28.9 mmol) and 118 (5.88 g, 28.9 mmol) and was obtained as a yellow solid (5.62 g, 
20.35 mmol, 70.42 % yield).  
C13H9FN2O4 (M = 276.22 g/mol), mp 245.2 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.02 
(s, 1H), δ 9.79 (d, J = 4.5Hz, 1H), δ 8.27 (d, J = 10.3Hz, 1H), δ 8.20 (d, J = 8.6Hz, 1H), 
δ 8.04 (m, 1H), δ 7.95 (d, J = 9.3Hz, 1H), δ 7.03 (m, 1H), δ 6.93 (d, J = 9.4Hz, 1H), δ 
6.84 (t, J = 8.3Hz, 1H). ESI-MS m/z 276.0 [M]. CHN (C13H9FN2O4 · 31 H2O) calc.: C 
55.32; H 3.45; N 9.92; exp.: C 55.67; H 3.42; N 9.52. 
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6.9. General procedure H:  
Preparation of compounds 86, 90, 122, 123, 133, 139, 147, 154, 155 
Compounds 85, 89, 119, 120, 132, 138, 146, 152, or 153 (10 mmol) were dissolved in 
40 ml DMF and one equivalent of freshly powdered NaOH (10 mmol) was added. The 
mixture was heated at reflux for 5 h and after re-cooling to room temperature it was 
diluted with 300 ml water. The precipitated solid was filtered over a glass filter, washed 
with NaOH (w = 5%) and water and then dried in vacuo over night. Compounds 86, 
90, 122, 123, 133, 139, 147, 154, or 155 were obtained as solids of different colours 
and were used in the next step without further purification. 
 
8-Chlorodibenzo[b,f][1,4]oxazepin-11(10H)-one (86) 
   
C13H8ClNO2 (M = 245.66 g/mol) 
86 was prepared according to general procedure H from 85 (7.97 g, 30.00 mmol) and 
was obtained as a very light brown solid (5.96 g, 24.26 mmol, 80.9 % yield).  
C13H8ClNO2 (M = 245.66 g/mol), mp 255.3 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 10.63 (s, 1H), δ 7.78 (d, J = 9.3Hz, 1H), δ 7.63 (t, J = 7.7Hz, 1H), δ 7.36 
(m, 3H), δ 7.19 (d, J = 6.8Hz, 2H). GC-MS m/z 230 (1), 245 (4), 246 (28, MH+), 247 
(5), 248 (9), 249 (1), 263 (100, MNH4+), 264 (15), 265 (32), 266 (4), 280 (5), 282 (2). 
CHN (C13H8ClNO2 · ¼ H2O) calc.: C 62.41; H 3.42; N 5.60; exp.: C 62.45; H 3.28; N 
5.66. 
 
7-Chlorodibenzo[b,f][1,4]oxazepin-11(10H)-one (90) 
   
C13H8ClNO2 (M = 245.66 g/mol) 
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90 was prepared according to general procedure H from 89 (3.45 g, 13.00 mmol) and 
was obtained as a violett solid (3.0 g, 12.20 mmol, 93.9 % yield).  
C13H8ClNO2 (M = 245.66 g/mol), mp 286.2 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 10.63 (s, 1H), δ 7.77 (d, J = 9.4Hz, 1H), δ 7.64 (m, 1H), δ 7.51 (d, J = 
2.3Hz, 1H), δ 7.33 (m, 3H), δ 7.17 (d, J = 8.6Hz, 1H). GC-MS m/z 50.1 (31), 63.1 (35), 
76.1 (40), 154.1 (33), 182.1 (55), 210.1 (100), 245 (99, MH+˙), 247.1 (33). CHN 
(C13H8ClNO2 · ¼ H2O) calc.: C 62.41; H 3.42; N 5.60; exp.: C 62.27; H 3.60; N 5.73. 
 
Dibenzo[b,f][1,4]oxazepin-11(10H)-one (139) 
   
C13H9NO2 (M = 211.22 g/mol) 
139 was prepared according to general procedure H from 138 (3.98 g, 18.84 mmol) 
and was obtained as light brown solid (3.51 g, 16.62 mmol, 88.2 % yield).  
C13H9NO2 (M = 211.22 g/mol), mp 213.9 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 10.54 (s, 1H), δ 7.77 (d, J = 9.4Hz, 1H), δ 7.61 (m, 1H), δ 7.33 – 7.27 (m, 
3H), δ 7.16 – 7.11 (m, 3H). ESI-MS m/z 212.0 [MH+]. CHN (C13H9NO2) calc.: C 73.92; 
H 4.29; N 6.63; exp.: C 73.69; H 4.33; N 6.61. 
 
3-Chlorodibenzo[b,f][1,4]oxazepin-11(10H)-one (147) 
    
C13H8ClNO2 (M = 245.66 g/mol) 
147 was prepared according to general procedure H from 146 (4.94 g, 18.59 mmol) 
and was obtained as light brown solid (4.12 g, 16.77 mmol, 90.2 % yield).  
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C13H8ClNO2 (M = 245.66 g/mol), mp 252.9 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 8.54 (s, 1H), δ 7.72 (d, J = 8.4Hz, 1H), δ 7.47 (s, 1H), δ 7.32 (m, 2H), δ 
7.07 (m, 3H). GC-MS m/z 246 [MH+]. CHN (C13H8ClNO2 ∙ ¼ H2O) calc.: C 62.41; H 
3.42; N 5.60; exp.: C 62.24; H 3.46; N 5.36. 
 
3,8-Dichlorodibenzo[b,f][1,4]oxazepin-11(10H)-one (154) 
   
C13H7Cl2NO2 (M = 280.11 g/mol) 
154 was prepared according to general procedure H from 152 (2.00 g, 6.66 mmol) and 
was obtained as light brown solid (1.25 g, 4.46 mmol, 67.0 % yield).  
C13H7Cl2NO2 (M = 280.11 g/mol), mp 271.9 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 8.53 (s, 1H), δ 7.60 (d, J = 8.3Hz, 1H), δ 7.29 (m, 2H), δ 7.13 (d, J = 
8.5Hz, 1H), δ 6.95 (s, 1H), δ 6.81 (d, J = 10.8Hz, 1H). ESI-MS m/z 280.0 [MH+]. CHN 
(C13H7Cl2NO2 · 31  H2O) calc.: C 54.57; H 2.70; N 4.90; exp.: C 54.68; H 2.57; N 4.67. 
 
3,7-Dichlorodibenzo[b,f][1,4]oxazepin-11(10H)-one (155) 
     
C13H7Cl2NO2 (M = 280.11 g/mol) 
155 was prepared according to general procedure H from 153 (6.75 g, 22.49 mmol) 
and was obtained as red-brown solid (6.19 g, 22.10 mmol, 98.3 % yield).  
C13H7Cl2NO2 (M = 280.11 g/mol), mp 310.2 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 10.72 (s, 1H), δ 7.78 (d, J = 8.4Hz, 1H), δ 7.57 (d, J = 13.2Hz, 2H), δ 7.43 
(d, J = 10.5Hz, 1H), δ 7.30 (d, J = 10.9Hz, 1H), δ 7.18 (d, J = 8.6Hz, 1H). EI-MS m/z 
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278.9 [M+•]. CHN (C13H7Cl2NO2 ·  H2O) calc.: C 54.57; H 2.70; N 4.90; exp.: C 54.80; 
H 2.65; N 4.67. 
 
8-Chloro-3-nitrodibenzo[b,f][1,4]oxazepin-11(10H)-one (122) 
   
C13H7ClN2O4 (M = 290.66 g/mol) 
122 was prepared according to general procedure H from 119 (1.59 g, 5.12 mmol) and 
was obtained as light brown solid (1.46 g, 5.02 mmol, 98.1 % yield).  
C13H7ClN2O4 (M = 290.66 g/mol), mp 297.9 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 10.67 (s, 1H), δ 8.21 (d, J = 2.2Hz, 1H), δ 8.12 (d, J = 10.8Hz, 1H), δ 7.97 
(d, J = 8.6Hz, 1H), δ 7.47 (d, J = 9.0Hz, 1H), δ 7.15 (d, J = 7.3Hz, 2H). EI-MS m/z 
289.9 [M+•]. CHN (C13H7ClN2O4 · H2O) calc.: C 50.58; H 2.94; N 9.08; exp.: C 50.92; H 
2.57; N 9.00. 
 
7-Chloro-3-nitrodibenzo[b,f][1,4]oxazepin-11(10H)-one (123) 
   
C13H7ClN2O4 (M = 290.66 g/mol) 
123 was prepared according to general procedure H from 120 (3.24 g, 10.43 mmol) 
and was obtained as grey-brown solid (2.79 g, 9.60 mmol, 92.0 % yield).  
C13H7ClN2O4 (M = 290.66 g/mol), mp 320.0 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 11.03 (s, 1H), δ 8.28 (s, 1H), δ 8.15 (d, J = 8.6Hz, 1H), δ 8.00 (d, J = 
8.6Hz, 1H), δ 7.69 (s, 1H), δ 7.25 (d, J = 7.5Hz, 2H). EI-MS m/z 290.0 [M+•]. CHN 
(C13H7ClN2O4 · H2O) calc.: C 50.58; H 2.94; N 9.08; exp.: C 50.28; H 2.60; N 8.76. 
3
1
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3-Nitrodibenzo[b,f][1,4]oxazepin-11(10H)-one (133) 
   
C13H8N2O4 (M = 256.21 g/mol) 
133 was prepared according to general procedure H from 132 (4.00 g, 14.48 mmol) 
and was obtained as light brown solid (3.41 g, 13.31 mmol, 91.9 % yield).  
C13H8N2O4 (M = 256.21 g/mol), mp 286.0 °C (decomposition). 1H-NMR (300 MHz, 
DMSO-d6) δ 10.88 (s, 1H), δ 8.24 (d, J = 1.8Hz, 1H), δ 8.14 (d, J = 10.5 Hz, 1H), δ 
8.02 (d, J = 8.6Hz, 1H), δ 7.49 (d, J = 7.5Hz, 1H), δ 7.21 (t, 3H, J = 7.7Hz). EI-MS m/z 
63 (27), 75 (27), 77 (17), 127 (30), 153 (16), 154 (21), 182 (34), 183 (18), 210 (35), 
256 (100) (M+•). CHN (C13H8N2O4 · 31 H2O) calc.: C 59.55; H 3.33; N 10.68; exp.: C 
59.70; H 3.39; N 10.46. 
 
6.10. General procedure I:  
Preparation of compounds 88, 92, 126, 127, 135, 141, 149, 158, 159 and 
193, 196, 232 - 235 
A solution of 86, 90, 122, 123, 133, 139, 147, 154, or 155 in POCl3 and acetonitrile was 
heated at reflux over night. Solvent and formed POCl3 were removed under reduced 
pressure and the resulting 11-chlorodibenzo[b,f][1,4]oxazepin intermediates were 
used in the next step without further purification. 
To a solution of the 11-chlorodibenzo[b,f][1,4]oxazepin intermediates in toluene the 10-
fold excess of N-methylpiperazine (compounds 88, 92, 128, 129, 136, 141, 149, 158, 
159) or piperazine (compounds 193, 196, 232 – 235; piperazine dissolved in CH3OH 
quantum satis) was added and the resulting mixture was then heated at reflux for 4 h. 
After cooling to room temperature, the mixture was added to ethyl acetate and a 
solution of Na2CO3 in water (3 : 2). The aqueous layer was extracted with ethyl acetate 
and the combined organic layers were dried over Na2SO4. After concentration in vacuo, 
the crude product was purified by column chromatography (EtOAc / methanol (1 : 1)) 
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to give the title compounds 88, 92, 128, 129, 136, 141, 149, 158, 159, 193, 196, 232 - 
235 as solids of different colours.  
 
8-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine (88) 
  
C18H18ClN3O (M = 327.81 g/mol) 
88 was prepared according to general procedure I from 86 (3.00 g, 12.20 mmol) in 15 
ml POCl3 and 30 ml acetonitrile giving intermediate 8,11-dichloro-
dibenzo[b,f][1,4]oxazepine (3.22 g, 12.20 mmol) to which N-methylpiperazine (12.22 
g, 122.00 mmol) and 60 ml toluene were added to give 88 as a light yellow solid (0.64 
g, 1.95 mmol, 16.0 % yield).  
C18H18ClN3O (M = 327.81 g/mol), mp 166.3 °C. 1H-NMR (300 MHz, CDCl3) δ 7.42 (t, 
J = 8.2, 7.3, 1.7Hz, 1H), δ 7.32 (d, J = 7.7Hz, 1H), δ 7.22 (d, J = 8.2Hz, 1H), 7.17 (t, J 
= 7.6, 1.2Hz 1H), δ 7.12 (d, J = 2.5Hz, 1H), δ 7.01 (d, J = 8.5Hz, 1H), δ 6.88 (d, J = 
11.1Hz, 1H), δ 3.61 (bs, 4H), δ 2.55 (bs, 4H), δ 2.38 (s, 3H). 13C-NMR (400 MHz, 
CDCl3) δ 160.63 (Cquat), 150.69 (Cquat), 141.81 (Cquat), 132.75 (+, Ar-CH), 130.29 
(Cquat), 129.50 (+, Ar-CH), 126.5 (+, Ar-CH), 124.93 (+, Ar-CH), 123.47 (+, Ar-CH), 
123.31 (Cquat), 121.14 (+, Ar-CH), 120.96 (+, Ar-CH), 54.91 (-, 2 Pip-CH2), 47.18 (-, 2 
Pip-CH2), 46.10 (+, CH3). ESI-MS m/z 328.9 [MH+]. CHN (C18H18ClN3O) calc.: C 65.95; 
H 5.53; N 12.82; exp.: C 65.63; H 5.63; N 12.67. 
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7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine (92) 
  
C18H18ClN3O (M = 327.81 g/mol) 
92 was prepared according to general procedure I from 90 (3.22 g, 12.20 mmol) in 15 
ml POCl3 and 30 ml acetonitrile giving intermediate intermediate 7,11-
dichlorodibenzo[b,f][1,4]oxazepine (3.22 g, 12.20 mmol) to which N-methylpiperazine 
(12.22 g, 122.00 mmol) and 60 ml toluene were added to give 90 as a light red solid 
(0.68 g, 2.08 mmol, 17.1 %).  
C18H18ClN3O (M = 327.81 g/mol), mp 149.7 °C. 1H-NMR (300 MHz, CDCl3) δ 7.47 (m, 
1H), δ 7.34 (d, J = 9.4Hz, 1H), δ 7.21 (m, 1H), δ 7.13 (m, 2H), δ 7.04 (d, J = 1.1Hz, 
2H), δ 3.69 (bs, 4H), δ 2.67 (bs, 4H), δ 2.45 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 
160.52 (Cquat), 160.34 (Cquat), 152.08 (Cquat), 139.46 (Cquat), 132.84 (+, Ar-CH), 129.61 
(+, Ar-CH), 128.52 (Cquat), 127.54 (+, Ar-CH), 125.67 (+, Ar-CH), 125.15 (+, Ar-CH), 
123.40 (Cquat), 121.29 (+, Ar-CH), 120.60 (+, Ar-CH), 54.90 (-, 2 Pip-CH2), 47.20 (-, 2 
Pip-CH2), 46.09 (+, CH3). ESI-MS m/z 327.9 [MH+]. CHN (C18H18ClN3O) calc.: C 65.95; 
H 5.53; N 12.82; exp.: C 65.74; H 5.58; N 12.76. 
 
11-(4-Methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine (141) 
  
C18H19N3O (M = 293.36 g/mol) 
141 was prepared according to general procedure I from 139 (3.0 g, 14.20 mmol) in 
15 ml POCl3 and a mixture of 100 ml acetonitrile and 40 ml toluene giving intermediate 
11-chlorodibenzo[b,f][1,4]oxazepine (3.26 g, 14.20 mmol) to which N-methylpiperazine 
Chapter 6 
___________________________________________________________________ 
221 
 
(14.22 g, 142.90 mmol) and a mixture of 100 ml acetonitrile and 40 ml toluene were 
added to give 141 as a light yellow hygroscopic foam (0.97 g, 3.31 mmol, 23.3 % yield).  
C18H19N3O (M = 293.36 g/mol), mp 60.2 °C. 1H-NMR (300 MHz, CDCl3) δ 7.43 (m, 1H), 
δ 7.35 (d, J = 9.4Hz, 1H), δ 7.14 (m, 5H), δ 6.98 (m, 1H), δ 3.61 (bs, 4H), δ 2.58 (bs, 
4H), δ 2.39 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 161.01 (Cquat), 160.37 (Cquat), 152.18 
(Cquat), 140.61 (Cquat), 132.62 (+, Ar-CH), 129.59 (+, Ar-CH), 126.95 (+, Ar-CH), 125.54 
(+, Ar-CH), 124.79 (+, Ar-CH), 124.18 (+, Ar-CH), 123.66 (Cquat), 121.29 (+, Ar-CH), 
120.20 (+, Ar-CH), 54.99 (-, 2 Pip-CH2), 47.29 (-, 2 Pip-CH2),46.16 (+, CH3). ESI-MS 
m/z 294.1 [MH+]. CHN (C18H19N3O ·  H2O) calc.: C 72.22; H 6.62; N 14.04; exp.: C 
72.46; H 6.35; N 13.76. 
  
3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine (149) 
    
C18H18ClN3O (M = 327.81 g/mol) 
149 was prepared according to general procedure I from 147 (3.75 g, 15.27 mmol) in 
15 ml POCl3 and a mixture of 100 ml acetonitrile and 30 ml toluene giving intermediate 
3,11-dichlorodibenzo[b,f][1,4]oxazepine (4.03 g, 15.27 mmol) to which N-
methylpiperazine (15.29 g, 152.7 mmol) and a mixture of 100 ml acetonitrile and 40 ml 
toluene were added to give 149 as a light yellow hygroscopic foam (0.59 g, 1.80 mmol, 
12.6 % yield).  
C18H18ClN3O (M = 327.81 g/mol), mp 65.6 °C. 1H-NMR (300 MHz, CDCl3) δ 7.30 (s, 
1H), δ 7.27 (m, 2H), δ 7.18 (d, J = 10.4Hz, 1H), δ 7.10 – 7.01 (m, 3H), δ 3.60 (bs, 4H), 
δ 2.60 (bs, 4H), δ 2.41 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 161.10 (Cquat), 159.37 
(Cquat), 151.72 (Cquat), 140.29 (Cquat), 137.90 (Cquat), 130.33 (+, Ar-CH), 127.09 (+, Ar-
CH), 125.87 (+, Ar-CH), 125.33 (+, Ar-CH), 124.47 (+, Ar-CH), 122.21 (Cquat), 121.91 
(+, Ar-CH), 120.22 (+, Ar-CH), 54.89 (-, 2 Pip-CH2), 47.28 (-, 2 Pip-CH2), 46.11 (+, 
3
1
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CH3). ESI-MS m/z 328.0 [MH+]. CHN (C18H18ClN3O · ¼ H2O) calc.: C 65.06; H 5.61; N 
12.64; exp.: C 65.30; H 5.61; N 12.50. 
 
3,8-Dichloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine (158) 
     
C18H17Cl2N3O (M = 362.25 g/mol) 
158 was prepared according to general procedure I from 154 (1.00 g, 3.57 mmol) in 5 
ml POCl3 and a mixture of 40 ml acetonitrile and 20 ml toluene giving intermediate 
3,8,11-trichlorodibenzo[b,f][1,4]oxazepine (1.07 g, 3.57 mmol) to which N-
methylpiperazine (3.58 g, 35.70 mmol) and a mixture of 40 ml acetonitrile and 20 ml 
toluene were added to give 158 according to general procedure as a light brown solid 
(0.64 g, 1.77 mmol, 49.6 % yield).  
C18H17Cl2N3O (M = 362.25 g/mol), mp 155.8 °C. 1H-NMR (300 MHz, CDCl3) δ 7.26 (s, 
2H), δ 7.20 (d, J = 10.1Hz, 1H), δ 7.12 (d, J = 2.4Hz, 1H), δ 7.02 (d, J = 8.5Hz, 1H), δ 
6.93 (d, J = 11.0Hz, 1H), δ 3.62 (bs, 4H), δ 2.59 (bs, 4H), δ 2.40 (s, 3H). 13C-NMR (75 
MHz, CDCl3) δ 160.58 (Cquat), 159.41 (Cquat), 151.60 (Cquat), 139.19 (Cquat), 138.12 
(Cquat), 130.36 (+, Ar-CH), 128.81 (Cquat), 127.68 (+, Ar-CH), 126.02 (+, Ar-CH), 125.68 
(+, Ar-CH), 121.95 (Cquat), 121.90 (+, Ar-CH), 120.60 (+, Ar-CH), 54.84 (-, 2 Pip-CH2), 
47.30 (-, 2 Pip-CH2), 46.08 (+, CH3). ESI-MS m/z 362.1 [MH+]. CHN (C18H17Cl2N3O · 
3
1  H2O) calc.: C 58.71; H 4.84; N 11.41; exp.: C 58.71; H 4.81; N 11.20. 
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3,7-Dichloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine (159) 
    
C18H17Cl2N3O (M = 362.25 g/mol) 
159 was prepared according to general procedure I from 155 (5.50 g, 19.64 mmol) in 
20 ml POCl3 and a mixture of 100 ml acetonitrile and 40 ml toluene giving intermediate 
3,7,11-trichlorodibenzo[b,f][1,4]oxazepine (5.86 g, 19.64 mmol) to which N-
methylpiperazine (19.67 g, 196.40 mmol) and a mixture of 100 ml acetonitrile and 40 
ml toluene were added to give 159 as a red-brown solid (124 mg, 3.42 mmol, 17.4 % 
yield).  
C18H17Cl2N3O (M = 362.25 g/mol), mp 154.3 °C. 1H-NMR (300 MHz, CDCl3) δ 7.26 (s, 
2H), δ 7.21 (d, J = 1.9Hz, 1H), δ 7.12 (m, 1H), δ 7.05 (d, J = 1.3Hz, 2H), δ 3.59 (bs, 
4H), δ 2.57 (bs, 4H), δ 2.43 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 160.59 (Cquat), 159.38 
(Cquat), 151.59 (Cquat), 139.15 (Cquat), 138.14 (Cquat), 130.35 (+, Ar-CH), 128.82 (Cquat), 
127.69 (+, Ar-CH), 126.01 (+, Ar-CH), 125.68 (+, Ar-CH), 121.96 (Cquat), 121.91 (+, Ar-
CH), 120.62 (+, Ar-CH), 54.82 (-, 2 Pip-CH2), 47.19 (-, 2 Pip-CH2), 46.06 (+, CH3). ESI-
MS m/z 362.1 [MH+]. CHN (C18H17Cl2N3O · 31  H2O) calc.: C 58.71; H 4.84; N 11.41; 
exp.: C 58.74; H 4.89; N 11.06. 
 
8-Chloro-11-(4-methylpiperazin-1-yl)-3-nitrodibenzo[b,f][1,4]oxazepine (126) 
   
C18H17ClN4O3 (M = 372.81 g/mol) 
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126 was prepared according to general procedure I from 122 (1.35 g, 4.64 mmol) in 7 
ml POCl3 and 20 ml acetonitrile giving intermediate 8,11-dichloro-3-
nitrodibenzo[b,f][1,4]oxazepine (1.43 g, 4.64 mmol) to which N-methylpiperazine (4.65 
g, 46.4 mmol) and 100 ml toluene were added to give 126 as a light yellow oil (0.40 g, 
1.22 mmol, 26.3 % yield).  
C18H17ClN4O3 (M = 372.81 g/mol). 1H-NMR (300 MHz, CDCl3) δ 8.10 (d, J = 5.5Hz, 
2H), δ 7.52 (d, J = 9.1Hz, 1H), δ 7.16 (d, J = 2.5Hz, 1H), δ 7.10 (d, J = 8.6Hz, 1H), δ 
7.01 (m, 1H), δ 3.80 (bs, 4H), δ 2.82 (bs, 4H), δ 2.55 (s, 3H). ESI-MS m/z 373.0 [MH+]. 
 
7-Chloro-11-(4-methylpiperazin-1-yl)-3-nitrodibenzo[b,f][1,4]oxazepine (127) 
   
C18H17ClN4O3 (M = 372.81 g/mol) 
127 was prepared according to general procedure I from 123 (2.60 g, 8.95 mmol) in 
14 ml POCl3 and 50 ml acetonitrile giving intermediate 7,11-dichloro-3-
nitrodibenzo[b,f][1,4]oxazepine (2.77 g, 8.95 mmol) to which N-methylpiperazine (8.96 
g, 89.50 mmol) and 120 ml toluene were added to give 127 as a light yellow oil (0.24 
g, 0.64 mmol, 7.2 % yield).  
C18H17ClN4O3 (M = 372.81 g/mol). 1H-NMR (300 MHz, CDCl3) δ 8.10 (m, 2H), δ 7.53 
(d, J = 9.1Hz, 1H), δ 7.19 (d, J = 1.8Hz, 1H), δ 7.09 (d, J = 2.4Hz, 2H), δ 3.70 (bs, 4H), 
δ 2.72 (bs, 4H), δ 2.49 (s, 3H). ESI-MS m/z 373.0 [MH+]. 
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11-(4-Methylpiperazin-1-yl)-3-nitrodibenzo[b,f][1,4]oxazepine (135) 
     
C18H18N4O3 (M = 338.36 g/mol) 
135 was prepared according to general procedure I from 133 (3.14 g, 12.26 mmol) in 
13 ml POCl3 and a mixture of 120 ml acetonitrile and 30 ml toluene giving intermediate 
11-chloro-3-nitrodibenzo[b,f][1,4]oxazepine (3.37 g, 12.26 mmol) to which N-
methylpiperazine (12.28 g, 122.60 mmol) and a mixture of 100 ml acetonitrile and 40 
ml toluene were added to give 135 as yellow hygroscopic solid (1.70 g, 5.02 mmol, 
41.0 % yield).  
C18H18N4O3 (M = 338.36 g/mol), mp 177.8°C. 1H-NMR (300 MHz, CDCl3) δ 8.08 (m, 
2H), δ 7.53 (d, J = 8.5Hz, 1H), δ 7.14 (m, 3H), δ 7.04 (m, 1H), δ 3.62 (bs, 4H), δ 2.63 
(bs, 4H), δ 2.42 (s, 3H). ESI-MS m/z 339.0 [MH+]. CHN (C18H18N4O3 · ¼ H2O) calc.: C 
63.05; H 5.44; N 16.34; exp.: C 63.16; H 5.41; N 15.94. 
 
3,7-Dichloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine (193) 
 
C17H15Cl2N3O (M = 348.23 g/mol) 
193 was prepared according to general procedure I from 155 (4.50 g, 16.07 mmol) in 
12 ml POCl3 and a mixture of 100 ml acetonitrile and 50 ml toluene giving intermediate 
3,7,11-trichlorodibenzo[b,f][1,4]oxazepine (4.75 g, 16.07 mmol) to which piperazine 
(13.84 g, 160.70 mmol, dissolved in 35 ml CH3OH) and a mixture of 100 ml acetonitrile 
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and 50 ml toluene were added to give 193 as yellow hygroscopic solid (2.62 g, 7.52 
mmol, 46.8 % yield).  
C17H15Cl2N3O (M = 348.23 g/mol), mp 69.8 °C. 1H-NMR (300 MHz, CDCl3) δ 7.24 (m, 
2H), 7.20 (dd, J = 8.6, 1.8Hz, 1H), 7.15 – 7.08 (t, 1H), 7.06 (d, J = 4.4Hz, 2H), 3.48 (bs, 
4H), 3.02 (bs, 4H), 1.86 (s, 1H). 13C-NMR (75 MHz, CDCl3) δ 160.61 (Cquat), 159.68 
(Cquat), 151.61 (Cquat), 139.14 (Cquat), 138.11 (Cquat), 130.36 (+, Ar-CH), 128.80 (Cquat), 
127.68 (+, Ar-CH), 126.01 (+, Ar-CH), 125.69 (+, Ar-CH), 121.96 (Cquat), 121.91 (+, Ar-
CH), 120.61 (+, Ar-CH), 48.63 (-, 2 Pip-CH2), 45.89 (-, 2 Pip-CH2). ESI-MS m/z 348.1 
[MH+]. CHN (C17H15Cl2N3O ∙ CH3OH) calc. C 56.85; H 5.04; N 11.05; exp. C 56.75; H 
4.74; N 11.21.  
 
3,8-Dichloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine (196) 
  
C17H15Cl2N3O (M = 348.23 g/mol) 
196 was prepared according to general procedure I from 154 (10.46 g, 37.34 mmol) in 
25 ml POCl3 and a mixture of 120 ml acetonitrile and 60 ml toluene giving intermediate 
3,8,11-trichlorodibenzo[b,f][1,4]oxazepine (11.15 g, 37.34 mmol) to which piperazine 
(32.16 g, 373.40 mmol, dissolved in 50 ml CH3OH) and a mixture of 120 ml acetonitrile 
and 60 ml toluene were added to give 196 as yellow hygroscopic foam (5.38 g, 15.45 
mmol, 41.4 % yield).  
C17H15Cl2N3O (M = 348.23 g/mol), mp 55.6 °C. 1H-NMR (300 MHz, CDCl3) δ 7.26 (m, 
J = 4.8Hz, 2H), 7.20 (dd, J = 8.4, 3.7Hz 1H), 7.12 (d, J = 2.5Hz, 1H), 7.02 (d, J = 8.6Hz, 
1H), 6.92 (dd, J = 8.5, 2.5 Hz, 1H), 3.51 (bs, 4H), 3.00 (bs, 4H), 2.01 (s, 1H). 13C-NMR 
(75 MHz, CDCl3) δ 160.83 (Cquat), 159.95 (Cquat), 150.29 (Cquat), 141.51 (Cquat), 138.14 
(Cquat), 130.76 (Cquat), 130.32 (+, Ar-CH), 126.71 (+, Ar-CH), 125.59 (+, Ar-CH), 123.87 
(+, Ar-CH), 121.88 (+, Ar-CH), 121.09 (+, Ar-CH), 48.54 (-, 2 Pip-CH2), 45.82 (-, 2 Pip-
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CH2). ESI-MS m/z 348.1 [MH+]. CHN (C17H15Cl2N3O ∙ 3 5⁄ CH3OH) calc. C 57.41; H 4.82; 
N 11.37; C 57.41; H 4.60; N 11.00  
 
3-Chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine (232) 
  
C17H16ClN3O (M = 313.78 g/mol) 
232 was prepared according to general procedure I from 147 (10.46 g, 42.58 mmol) in 
25 ml POCl3 and a mixture of 200 ml acetonitrile and 100 ml toluene giving intermediate 
3,11-dichlorodibenzo[b,f][1,4]oxazepine (11.25 g, 42.58 mmol) to which piperazine 
(25.84 g, 300.00 mmol, dissolved in 40 ml CH3OH) and a mixture of 100 ml acetonitrile 
and 100 ml toluene were added to give 232 as a yellow solid that was re-crystallized 
from EtOAc (6.16 g, 19.63 mmol, 46.1 % yield).  
C17H16ClN3O (M = 313.78 g/mol), mp 154.9 °C. 1H-NMR (300 MHz, CDCl3) δ 7.29 – 
7.24 (m, 2H), 7.17 (d, J = 8.3Hz, 1H), 7.15 – 7.04 (m, 3H), 6.95 (m, 1H), 3.49 (bs, 4H), 
2.99 (bs, 4H), 1.72 (s, 1H). 13C-NMR (75 MHz, CDCl3) δ 161.12 (Cquat), 159.69 (Cquat), 
151.75 (Cquat), 140.28 (Cquat), 137.87 (Cquat), 130.34 (+, Ar-CH), 127.07 (+, Ar-CH), 
125.87 (+, Ar-CH), 125.33 (+, Ar-CH), 124.45 (+, Ar-CH), 122.22 (Cquat), 121.89 (+, Ar-
CH), 120.21 (+, Ar-CH), 48.69 (-, 2 Pip-CH2), 45.95 (-, 2 Pip-CH2). ESI-MS m/z 314.1 
[MH+]. CHN (C17H16ClN3O ∙ 1 5⁄  H2O) calc. C 64.33; H 5.21; N 13.24; exp. 64.55; H 5.26; 
N 13.46 
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11-(Piperazin-1-yl)dibenzo[b,f][1,4]oxazepine (233) 
 
C17H17N3O (M = 279.34 g/mol) 
233 was prepared according to general procedure I from 139 (7.02 g, 33.24 mmol) in 
20 ml POCl3 and a mixture of 150 ml acetonitrile and 150 ml toluene giving intermediate 
11-chlorodibenzo[b,f][1,4]oxazepine (7.63 g, 33.24 mmol) to which piperazine (21.54 
g, 250.00 mmol, dissolved in 40 ml CH3OH) and a mixture of 150 ml acetonitrile and 
150 ml toluene were added to give 233 as yellow hygroscopic foam (2.69 g, 9.63 mmol, 
29.0 % yield).  
C17H17N3O (M = 279.34 g/mol), mp 62.2 °C. 1H-NMR (300 MHz, CDCl3) δ 7.43 (m, 1H), 
7.35 (dd, J = 7.8, 1.7Hz, 1H), 7.30 – 7.11 (m, 5H), 7.01 - 6.92 (m, 1H), 3.29 (bs, 4H), 
2.99 (bs, 4H), 1.93 (s, 1H). 13C-NMR (75 MHz, CDCl3) δ 161.03 (Cquat), 160.66 (Cquat), 
152.20 (Cquat), 140.61 (Cquat), 132.59 (+, Ar-CH), 129.61 (+, Ar-CH), 126.94 (+, Ar-CH), 
125.53 (+, Ar-CH), 124.80 (+, Ar-CH), 124.16 (+, Ar-CH), 123.67 (Cquat), 121.28 (+, Ar-
CH), 120.19 (+, Ar-CH), 48.70 (-, 2 Pip-CH2), 46.03 (-, 2 Pip-CH2). ESI-MS m/z 280.2 
[MH+]. CHN (C17H17N3O ∙ ¼ H2O) calc. C 71.94; H 6.21; N 14.80; exp. C 72.04; H 5.95; 
N 14.57. 
 
8-Chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine (234) 
  
C17H16ClN3O (M = 313.78 g/mol) 
234 was prepared according to general procedure I from 86 (5.34 g, 21.74 mmol) in 
15 ml POCl3 and a mixture of 75 ml acetonitrile and 75 ml toluene giving intermediate 
8,11-dichlorodibenzo[b,f][1,4]oxazepine (5.74 g, 21.74 mmol) to which piperazine 
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(15.51 g, 180.00 mmol, dissolved in 40 ml CH3OH) and a mixture of 100 ml acetonitrile 
and 100 ml toluene were added to give 234 as light brown hygroscopic foam (1.79 g, 
5.70 mmol, 26.2 % yield).  
C17H16ClN3O (M = 313.78 g/mol), mp 59.8 °C. 1H-NMR (300 MHz, CDCl3) δ 7.44 (m, 
1H), 7.33 (dd, J = 7.7, 1.7Hz, 1H), 7.28 – 7.15 (m, 2H), 7.12 (d, J = 2.5Hz, 1H), 7.03 
(d, J = 8.5Hz, 1H), 6.90 (dd, J = 8.5, 2.6 Hz, 1H), 3.51 (bs, 4H), 2.98 (bs, 4H), 1.81 (s, 
1H). 13C-NMR (75 MHz, CDCl3) δ 160.97 (Cquat), 160.73 (Cquat), 150.77 (Cquat), 141.86 
(Cquat), 132.81 (+, Ar-CH), 130.38 (Cquat), 129.59 (+, Ar-CH), 126.55 (+, Ar-CH), 125.03 
(+, Ar-CH), 123.55 (+, Ar-CH), 123.39 (Cquat), 121.23 (+, Ar-CH), 121.03 (+, Ar-CH), 
48.54 (-, 2 Pip-CH2), 46.04 (-, 2 Pip-CH2). ESI-MS m/z 314.1 [MH+]. CHN (C17H16ClN3O 
∙ 7 3 ⁄ H2O) calc. C 63.51; H 5.28; N 13.07; exp. C 63.76; H 5.24; N 12.68. 
 
7-Chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine (235) 
  
C17H16ClN3O (M = 313.78 g/mol) 
235 was prepared according to general procedure I from 90 (7.32 g, 29.80 mmol) in 
15 ml POCl3 and a mixture of 75 ml acetonitrile and 75 ml toluene giving intermediate 
7,11-dichlorodibenzo[b,f][1,4]oxazepine (7.87 g, 29.80 mmol) to which piperazine 
(21.54 g, 250.00 mmol, dissolved in 40 ml MeOH) and a mixture of 100 ml acetonitrile 
and 100 ml toluene were added to give 235 as grey-violet hygroscopic foam (6.28 g, 
20.01 mmol, 67.2 % yield).  
C17H16ClN3O (M = 313.78 g/mol), mp 60.2 °C. 1H-NMR (300 MHz, CDCl3) δ 7.45 (m, 
1H), 7.34 (d, J = 7.7Hz, 1H), 7.29 – 7.16 (m, 2H), 7.12 (m, 2H), 7.04 (m, 1H), 3.66 (bs, 
4H), 2.99 (bs, 4H), 1.84 (s, 1H). 13C-NMR (75 MHz, CDCl3) δ 160.64 (Cquat), 160.55 
(Cquat), 152.10 (Cquat), 139.49 (Cquat), 132.78 (+, Ar-CH), 129.62 (+, Ar-CH), 128.46 
(Cquat), 127.53 (+, Ar-CH), 125.66 (+, Ar-CH), 125.13 (+, Ar-CH), 123.45 (Cquat), 121.27 
(+, Ar-CH), 120.57 (+, Ar-CH), 48.67 (-, 2 Pip-CH2), 46.02 (-, 2 Pip-CH2). ESI-MS m/z 
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314.1 [MH+]. CHN (C17H16ClN3O ∙ ¼ H2O) calc. C 64.15; H 5.23; N 13.20; exp. C 64.26; 
H 5.26; N 12.89. 
 
6.11. General procedure J: 
Preparation of compounds 128, 129, 136 
To a solution of 126, 127, or 135 in ethanol the 5-fold excess of SnCl2 · 2 H2O was 
added and the mixture was heated at reflux over night. The next day the mixture was 
cooled to room temperature and the solvent was evaporated under reduced pressure. 
Water and DCM (2 : 7) were added to the resulting solid and the pH was adjusted to 7 
using a saturated solution of Na2CO3. The aqueous layer was then extracted with DCM 
and the combined organic layers were dried over Na2SO4. Evaporation of the solvent 
yielded the crude product, which was purified by column chromatography (EtOAc / 
methanol (1 : 1)) to give the title compounds 128, 129, 136. 
 
8-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepin-3-amine (128) 
     
C18H19ClN4O (M = 342.82 g/mol) 
128 was prepared according to general procedure J from 126 (0.40 g, 1.22 mmol) in 
50 ml ethanol and was obtained as a colorless solid (0.11 g, 0.33 mmol, 26.8 % yield). 
C18H19ClN4O (M = 342.82 g/mol), mp 209.5 °C. 1H-NMR (300 MHz, CDCl3) δ 7.08 (d, 
J = 7.7Hz, 2H), δ 6.96 (d, J = 8.5Hz, 1H), δ 6.88 (d, J = 11.0Hz, 1H), δ 6.46 (m, 2H), δ 
3.96 (s, 2H), δ 3.56 (bs, 4H), δ 2.52 (bs, 4H), δ 2.35 (s, 3H). 13C-NMR (75 MHz, CDCl3) 
δ 162.20 (Cquat), 161.23 (Cquat), 151.05 (Cquat), 150.85 (Cquat), 142.32 (Cquat), 130.87 (+, 
Ar-CH), 130.22 (Cquat), 126.57 (+, Ar-CH), 123.31 (+, Ar-CH), 121.10 (+, Ar-CH), 
112.91 (Cquat), 111.26 (+, Ar-CH), 106.12 (+, Ar-CH), 54.99 (-, 2 Pip-CH2), 47.37 (-, 2 
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Pip-CH2), 46.09 (+, CH3). ESI-MS m/z 342.9 [MH+]. CHN (C18H19ClN4O · 31  H2O) calc.: 
C 61.98; H 5.68; N 16.06; exp.: C 61.65; H 5.66; N 15.68. 
 
7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepin-3-amine (129) 
    
C18H19ClN4O (M = 342.82 g/mol) 
129 was prepared according to general procedure J from 127 (0.24 g, 0.64 mmol) in 
35 ml ethanol and was obtained as colorless solid (0.08 g, 0.23 mmol, 35.9 % yield).  
C18H19ClN4O (M = 342.82 g/mol), mp 222.2 °C. 1H-NMR (300 MHz, CDCl3) δ 7.07 (m, 
4H), δ 6.46 (m, 2H), δ 3.98 (s, 2H), δ 3.62 (bs, 4H), δ 2.61 (bs, 4H), δ 2.41 (s, 3H). 13C-
NMR (75 MHz, CDCl3) δ 162.00 (Cquat), 160.91 (Cquat), 152.18 (Cquat), 151.03 (Cquat), 
139.95 (Cquat), 130.90 (+, Ar-CH), 128.13 (Cquat), 127.54 (+, Ar-CH), 125.52 (+, Ar-CH), 
120.63 (+, Ar-CH), 112.95 (Cquat), 111.35 (+, Ar-CH), 106.15 (+, Ar-CH), 55.03 (-, 2 
Pip-CH2), 47.35 (-, 2 Pip-CH2), 46.12 (+, CH3). ESI-MS m/z 342.9 [MH+]. CHN 
(C18H19ClN4O · 31  H2O) calc.: C 61.98; H 5.68; N 16.06; exp.: C 61.82; H 5.68; N 15.69. 
 
11-(4-Methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepin-3-amine (136) 
    
C18H20N4O (M = 308.38 g/mol) 
136 was prepared according to general procedure J from 135 (1.70 g, 5.02 mmol) in 
140 ml ethanol and was obtained as colorless solid (1.07 g, 3.47 mmol, 69.1 % yield).  
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C18H20N4O (M = 308.38 g/mol), mp 191.4 °C. 1H-NMR (300 MHz, CDCl3) δ 7.08 (m, 
4H), δ 6.95 (m, 1H), δ 6.50 (d, J=2.3Hz, 1H), δ 6.43 (d, J=10.6Hz, 1H), δ 3.95 (s, 2H), 
δ 3.61 (bs, 4H), δ 2.60 (bs, 4H), δ 2.40 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 162.47 
(Cquat), 160.88 (Cquat), 152.24 (Cquat), 150.91 (Cquat), 141.04 (Cquat), 130.85 (+, Ar-CH), 
126.95 (+, Ar-CH), 125.42 (+, Ar-CH), 123.91 (+, Ar-CH), 120.24 (+, Ar-CH), 113.28 
(Cquat), 111.12 (+, Ar-CH), 106.25 (+, Ar-CH), 55.08 (-, 2 Pip-CH2), 47.44 (-, 2 Pip-CH2), 
46.16 (+, CH3). ESI-MS m/z 309.1 [MH+]. CHN (C18H20N4O · ¼ CH3OH) calc.: C 69.28; 
H 6.69; N 17.71; exp.: C 69.48; H 6.50; N 17.37. 
 
6.12. General procedure K:  
Preparation of compounds 205 – 210, 212, 213 
To a solution of two equivalents of 193, or 196 in acetonitrile, one equivalent of 1,w-
dibromo or 1,w-diiodo alkane of different length was added dropwise in presence of 
one equivalent of K2CO3. The reaction mixture was heated at reflux for 12 h under 
nitrogen atmosphere. The reaction status was monitored by TLC and if after 12 h any 
starting material remained, further 0.5 equivalents of 1,w-dibromo or 1,w-diiodo alkane 
was added and the reaction was continued for at least further 6 h. When the reaction 
was completed, the solvent was evaporated and the remaining oil was poured into 
water. The aqueous layer was extracted with CHCl3 and the combined organic layers 
were dried over Na2SO4. The solvent was removed under reduced pressure and the 
remaining foam was purified by column chromatography over silica gel using three 
different solvents (gradual modification of the solvent within one column 
chromatography run): solvent 1: EtOAc / HX (3 : 2); solvent 2: EtOAc; solvent 3: EtOAc 
/ 7 N NH3 in methanol (9 : 1). 
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1,9-Bis(4-(3,8-dichlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)nonane 
(205) 
 
C43H46Cl4N6O2 (M = 820.68 g/mol)  
205 was prepared according to general procedure K using 196 (600 mg, 1.73 mmol) 
and 1,9-dibromononane (246 mg, 0.86 mmol) and was obtained as a light yellow foam 
(440 mg, 0.54 mmol, 62.3 % yield).  
C43H46Cl4N6O2 (M = 820.68 g/mol), mp 82.5 – 82.9 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.29 – 7.23 (m, 3H), δ 7.19 (dd, J = 8.4, 1.9Hz, 2H), δ 7.12 (d, J = 2.5Hz, 2H), δ 7.02 
(d, J = 8.5Hz, 2H), δ 6.92 (dd, J = 8.5, 2.5Hz, 3H), δ 3.51 (bs, 8H), δ 2.51 (bs, 8H), δ 
2.45 – 2.31 (m, 4H), δ 1.58 (s, 4H), δ 1.30 (s, 10H). 13C-NMR (75 MHz, CDCl3) δ 160.79 
(2 Cquat), 159.64 (2 Cquat), 150.28 (2 Cquat), 141.55 (2 Cquat), 138.14 (2 Cquat), 130.77 (2 
Cquat), 130.35 (+, 2 Ar-CH), 126.71 (+, 2 Ar-CH), 125.56 (+, 2 Ar-CH), 123.84 (+, 2 Ar-
CH), 121.87 (+, 2 Ar-CH), 121.08 (+, 2 Ar-CH), 58.74 (-, 4 Pip-CH2), 53.01 (-, 4 Pip-
CH2), 31.96 (-,  2 CH2), 29.48 (-, 2 CH2), 27.92 (-, CH2), 27.51 (-, 2 CH2), 26.67 (-, 2 
CH2). ESI-MS m/z 274.4 [(M+3H)3+]; 411.1 [(M+2H)2+]; 821.3 [MH+]. CHN 
(C43H46Cl4N6O2) calc. C 62.93; H 5.65; N 10.24; exp. C 62.85; H 5.79; N 9.95.  
 
1,9-Bis(4-(3,7-dichlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)nonane 
(206) 
 
C43H46Cl4N6O2 (M = 820.68 g/mol) 
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206 was prepared according to general procedure K using 193 (500 mg, 1.44 mmol) 
and 1,9-dibromononane (205 mg, 0.72 mmol) and was obtained as a light red solid  
(240 mg, 0.29 mmol, 40.8 % yield).  
C43H46Cl4N6O2 (M = 820.68 g/mol), mp 75.7 – 76.0 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.29 – 7.24 (m, 4H), δ 7.19 (dd, J = 8.4, 1.9Hz, 2H), δ 7.12 (t, J = 7.3Hz, 2H), δ 7.07 - 
7.03 (m, 4H), δ 3.61 (bs, 8H), δ 2.62 (bs, 8H), δ 2.45 (s, 4H), δ 1.56 (s, 4H), δ 1.21 (s, 
10H). 13C-NMR (75 MHz, CDCl3) δ 160.57 (2 Cquat), 159.25 (2 Cquat), 151.58 (2 Cquat), 
139.15 (2 Cquat), 138.15 (2 Cquat), 130.37 (+, 2 Ar-CH), 128.81 (2 Cquat), 127.67 (+, 2 
Ar-CH), 126.02 (+, 2 Ar-CH), 125.68 (+, 2 Ar-CH), 121.91 (+, 2 Ar-CH), 120.62 (+, 2 
Ar-CH), 58.70 (-, 4 Pip-CH2), 52.92 (-, 4 Pip-CH2), 31.19 (-,  2 CH2), 29.43 (-, 2 CH2), 
27.97 (-, CH2), 27.46 (-, 2 CH2), 26.52 (-, 2 CH2). ESI-MS m/z 274.4 [(M+3H)3+]; 411.1 
[(M+2H)2+]; 821.2 [MH+]. CHN (C43H46Cl4N6O2 ∙ 8 5 ⁄ H2O) calc. C 60.71; H 5.85; N 9.88; 
exp. C 60.51; H 5.79; N 9.84. 
 
1,12-Bis(4-(3,8-dichlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)dodecane 
(207) 
 
C46H52Cl4N6O2 (M = 862.76 g/mol) 
207 was prepared according to general procedure K using 196 (600 mg, 1.73 mmol) 
and 1,12-dibromododecane (283 mg, 0.86 mmol) and was obtained as a light yellow 
solid (440 mg, 0.51 mmol, 59.3 % yield).  
C46H52Cl4N6O2 (M = 862.76 g/mol), 179.1 – 179.4 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.30 – 7.23 (m, 4H), δ 7.19 (dd, J = 8.4, 1.9Hz, 2H), δ 7.12 (d, J = 2.5Hz, 2H), δ 7.02 
(d, J = 8.5Hz, 2H), δ 6.93 (dd, J = 8.5, 2.5Hz, 2H), δ 3.61 (bs, 8H), δ 2.54 (bs, 8H), δ 
2.49 – 2.34 (m, 4H), δ 1.54 (s, 4H), δ 1.33 (s, 16H). 13C-NMR (75 MHz, CDCl3) δ 160.79 
(2 Cquat), 159.64 (2 Cquat), 150.28 (2 Cquat), 141.57 (2 Cquat), 138.12 (2 Cquat), 130.76 (2 
Cquat), 130.34 (+, 2 Ar-CH), 126.71 (+, 2 Ar-CH), 125.54 (+, 2 Ar-CH), 123.81 (+, 2 Ar-
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CH), 121.91 (2 Cquat), 121.86 (+, 2 Ar-CH), 121.07 (+, 2 Ar-CH), 58.77 (-, 4 Pip-CH2), 
53.02 (-, 4 Pip-CH2), 31.14 (-, 2 CH2),  29.61 (-, 2 CH2), 29.58 (-, 2 CH2), 27.54 (-, 2 
CH2), 26.78 (-, 2 CH2), 26.70 (-, 2 CH2). ESI-MS m/z 288.4 [(M+3H)3+]; 432.1 
[(M+2H)2+]; 863.3 [MH+]. CHN (C46H52Cl4N6O2) calc. C 64.04; H 6.08; N 9.74; exp. C 
63.78; H 6.14; N 9.44. 
 
1,10-Bis(4-(3,8-dichlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)decane 
(208) 
 
C44H48Cl4N6O2 (M = 834.70 g/mol) 
208 was prepared according to general procedure K using 196 (600 mg, 1.73 mmol) 
and 1,10-diiododecane (339 mg, 0.86 mmol) and was obtained as a light yellow solid 
(510 mg, 0.61 mmol, 71.0 % yield).  
C44H48Cl4N6O2 (M = 834.70 g/mol), mp 161.5 – 162.2 °C. 1H-NMR (300 MHz, CDCl3) 
δ 7.31 – 7.23 (m, 4H), δ 7.19 (dd, J = 8.4, 1.9Hz, 2H), δ 7.12 (d, J = 2.5Hz, 2H), δ 7.02 
(d, J = 8.5Hz, 2H), δ 6.93 (dd, J = 8.5, 2.5Hz, 2H), δ 3.61 (bs, 8H), δ 2.53 (bs, 8H), δ 
2.42 – 2.31 (m, 4H), δ 1.54 (s, 4H), δ 1.36 (s, 12H). 13C-NMR (75 MHz, CDCl3) δ 160.80 
(2 Cquat), 159.64 (2 Cquat), 150.28 (2 Cquat), 141.56 (2 Cquat), 138.14 (2 Cquat), 130.77 (2 
Cquat), 130.34 (+, 2 Ar-CH), 126.71 (+, 2 Ar-CH), 125.54 (+, 2 Ar-CH), 123.83 (+, 2 Ar-
CH), 121.90 (2 Cquat), 121.86 (+, 2 Ar-CH), 121.08 (+, 2 Ar-CH), 58.75 (-, 4 Pip-CH2), 
53.00 (-, 4 Pip-CH2), 29.50 (-, 2 CH2), 29.38 (-, 2 CH2), 27.52 (-, 2 CH2), 26.67 (-, 2 
CH2), 26.59 (-, 2 CH2). ESI-MS m/z 279.1 [(M+3H)3+]; 418.1 [(M+2H)2+]; 835.3 [MH+]. 
CHN (C44H48Cl4N6O2 ∙ 2 3 ⁄ H2O) calc. C 62.41; H 5.87; N 9.93; exp. C 62.69; H 5.97; N 
9.57. 
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1,12-Bis(4-(3,7-dichlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)dodecane 
(209) 
  
C46H52Cl4N6O2 (M = 862.76 g/mol) 
209 was prepared according to general procedure K using 193 (380 mg, 1.09 mmol) 
and 1,12-dibromododecane (179 mg, 0.55 mmol) and was obtained as a light red solid 
(200 mg, 0.54 mmol, 42.5 % yield).  
C46H52Cl4N6O2 (M = 862.76 g/mol), mp 145.9 – 146.3 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.29 – 7.23 (m, 4H), δ 7.19 (dd, J = 8.4, 1.9Hz, 2H), δ 7.14 – 7.09 (m, 2H), δ 7.05 (d, 
J = 1.2Hz, 4H), δ 3.59 (bs, 8H), 2.60 (bs, 8H), δ 2.44 – 2.32 (m, 4H), δ 1.54 (s, 4H), δ 
1.33 (s, 16H). 13C-NMR (75 MHz, CDCl3) δ 160.58 (2 Cquat), 159.28 (2 Cquat), 151.58 
(2 Cquat), 139.19 (2 Cquat), 138.11 (2 Cquat), 130.37 (+, 2 Ar-CH), 128.77 (2 Cquat), 127.68 
(+, 2 Ar-CH), 126.02 (+, 2 Ar-CH), 125.66 (+, 2 Ar-CH), 121.95 (2 Cquat), 121.91 (+, 2 
Ar-CH), 120.62 (+, 2 Ar-CH), 58.78 (-, 4 Pip-CH2), 53.01 (-, 4 Pip-CH2), 31.07 (-, 2 
CH2), 29.57 (-, 2 CH2), 29.49 (-, 2 CH2), 27.54 (-, 2 CH2), 26.74 (-, 2 CH2), 26.67 (-, 2 
CH2). ESI-MS m/z 288.4 [(M+3H)3+]; 432.2 [(M+2H)2+]; 863.3 [MH+]. CHN 
(C46H52Cl4N6O2  ∙ 1 3⁄  H2O) calc. C 63.60; H 6.11; N 9.67; exp. C 63.53; H 6.14; N 9.44. 
 
1,10-Bis(4-(3,7-dichlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)decane 
(210) 
 
C44H48Cl4N6O2 (M = 834.70 g/mol) 
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210 was prepared according to general procedure K using 193 (600 mg, 1.73 mmol) 
and 1,10-diiododecane (339 mg, 0.86 mmol) and was obtained as a light yellow solid 
(440 mg, 0.53 mmol, 61.9 % yield).  
C44H48Cl4N6O2 (M = 834.70 g/mol), mp 178.7 – 179.0 °C. 1H-NMR (300 MHz, CDCl3) 
δ 28 – 7.24 (m, 4H), δ 7.19 (dd, J = 8.4, 1.9Hz, 2H), δ 7.14 – 7.09 (m, 2H), δ 7.05 (d, 
J = 1.8Hz, 4H), δ 3.60 (bs, 8H), δ 2.61 (bs, 8H), δ 2.45 (s, 4H), δ 1.55 (s, 4H), δ 1.30 
(s, 12H). 13C-NMR (75 MHz, CDCl3) δ 160.57 (2 Cquat), 159.29 (2 Cquat), 151.58 (2 
Cquat), 139.19 (2 Cquat), 138.11 (2 Cquat), 130.37 (+, 2 Ar-CH), 128.76 (2 Cquat), 127.67 
(+, 2 Ar-CH), 126.01 (+, 2 Ar-CH), 125.65 (+, 2 Ar-CH), 121.95 (2 Cquat), 121.90 (+, 2 
Ar-CH), 120.62 (+, 2 Ar-CH), 58.77 (-, 4 Pip-CH2), 53.02 (-, 4 Pip-CH2), 29.51 (-, 2 
CH2), 29.43 (-, 2 CH2), 27.53 (-, 2 CH2), 26.69 (-, 2 CH2), 26.57 (-, 2 CH2). ESI-MS m/z 
279.1 [(M+3H)3+]; 418.1 [(M+2H)2+]; 835.3 [MH+]. CHN (C44H48Cl4N6O2 ∙ 1 6 ⁄ H2O) calc. 
63.09; H 5.82; N 10.03; exp. C 63.23; H 6.03; N 9.65.  
 
1,8-Bis(4-(3,8-dichlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)octane 
(212) 
 
C42H44Cl4N6O2 (M = 806.65 g/mol) 
212 was prepared according to general procedure K using 196 (600 mg, 1.73 mmol) 
and 1,8-diiodooctane (315 mg, 0.86 mmol) and was obtained as a light yellow solid 
(400 mg, 0.50 mmol, 57.6 % yield).  
C42H44Cl4N6O2 (M = 806.65 g/mol), 176.7 – 177.2 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.30 - 7.23 (m, 4H), δ 7.19 (dd, J = 8.4, 1.9Hz, 2H), δ 7.12 (d, J = 2.5Hz, 2H), δ 7.02 
(d, J = 8.5Hz, 2H), δ 6.93 (dd, J = 8.5, 2.5Hz, 2H), δ 3.61 (bs, 8H), δ 2.59 (bs, 8H), δ 
2.43 (s, 4H), δ 1.55 (s, 4H), δ 1.28 (s, 8H). 13C-NMR (75 MHz, CDCl3) δ 160.79 (2 
Cquat), 159.64 (2 Cquat), 150.28 (2 Cquat), 141.55 (2 Cquat), 138.13 (2 Cquat), 130.77 (2 
Cquat), 130.34 (+, 2 Ar-CH), 126.71 (+, 2 Ar-CH), 125.55 (+, 2 Ar-CH), 123.83 (+, 2 Ar-
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CH), 121.87 (+, 2 Ar-CH), 121.08 (+, 2 Ar-CH), 58.74 (-, 4 Pip-CH2), 53.02 (-, 4 Pip-
CH2), 29.45 (-, 2 CH2), 27.47 (-, 2 CH2), 26.72 (-, 2 CH2), 26.67 (-, 2 CH2). ESI-MS m/z 
269.8 [(M+3H)3+]; 404.1 [(M+2H)2+]; 807.2 [MH+]. CHN (C42H44Cl4N6O2 ∙ 1 7⁄  EtOAc) 
calc. C 62.41; H 5.55; N 10.26; exp. C 62.40; H 5.78; N 9.92. 
 
1,8-Bis(4-(3,7-dichlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)octane 
(213) 
  
C42H44Cl4N6O2 (M = 806.65 g/mol) 
213 was prepared according to general procedure K using 193 (600 mg, 1.73 mmol) 
and 1,8-diiodooctane (315 mg, 0.86 mmol) and was obtained as a light yellow solid 
(350 mg, 0.43 mmol, 50.4 % yield).  
C42H44Cl4N6O2 (M = 806.65 g/mol), 148.3 – 148.7 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.26 (m, 4H), δ 7.19 (dd, J = 8.4, 1.9Hz, 2H), δ 7.12 (t, J = 7.1Hz, 2H), δ 7.05 (d, J = 
1.2Hz, 4H), δ 3.57 (bs, 8H), δ 2.58 (bs, 8H), δ 2.48 – 2.33  (m, 4H), δ 1.53 (s, 4H), δ 
1.27 (s, 8H). 13C-NMR (75 MHz, CDCl3) δ 160.71 (2 Cquat), 159.22 (2 Cquat), 151.48 (2 
Cquat), 139.18 (2 Cquat), 138.20 (2 Cquat), 130.37 (+, 2 Ar-CH), 128.79 (2 Cquat), 127.67 
(+, 2 Ar-CH), 126.02 (+, 2 Ar-CH), 125.67 (+, 2 Ar-CH), 121.92 (+, 2 Ar-CH), 120.62 
(+, 2 Ar-CH), 58.73 (-, 4 Pip-CH2), 53.13 (-, 4 Pip-CH2), 29.43 (-, 2 CH2), 27.45 (-, 2 
CH2), 26.24 (-, 2 CH2), 26.20 (-, 2 CH2). ESI-MS m/z 269.8 [(M+3H)3+]; 404.1 
[(M+2H)2+]; 807.2 [MH+]. CHN (C42H44Cl4N6O2) calc. C 62.54; H 5.50; N 10.42; exp. C 
62.40; H 5.66; N 10.13.  
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6.13. General procedure L: 
Preparation of compounds 217, 224 
Piperazine or homopiperazine was dissolved in dioxane under gentle warming. A 
solution of succinic or glutaric anhydride in 15 ml dioxane was added dropwise and 
under constant stirring and the reaction mixture was heated at reflux for 24 h. After 
cooling to room temperature the solvent was evaporated in vacuo yielding the title 
compounds 217, 224 which were used in the next step without further purification.  
 
4,4'-(Piperazine-1,4-diyl)bis(4-oxobutanoic acid) (217) 
 
C12H18N2O6 (M = 286.28 g/mol) 
217 was prepared according to general procedure L using piperazine (1.00 g, 11.61 
mmol, dissolved in 25 ml dioxane) and succinic anhydride (2.28 g, 22.83 mmol, 
dissolved in 15 ml dioxane) and was obtained as colorless crystalline solid after re-
crystallization from ethanol (2.39 g, 8.35 mmol, 71.9 % yield). 
C12H18N2O6 (M = 286.28 g/mol), 171.2 °C.  1H-NMR (300 MHz, CD3OD) δ 4.92 (s, 2H), 
δ 3.78 (d, J = 7.8Hz, 8H), δ 2.48 (bs, 8H). ESI-MS m/z 287.1 [MH+]. CHN (C12H18N2O6) 
calc. C 50.35; H 6.34; N 9.79; exp. C 50.28; H 6.45; N 9.82. 
 
5,5'-(1,4-Diazepane-1,4-diyl)bis(5-oxopentanoic acid) (224) 
 
C15H24N2O6 (M = 328.36 g/mol) 
224 was prepared according to general procedure L using homopiperazine (500 mg, 
4.99 mmol, dissolved in 15 ml dioxane) and  glutaric anhydride (1.15 g, 10.12 mmol, 
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dissolved in 10 ml dioxane) and was obtained as a light yellow oil (1.31 g, 4.00 mmol, 
79.5 % yield). 
C15H24N2O6 (M = 328.36 g/mol). 1H-NMR (300 MHz, CD3OD) δ 4.98 (s, 2H), δ 3.80 – 
3.67 (m, 12H), δ 2.54 (bs, 8H), δ 1.56 (m, 2H). ESI-MS m/z 329.2 [MH+]. 
 
6.14. General procedure M: 
Preparation of compounds 225, 238 – 242, 244 
The dioic acid 217 or 224 was suspendend in DCM under nitrogen atmosphere. A drop 
of DMF and 2.2 equivalents of oxalylchlorid were added and the reaction mixture was 
stirred at room temperature for 1 h. As soon as the reaction was completed (colour 
turned deeply yellow) the solution was carefully added to a solution of 193, 196, 232, 
233, 234, or 235 that was prepared in the meantime and to which a drop of pyridine 
and 2.5 equivalents of DIPEA were added. The mixture was stirred at room 
temperature over night and the next day partitioned between ethyl acetate and 
aqueous Na2CO3 solution. The organic layer was separated and the aqueous layer 
was extracted with ethyl acetate. The combined organic layers were washed with water 
and brine and afterwards dried over Na2SO4. The solvent was evaporated in vacuo 
and the resulting crude product was purified by column chromatography over silica gel 
(gradual modification of the solvent within one column chromatography run, solvent 1: 
EtOAc / HX (3 : 2), solvent 2: EtOAc, solvent 3: methanol). 
 
4,4'-(Piperazine-1,4-diyl)bis(1-(4-(3,8-dichlorodibenzo[b,f][1,4]oxazepin-11-
yl)piperazin-1-yl)butane-1,4-dione) (225) 
 
C46H44Cl4N8O6 (M = 946.70 g/mol) 
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225 was prepared according to general procedure M using 196 (600 mg, 1.72 mmol) 
and 217 (421 mg, 1.47 mmol) and was obtained as a light yellow solid (273 mg, 0.29 
mmol, 33.5 % yield).  
C46H44Cl4N8O6 (M = 946.70 g/mol), mp 164.2 – 165.0 °C. 1H-NMR (300 MHz, CDCl3) 
δ 7.30 – 7.25 (m, 4H), δ 7.22 (dd, J = 8.4, 1.8Hz, 2H), δ 7.14 (d, J = 2.3Hz, 2H), δ 7.03 
(d, J = 8.5Hz, 2H), δ 6.96 (dd, J = 8.6, 2.5Hz, 2H), δ 3.74 – 3.44 (m, 16H), δ 2.72 (s, 
8H), δ 1.89 (bs, 8H). 13C-NMR (75 MHz, CDCl3) δ 170.70 (2 Cquat, C=O), 170.68 (2 
Cquat, C=O), 160.88 (2 Cquat), 159.60 (2 Cquat), 150.24 (2 Cquat), 141.18 (2 Cquat), 138.54 
(2 Cquat), 130.96 (2 Cquat), 130.09 (+, 2 Ar-CH), 126.76 (+, 2 Ar-CH), 125.79 (+, 2 Ar-
CH), 124.35 (+, 2 Ar-CH), 122.03 (+, 2 Ar-CH), 121.66 (2 Cquat), 121.18 (+, 2 Ar-CH), 
45.07 (-, 4 Pip-CH2), 45.02 (-, 4 Pip-CH2), 41.61 (-, 4 Pip-CH2), 28.07 (-, 2 CH2), 28.00 
(-, 2 CH2). ESI-MS m/z 474.1 [(M+2H)2+]; 947.2 [MH+]. CHN (C46H44Cl4N8O6 ∙ 3 H2O) 
calc. C 55.21, H 5.04, N 11.20; exp.: C 55.13, H 4.74, N 10.92 
 
4,4'-(Piperazine-1,4-diyl)bis(1-(4-(3-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-
piperazin-1-yl)butane-1,4-dione) (238) 
 
C46H46Cl2N8O6 (M = 877.81 g/mol) 
238 was prepared according to general procedure M using 232 (600 mg, 1.91 mmol) 
and 217 (467 mg, 1.63 mmol) and was obtained as a light yellow solid (258 mg, 0.29 
mmol, 30.8 % yield).  
C46H46Cl2N8O6 (M = 877.81 g/mol), 159.8 – 160.1 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.31 – 7.25 (m, 4H), δ 7.21 (d, J = 1.9Hz, 2H), δ 7.16 (dd, J = 6.8, 3.3Hz, 2H), δ 7.15 
– 7.12 (m, 2H), δ 7.11 – 7.06 (m, 2H), δ 7.02 (m, 2H), δ 3.64 – 3.51 (m, 14H), δ 3.47 
(bs, 4H), δ 2.64 (s, 8H), δ 2.12 (bs, 6H). 13C-NMR (75 MHz, CDCl3) δ 170.71 (2 Cquat, 
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C=O), 170.69 (2 Cquat, C=O), 160.90 (2 Cquat), 159.62 (2 Cquat), 150.28 (2 Cquat), 138.61 
(2 Cquat), 130.88 (2 Cquat), 130.13 (+, 2 Ar-CH), 126.76 (+, 2 Ar-CH), 125.81 (+, 2 Ar-
CH), 124.46 (+, 2 Ar-CH), 124.42 (+, 2 Ar-CH), 122.05 (+, 2 Ar-CH), 121.59 (2 Cquat), 
121.19 (+, 2 Ar-CH), 45.12 (-, 4 Pip-CH2), 45.08 (-, 4 Pip-CH2), 41.59 (-, 4 Pip-CH2), 
28.05 (-, 2 CH2), 28.01 (-, 2 CH2). ESI-MS m/z 439.15 [(M+2H)2+]; 877.30 [MH+]. CHN 
(C46H46Cl2N8O6 ∙ 5 2 ⁄ H2O) calc. C 59.87, H 5.57, N 12.14; exp. C 59.81, H 5.40, N 
12.23. 
 
4,4'-(Piperazine-1,4-diyl)bis(1-(4-(3,7-dichlorodibenzo[b,f][1,4]oxazepin-11-
yl)piperazin-1-yl)butane-1,4-dione) (239) 
 
C46H44Cl4N8O6 (M = 946.70 g/mol) 
239 was prepared according to general procedure M using 193 (250 mg, 0.73 mmol) 
and 217 (175 mg, 0.61 mmol) and was obtained as a light yellow solid (127 mg, 0.13 
mmol, 37.32 % yield).  
C46H44Cl4N8O6 (M = 946.70 g/mol), 160.4 – 160.8 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.31 – 7.24 (m, 4H), δ 7.22 (dd, J = 8.4, 1.9Hz, 2H), δ 7.15 – 7.10 (m, 2H), δ 7.06 (d, 
J = 1.6Hz, 4H), δ 3.62 – 3.54 (m, 12H), δ 3.46 (bs, 4H), δ 2.72 (s, 8H), δ 1.76 (bs, 8H). 
13C-NMR (75 MHz, CDCl3) δ 170.78 (2 Cquat, C=O), 170.68 (2 Cquat, C=O), 160.66 (2 
Cquat), 159.22 (2 Cquat), 151.54 (2 Cquat), 138.77 (2 Cquat), 138.51 (2 Cquat), 130.12 (+, 2 
Ar-CH), 129.32 (2 Cquat), 127.73 (+, 2 Ar-CH), 126.11 (+, 2 Ar-CH), 125.90 (+, 2 Ar-
CH), 122.08 (+, 2 Ar-CH), 121.72 (2 Cquat), 120.71 (+, 2 Ar-CH), 45.29 (-, 4 Pip-CH2), 
45.02 (-, 4 Pip-CH2), 41.57 (-, 4 Pip-CH2), 28.04 (-, 2 CH2), 28.00 (-, 2 CH2). ESI-MS 
m/z 474.1 [(M+2H)2+]; 947.2 [MH+]. CHN (C46H44Cl4N8O6 ∙ 4 H2O) calc. C 54.32, H 
5.14, N 11.00; exp. C 54.70, H 4.76, N 10.66. 
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4,4'-(Piperazine-1,4-diyl)bis(1-(4-(dibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-
yl)butane-1,4-dione) (240) 
 
C46H48N8O6 (M = 808.92 g/mol) 
240 was prepared according to general procedure M using 233 (300 mg, 1.07 mmol) 
and 217 (261 mg, 0.91 mmol) and was obtained as a light yellow solid (152 mg, 0.19 
mmol, 35.1 % yield).  
C46H48N8O6 (M = 808.92 g/mol), mp 164.2 – 164.9 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.50 – 7.41 (m, 2H), δ 7.35 (dd, J = 7.7, 1.6Hz, 2H), δ 7.30 – 7.04 (m, 10H), δ 7.03 – 
6.95 (m, 2H), δ 3.67 – 3.61 (m, 10H), δ 3.46 (bs, 8H), δ 2.73 (s, 8H), δ 2.06 (s, 1H), δ 
1.76 (bs, 4H), δ 1.25 (s, 1H). 13C-NMR (75 MHz, CDCl3) δ 170.81 (2 Cquat, C=O), 
170.64 (2 Cquat, C=O), 161.07 (2 Cquat), 160.16 (2 Cquat), 152.11 (2 Cquat), 140.22 (2 
Cquat), 132.96 (+, 2 Ar-CH), 129.36 (+, 2 Ar-CH), 126.96 (+, 2 Ar-CH), 125.62 (+, 2 Ar-
CH), 125.03 (+, 2 Ar-CH), 124.64 (+, 2 Ar-CH), 123.38 (2 Cquat), 121.45 (+, 2 Ar-CH), 
120.29 (+, 2 Ar-CH), 45.33 (-, 4 Pip-CH2), 45.11 (-, 4 Pip-CH2), 41.67 (-, 4 Pip-CH2), 
28.03 (-, 2 CH2), 28.01 (-, 2 CH2). ESI-MS m/z 405.2 [(M+2H)2+]; 809.4 [MH+]. CHN 
(C46H48N8O6 ∙ 4 H2O) calc. C 62.71, H 6.41, N 12.72; exp. C 62.63, H 6.09, N 12.52.  
 
4,4'-(Piperazine-1,4-diyl)bis(1-(4-(8-chlorodibenzo[b,f][1,4]oxazepin-11-yl) 
piperazin-1-yl)butane-1,4-dione) (241) 
 
C46H46Cl2N8O6 (M = 877.81 g/mol) 
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241 was prepared according to general procedure M using 234 (300 mg, 0.96 mmol) 
and 217 (234 mg, 0.82 mmol) and was obtained as a colorless solid (148 mg, 0.17 
mmol, 35.4 % yield).  
C46H46Cl2N8O6 (M = 877.81 g/mol), mp 161.1 – 162.0 °C.  1H-NMR (300 MHz, CDCl3) 
δ 7.53 – 7.42 (m, 2H), δ 7.33 (dd, J = 7.7, 1.6Hz, 2H), δ 7.28 – 7.17 (m, 4H), δ 7.13 (d, 
J = 2.5Hz, 2H), δ 7.03 (d, J = 8.5Hz, 2H), δ 6.93 (dd, J = 8.5, 2.6Hz, 2H), δ 3.78 – 3.60 
(m, 10H), δ 3.53 (bs, 8H), δ 2.72 (s, 8H), δ 1.67 (bs, 6H). 13C-NMR (75 MHz, CDCl3) δ 
170.78 (2 Cquat, C=O), 170.66 (2 Cquat, C=O), 160.78 (2 Cquat), 160.57 (2 Cquat), 150.71 
(2 Cquat), 141.43 (2 Cquat), 133.19 (+, 2 Ar-CH), 130.48 (2 Cquat), 129.36 (+, 2 Ar-CH), 
126.61 (+, 2 Ar-CH), 125.27 (+, 2 Ar-CH), 124.08 (+, 2 Ar-CH), 123.10 (2 Cquat), 121.40 
(+, 2 Ar-CH), 121.15 (+, 2 Ar-CH), 45.24 (-, 4 Pip-CH2), 45.09 (-, 4 Pip-CH2), 41.63 (-, 
4 Pip-CH2), , 28.04 (-, 2 CH2), 28.01 (-, 2 CH2). ESI-MS m/z 439.2 [(M+2H)2+]; 877.3 
[MH+]. CHN (C46H46Cl2N8O6 ∙ 3 H2O) calc. C 59.29, H 5.62, N 12.02; exp. C  59.20, H 
5.65, N 11.82.   
 
4,4'-(Piperazine-1,4-diyl)bis(1-(4-(7-chlorodibenzo[b,f][1,4]oxazepin-11-yl) 
piperazin-1-yl)butane-1,4-dione) (242) 
  
C46H46Cl2N8O6 (M = 877.81 g/mol) 
242 was prepared according to general procedure M using 235 (500 mg, 1.59 mmol) 
and 217 (386 mg, 1.35 mmol) and was obtained as a colorless solid (193 mg, 0.22 
mmol, 27.7 % yield).  
C46H46Cl2N8O6 (M = 877.81 g/mol), mp 165.3 °C.  1H-NMR (300 MHz, CDCl3) δ 7.31 
(m, 2H), δ 7.29 – 7.25 (m, 4H), δ 7.22 (dd, J = 8.2, 2.3 Hz, 2H), δ 7.15 – 7.11 (m, 2H), 
δ 7.03 (d, J = 8.5Hz, 2H), δ 6.95 (dd, J = 7.8, 2.6Hz, 2H), δ 3.74 – 3.60 (m, 10H), δ 
3.51 (bs, 8H), δ 2.72 (s, 8H), δ 1.70 (bs, 6H). 13C-NMR (75 MHz, CDCl3) δ 170.79 (2 
Cquat, C=O), 170.69 (2 Cquat, C=O), 160.90 (2 Cquat), 159.62 (2 Cquat), 150.28 (2 Cquat), 
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130.88 (2 Cquat), 130.13 (+, 2 Ar-CH), 127.06 (2 Cquat), 126.76 (+, 2 Ar-CH), 125.82 (+, 
2 Ar-CH), 124.43 (+, 2 Ar-CH), 122.06 (+, 2 Ar-CH), 121.19 (+, 2 Ar-CH), 121.07 (+, 2 
Ar-CH), 45.23 (-, 4 Pip-CH2), 45.08 (-, 4 Pip-CH2), 41.58 (-, 4 Pip-CH2), 28.05 (-, 2 
CH2), 28.02 (-, 2 CH2). ESI-MS m/z 439.2 [(M+2H)2+]; 877.3 [MH+]. CHN 
(C46H46Cl2N8O6 ∙ 3 H2O) calc. C 59.29, H 5.62, N 12.02; exp. C 59.46, H 5.48, N 12.08.   
 
5,5'-(1,4-Diazepane-1,4-diyl)bis(1-(4-(3,7-dichlorodibenzo[b,f][1,4]oxazepin-11-
yl)piperazin-1-yl)pentane-1,5-dione) (244) 
 
C49H50Cl4N8O6 (M = 988.76 g/mol) 
244 was prepared according to general procedure M using 193 (300 mg, 0.86 mmol) 
and 224 (240 mg, 0.73 mmol). After additional purification by preparative HPLC*, 244 
was obtained as trifluoroacetate salt that was extracted with EtOAc to give the free 
base of 244 as a light yellow solid (116 mg, 0.12 mmol, 27.2 % yield).  
C49H50Cl4N8O6 (M = 988.76 g/mol), mp 139.4 – 139.8 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.29 – 7.26 (m, 4H), 7.22 (d, J = 8.4Hz, 2H), 7.11 (m, 2H), 7.07 (m, 4H), 3.73 – 3.37 
(m, 12H), 2.42 (d, J = 6.7 Hz, 8H), 2.04 – 1.80 (m, 8H), 1.36 – 1.14 (m, 8H), 1.11 - 1.04 
(m, 2H). 13C-NMR (75 MHz, CDCl3) δ 172.17 (2 Cquat, C=O), 171.53 (Cquat, C=O), 
171.41 (Cquat, C=O), 160.64 (2 Cquat), 159.25 (2 Cquat), 151.53 (2 Cquat), 138.78 (2 Cquat), 
138.51 (2 Cquat), 130.14 (+, 2 Ar-CH), 129.29 (2 Cquat), 127.73 (+, 2 Ar-CH), 126.10 (+, 
2 Ar-CH), 125.90 (+, 2 Ar-CH), 122.06 (+, 2 Ar-CH), 121.71 (2 Cquat), 120.70 (+, 2 Ar-
CH), 47.40 (-,  4 Pip-CH2), 47.31 (-,  4 Pip-CH2), 45.19 (-, 2 HomPip-CH2), 41.29 (-, 2 
HomPip-CH2), 32.81 (-, 2 CH2), 31.85 (-, 2 CH2), 27.14 (-, 2 CH2), 20.62 (-, HomPip-
CH2). ESI-MS m/z 495.1 [(M+2H)2+]; 989.3 [MH+]. CHN (C49H50Cl4N8O6 ∙ 3 H2O) calc. 
C 56.44, H 5.41, N 10.75; exp. C 56.53, H 5.48, N 10.57. 
* = see section 6.17 (Appendix) for experimental details 
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6.15. General procedure N: 
Preparation of compounds 215, 221, 227, 229 – 231, 243 
The dioic acid (1,8-octanedioic acid, 217, 224) was suspendend in DCM under nitrogen 
atmosphere. A drop of DMF and 2.2 equivalents of oxalylchlorid were added and the 
reaction mixture was stirred at room temperature for 2 h. As soon as the reaction was 
completed (colour turned deeply yellow) the solution was carefully added to a solution 
of 128, 129, or 136 that was prepared in the meantime and to which a drop of pyridine 
and 2.5 equivalents of DIPEA were added. The mixture was stirred at room 
temperature for 1 - 6 h (monitored by TLC) and afterwards partitioned between ethyl 
acetate and aqueous Na2CO3 solution. The organic layer was separated and the 
aqueous layer was extracted with ethyl acetate. The combined organic layers were 
washed with water and brine and afterwards dried over Na2SO4. The solvent was 
evaporated in vacuo and the resulting crude product was purified by column 
chromatography over silica gel (solvent 1: CH3OH, solvent 2: 7 N NH3 in CH3OH). 
 
N1,N8-Bis(7-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepin-3-yl)-
octanedioicacid diamide (215) 
  
C44H48Cl2N8O4 (M = 823.81 g/mol) 
215 was prepared according to general procedure N using 129 (250 mg, 0.73 mmol) 
and 1,8-octanedioic acid (120 mg, 0.69 mmol) and was obtained as a colorless solid 
(83 mg, 0.10 mmol, 27.7 % yield).  
C44H48Cl2N8O4 (M = 823.81 g/mol), mp 152.7 – 153.4 °C.  1H-NMR (300 MHz, CD3OD) 
δ 7.73 (d, J = 1.9Hz, 2H), δ 7.46 (dt, J = 15.3, 5.2Hz, 4H), δ 7.20 (d, J = 1.2Hz, 2H), δ 
7.15 (t, J = 5.0Hz, 4H), δ 3.82 (bs, 2H), δ 3.42 (bs, 8H), δ 3.30 (dt, J = 3.2, 1.6 Hz, 8H), 
δ 2.97 (s, 6H), δ 2.40 (t, J = 7.4Hz, 4H), δ 1.70 (m, 4H), δ 1.39 (m, 4H). 13C-NMR (75 
MHz, CD3OD) δ 175.08 (2 Cquat, C=O), 162.65 (2 Cquat), 161.39 (2 Cquat), 153.94 (2 
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Cquat), 145.79 (2 Cquat), 131.45 (+, 2 Ar-CH), 131.40 (2 Cquat), 128.79 (+, 2 Ar-CH), 
127.02 (+, 2 Ar-CH), 121.98 (+, 2 Ar-CH), 117.89 (2 Cquat), 117.70 (+, 2 Ar-CH), 112.81 
(+, 2 Ar-CH), 54.13 (-, 4 Pip-CH2), 48.19 (-, 4 Pip-CH2), 43.70 (+, 2 CH3), 37.94 (-, 2 
CH2), 30.00 (-, 2 CH2), 26.47 (-, 2 CH2). ESI-MS m/z 275.1 [(M+3H)3+]; 412.2 
[(M+2H)2+]; 823.3 [MH+]. CHN (C44H48Cl2N8O4 ∙ 3 H2O) calc.: C 60.20, H 6.20, N 12.76; 
exp.: C 60.49, H 6.34, N 12.65. 
 
4,4'-(Piperazine-1,4-diyl)bis(N-(11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]-
oxazepin-3-yl)-4-oxobutanamide) (221) 
  
C48H54N10O6 (M = 867.01 g/mol) 
221 was prepared according to general procedure N using 136 (200 mg, 0.65 mmol) 
and 217 (159 mg, 0.56 mmol) and was obtained as a colorless solid (70 mg, 0.08 
mmol, 25.0 % yield).   
C48H54N10O6 (M = 867.01 g/mol), 175.1 – 175.5 °C. 1H-NMR (300 MHz, CD3OD) δ 7.74 
(s, 2H), δ 7.44 (d, J = 0.9Hz, 4H), δ 7.32 – 7.02 (m, 8H), 3.70 (bs, 2H), δ 3.66 - 3.57 
(m, 8H), δ 3.50 (s, 8H), δ 3.42 (bs, 8H), δ 2.96 (s, 6H), δ 2.84 – 2.68 (m, 8H). 13C-NMR 
(75 MHz, CD3OD) δ 175.26 (2 Cquat, C=O), 172.68 (2 Cquat, C=O), 171.02, 161.39 (2 
Cquat), 159.97 (2 Cquat), 142.24 (2 Cquat), 140.57 (2 Cquat), 130.01 (+, 2 Ar-CH), 127.01 
(+, 2 Ar-CH), 125.60 (+, 2 Ar-CH), 124.59 (+, 2 Ar-CH), 121.71 (2 Cquat), 120.39 (+, 2 
Ar-CH), 118.73 (2 Cquat), 115.55 (+, 2 Ar-CH), 111.76 (+, 2 Ar-CH), 54.92 (-, 4 Pip-
CH2), 48.17 (-, 4 Pip-CH2), 45.97 (+, 2 CH3), 41.52 (-, 4 Pip-CH2), 32.52 (-, 2 CH2), 
28.77 (-, 2 CH2). ESI-MS m/z 289.8 [(M+3H)3+]; 434.2 [(M+2H)2+]; 867.4 [MH+]. CHN 
(C48H54N10O6 ∙ 3 H2O) calc.: C 62.59, H 6.57, N 13.21; exp.: C 62.98, H 6.60, N 13.37.  
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4,4'-(Piperazine-1,4-diyl)bis(N-(7-chloro-11-(4-methylpiperazin-1-yl)dibenzo-
[b,f][1,4]oxazepin-3-yl)-4-oxobutanamide) (227) 
 
C48H52Cl2N10O6 (M = 935.90 g/mol) 
227 was prepared according to general procedure N using 129 (200 mg, 0.59 mmol) 
and 217 (143 mg, 0.50 mmol) and was obtained as a light yellow solid (79 mg, 0.08 
mmol, 28.8 % yield).  
C48H52Cl2N10O6 (M = 935.90 g/mol), 162.4 – 162.8 °C. 1H-NMR (300 MHz, CD3OD) δ 
7.68 (s, 2H), δ 7.52 – 7.24 (m, 6H), δ 7.13 – 6.97 (m, 4H), δ 6.93 (dd, J = 8.6, 2.5Hz, 
2H), δ 3.72 – 3.51 (m, 16H), δ 2.74 (d, J = 8.0Hz, 8H), δ 2.54 (bs, 8H), δ 2.33 (s, 6H). 
13C-NMR (75 MHz, CD3OD) δ 173.51 (2 Cquat, C=O), 172.86 (2 Cquat, C=O), 162.68 (2 
Cquat), 152.46 (2 Cquat), 143.23 (2 Cquat), 131.43 (2 Cquat), 131.34 (+, 2 Ar-CH), 127.32 
(+, 2 Ar-CH), 126.31 (2 Cquat), 125.68 (2 Cquat), 124.96 (+, 2 Ar-CH), 122.53 (+, 2 Ar-
CH), 118.97 (2 Cquat), 117.10 (+, 2 Ar-CH), 112.51 (+, 2 Ar-CH), 55.71 (-, 4 Pip-CH2), 
48.09 (-, 4 Pip-CH2), 46.32 (+, 2 CH3), 46.12 (-, 4 Pip-CH2), 32.64 (-, 2 CH2), 28.78 (-, 
2 CH2). ESI-MS m/z 312.5 [(M+3H)3+]; 468.2 [(M+2H)2+]; 935.4 [MH+]. CHN 
(C48H52Cl2N10O6 ∙ 4 H2O) calc. C 57.20, H 6.00, N 13.90; exp. C 57.31, H 5.75, N 13.62.   
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5,5'-(1,4-Diazepane-1,4-diyl)bis(N-(8-chloro-11-(4-methylpiperazin-1-yl)dibenzo-
[b,f][1,4]oxazepin-3-yl)-5-oxopentanamide) (229) 
 
C51H58Cl2N10O6 (M = 977.98 g/mol) 
229 was prepared according to general procedure N using 128 (200 mg, 0.58 mmol) 
and 224 (164 mg, 0.50 mmol) and was obtained as a light yellow solid (81 mg, 0.08 
mmol, 28.5 % yield).  
C51H58Cl2N10O6 (M = 977.98 g/mol), 168.7 – 169.3 °C. 1H-NMR (300 MHz, CD3OD) δ 
7.66 (dd, J = 8.0, 3.5Hz, 2H), δ 7.46 – 7.13 (m, 4H), δ 7.11 – 6.72 (m, 6H), δ 3.65– 
3.39 (m, 16H), δ 2.76 – 2.33 (m, 16H), δ 2.32 (s, 6H), δ 1.93 (dd, J = 15.3, 8.5Hz, 4H), 
δ 1.75 (bs, 2H), δ 1.28 (bs, 2H). 13C-NMR (75 MHz, CD3OD) δ 174.17 (2 Cquat, C=O), 
173.96 (2 Cquat, C=O), 165.96 (2 Cquat), 162.41 (2 Cquat), 152.37 (2 Cquat), 144.81 (+, 2 
Ar-CH), 143.18 (2 Cquat), 131.35 (+, 2 Ar-CH), 127.35 (+, 2 Ar-CH), 124.96 (+, 2 Ar-
CH), 122.51 (+, 2 Ar-CH), 119.12 (2 Cquat), 117.21 (2 Cquat), 112.78 (+, 2 Ar-CH), 112.64 
(2 Cquat), 55.71 (-, 4 Pip-CH2), 48.12 (-, 4 Pip-CH2), 46.12 (+, 2 CH3), 37.04 (-, 2 
HomPip-CH2), 33.29 (-, 2 HomPip-CH2), 32.61 (-, 2 CH2), 28.16 (-, 2 CH2), 23.65 (-, 
HomPip-CH2), 22.06 (-, 2 CH2). ESI-MS m/z 326.5 [(M+3H)3+]; 489.2 [(M+2H)2+]; 977.4 
[MH+]. CHN (C51H58Cl2N10O6 ∙ 3 H2O) calc. C 59.35, H 6.25, N 13.57; exp. C 59.29, H 
6.19, N 13.21.  
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4,4'-(Piperazine-1,4-diyl)bis(N-(8-chloro-11-(4-methylpiperazin-1-yl)dibenzo-
[b,f][1,4]oxazepin-3-yl)-4-oxobutanamide) (230) 
  
C48H52Cl2N10O6 (M = 935.90 g/mol) 
230 was prepared according to general procedure N using 128 (250 mg, 0.73 mmol) 
and 217 (179 mg, 0.62 mmol) and was obtained as a light yellow solid (95 mg, 0.10 
mmol, 28.0 % yield).  
C48H52Cl2N10O6 (M = 935.90 g/mol), 173.4 – 173.9 °C. 1H-NMR (300 MHz, CD3OD) δ 
7.69 (s, 2H), δ 7.51 – 7.24 (m, 6H), δ 7.15 – 6.99 (m, 4H), δ 6.91 (dd, J = 8.4, 2.2Hz, 
2H), δ 3.65 - 3.48 (m, 16H), δ 2.72 (d, J = 8.2Hz, 8H), δ 2.50 (bs, 8H), δ 2.31 (s, 6H). 
13C-NMR (75 MHz, CD3OD) δ 172.71 (2 Cquat, C=O), 172.16 (2 Cquat, C=O), 160.17 (2 
Cquat), 151.20 (2 Cquat), 143.01 (2 Cquat), 131.97 (2 Cquat), 131.44 (+, 2 Ar-CH), 127.12 
(+, 2 Ar-CH), 126.56 (2 Cquat), 125.71 (2 Cquat), 124.80 (+, 2 Ar-CH), 122.35 (+, 2 Ar-
CH), 118.81 (2 Cquat), 117.02 (+, 2 Ar-CH), 112.47 (+, 2 Ar-CH), 55.74 (-, 4 Pip-CH2), 
48.16 (-, 4 Pip-CH2), 46.29 (+, 2 CH3), 46.11 (-, 4 Pip-CH2), 32.48 (-, 2 CH2), 28.80 (-, 
2 CH2). ESI-MS m/z 312.5 [(M+3H)3+]; 468.2 [(M+2H)2+]; 935.4 [MH+]. CHN 
(C48H52Cl2N10O6 ∙ 4 H2O) calc. C 57.20, H 6.00, N 13.90; exp. 57.16, H 5.98, N 13.68.   
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5,5'-(1,4-Diazepane-1,4-diyl)bis(N-(7-chloro-11-(4-methylpiperazin-1-yl)dibenzo-
[b,f][1,4]oxazepin-3-yl)-5-oxopentanamide) (231) 
 
C51H58Cl2N10O6 (M = 977.98 g/mol) 
231 was prepared according to general procedure N using 129 (220 mg, 0.64 mmol) 
and 224 (180 mg, 0.55 mmol) and was obtained as a light yellow solid (94 mg, 0.10 
mmol, 29.9 % yield).  
C51H58Cl2N10O6 (M = 977.98 g/mol), 159.1 – 159.8 °C. 1H-NMR (300 MHz, CD3OD) δ 
7.67 (s, 2H), δ 7.45 – 7.18 (m, 4H), δ 7.13 – 6.97 (m, 6H), δ 3.61 – 3.39 (m, 16H), δ 
2.70 – 2.36 (m, 16H), δ 2.32 (s, 6H), δ 2.05 – 1.86 (m, 4H), δ 1.72 (bs, 2H), δ 1.28 (bs, 
2H). 13C-NMR (75 MHz, CD3OD) δ 174.65 (2 Cquat, C=O), 174.03 (2 Cquat, C=O), 
162.37 (2 Cquat), 162.01 (2 Cquat), 153.75 (2 Cquat), 144.79 (2 Cquat), 140.80 (2 Cquat), 
131.34 (+, 2 Ar-CH), 129.86 (2 Cquat), 128.75 (+, 2 Ar-CH), 126.72 (+, 2 Ar-CH), 121.65 
(+, 2 Ar-CH), 119.18 (2 Cquat), 117.38 (+, 2 Ar-CH), 112.64 (+, 2 Ar-CH), 55.71 (-, 4 
Pip-CH2), 48.13 (-, 4 Pip-CH2), 46.14 (+, 2 CH3), 41.55 (-, 2 HomPip-CH2), 36.82 (-, 2 
HomPip-CH2), 33.31 (-, 2 CH2), 32.69 (-, 2 CH2), 23.51 (-, HomPip-CH2), 22.13 (-, 2 
CH2). ESI-MS m/z 326.5 [(M+3H)3+]; 489.2 [(M+2H)2+]; 977.4 [MH+]. CHN 
(C51H58Cl2N10O6 ∙ 3 CH3OH) calc. C 60.38; H 6.57; N 13.04; exp. C 60.11; H 6.29; N 
12.99. 
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5,5'-(1,4-Diazepane-1,4-diyl)bis(N-(11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]-
oxazepin-3-yl)-5-oxopentanamide) (243) 
 
 
C51H60N10O6 (M = 909.09 g/mol) 
243 was prepared according to general procedure N using 136 (80 mg, 0.26 mmol) 
and 224 (72 mg, 0.22 mmol). After additional purification by preparative HPLC*, 243 
was obtained as trifluoroacetate salt that was extracted with EtOAc to give the free 
base of 243 as a colorless solid (32 mg, 0.04 mmol, 27.0 % yield). 
C51H60N10O6 (M = 909.09 g/mol), 156.2 – 156.7 °C. 1H NMR (300 MHz, CD3OD) δ 7.67 
(dd, J = 8.2, 6.3Hz , 2H), δ 7.41 – 7.21 (m, 4H), δ 7.18 – 6.90 (m, 8H), δ 3.70 - 3.49 
(m, 16H), δ 2.64 (bs, 6H), δ 2.57 – 2.36 (m, 12H), δ 2.00 – 1.86 (m, 4H), δ 1.76 (bs, 
2H), δ 0.91 (m, 6H). 13C-NMR (75 MHz, CD3OD) δ 176.13 (2 Cquat, C=O), 174.02 (2 
Cquat, C=O), 167.51 (2 Cquat), 162.12 (2 Cquat), 153.82 (2 Cquat), 152.52 (2 Cquat), 147.31 
(2 Cquat), 141.61 (+, 2 Ar-CH), 138.72 (+, 2 Ar-CH), 131.36 (+, 2 Ar-CH), 129.43 (+, 2 
Ar-CH), 126.65 (+, 2 Ar-CH), 125.76 (+, 2 Ar-CH), 121.40 (2 Cquat), 117.02 (+, 2 Ar-
CH), 55.75 (-, 4 Pip-CH2), 48.09 (-, 4 Pip-CH2), 46.15 (+, 2 CH3), 43.16 (-, 2 HomPip-
CH2), 36.83 (-, 2 HomPip-CH2), 32.81 (-, 2 CH2), 30.85 (-, 2 CH2), 30.29 (-, 2 CH2), 
23.81 (-, HomPip-CH2). ESI-MS m/z 303.8 [(M+3H)3+]; 455.2 [(M+2H)2+]; 909.5 [MH+]. 
CHN (C51H60N10O6) calc. C 67.38, H 6.65, N 15.41; exp. C 62.24, H 7.46, N 9.28. 
Although the experimental CHN data did not match the calculated, the compound was 
used in the pharmacological assays without further purification.  
* = see section 6.17 (Appendix) for experimental details 
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6.16. Overview 
  
 
 6.2. General procedure A SG-22 
SG-23 
SG-25 
 
 
 
 6.4. General procedure C SG-28 
SG-58 
SG-64 
SG-67 
SG-70 
SG-73 
SG-76 
SG-180 
SG-181 
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 6.5. General procedure D SG-52 
SG-56 
SG-62 
SG-80 
SG-103 
SG-110 
SG-111 
 
 
 
 6.6. General procedure E SG-99 
SG-112 
SG-114 
SG-115 
SG-116 
SG-117 
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 6.10. General procedure I SG-88 
SG-92 
SG-141 
SG-149 
SG-158 
SG-159 
SG-193 
SG-196 
SG-232 
SG-233 
SG-234 
SG-235 
 
 
 
 6.11. General procedure J SG-128 
SG-129 
SG-136 
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 6.12. General procedure K SG-205 
SG-206 
SG-207 
SG-208 
SG-209 
SG-210 
SG-212 
SG-213 
 
 
 
 6.14. General procedure M SG-225 
SG-238 
SG-239 
SG-240 
SG-241 
SG-242 
SG-244 
Chapter 6 
___________________________________________________________________ 
257 
 
 
 
 
 6.15. General procedure N 
 
SG-215 
SG-221 
SG-227 
SG-229 
SG-230 
SG-231 
SG-243 
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6.17. Appendix 
6.17.1. HPLC parameters for compounds 243 and 244 
Preparative HPLC was performed by Dr. Rudolf Vasold and Simone Strauss (Institute 
of Organic Chemistry, Chair Prof Dr. Burkhard König, University of Regensburg, 
Germany). Method Information: 
Column:  
LabID 90 / Phenomenex Luna 10 µm C18 (2) 100A, 250 x 21.2 mm / [Part 00G-4253-
PO-AX [Ser 453159-3] / B/N 5293-46; column temperature 25 °C 
LC-System:  
Agilent1100 Series: G1361A PrepPump [DE23900589] 
G1316A PrepPump [DE23900591] / G1364A AFC [DE23900834] / G1365B MWD 
[DE30502172] / G1329A ALS [DE33211203] / G1330B ALS Therm [DE 13205892] / 
HPLC Column Chiller/Heater C030: Echo Therm Torrey Pines Scientific 
Software: 
ChemStation for LC 3D Systems Rev. B03.02 [341] 
 
Compound 243 
0 min w = 15% MeCN / H2O [w = 0.059% TFA] 
20 min w = 25% MeCN / H2O [w = 0.059% TFA] 
24 min w= 98% MeCN / H2O [w = 0.059% TFA] 
Inj. Vol. 300 µl / Flow: 21 ml/min 
 
Compound 244 
0 min w = 5% MeCN / H2O [w = 0.059% TFA] 
20 min w = 98% MeCN / H2O [w = 0.059% TFA] 
Inj. Vol. 900 µl / Flow: 21 ml/min 
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6.17.2. HSQC-, HMBC- and COSY-NMR spectra of compound 88 
 
Figure 6.1. Heteronuclear single quantum correlation spectrum (HSQC) of 88, spread. 
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Figure 6.2. Heteronuclear multiple bond correlation spectrum (HMBC) of 88, spread. 
 
 
Figure 6.3. Heteronuclear multiple bond correlation spectrum (HMBC) of 88, spread. 
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Figure 6.4. Correlation spectroscopy spectrum (COSY) of 88, spread. 
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Analytical details for compound 88 (= compound 7a, J. Med. Chem., 49, 15, 4512 – 
16, Smits et al. (2006)): 
 
Compound 7a, Smits et al. (2006) 
1H-NMR  
(200 MHz, DMSO-d6) δ 7.62-7.54 (m, 1H), 7.42-7.28 (m, 3H), 7.19 (d, J = 8.4, 1H), 
7.06-6.97 (m, 2H) 3.49 (m, 4H), 2.38 (m, 4H), 2.22 (s, 3H); 
13C-NMR  
(200 MHz, DMSO-d6) δ 159.88, 159.53, 150.10, 141.75, 133.12, 129.34, 129.05, 
125.38, 125.29, 122.84, 122.32, 121.39, 120.91, 54.08, 46.38, 45.43 
 
Compound 88: 
1H-NMR 
(300 MHz, CDCl3) δ 7.42 (t, J = 8.2, 7.3, 1.7Hz, 1H), δ 7.32 (d, J = 7.7Hz, 1H), δ 7.22 
(d, J = 8.2 Hz, 1H), 7.17 (t, J = 7.6, 1.2Hz, 1H), δ 7.12 (d, J = 2.5Hz, 1H), δ 7.01 (d, J 
= 8.5Hz, 1H), δ 6.88 (d, J = 11.1Hz, 1H), δ 3.61 (bs, 4H), δ 2.55 (bs, 4H), δ 2.38 (s, 
3H). 
13C-NMR 
(400 MHz, CDCl3) δ 160.63 (Cquat), 150.69 (Cquat), 141.81 (Cquat), 132.75 (+, Ar-CH), 
130.29 (Cquat), 129.49 (+, Ar-CH), 126.49 (+, Ar-CH), 124.93 (+, Ar-CH), 123.47 (+, Ar-
CH), 123.31 (Cquat), 121.14 (+, Ar-CH), 120.96 (+, Ar-CH), 54.91 (-, 2 Pip-CH2), 47.18 
(-, 2 Pip-CH2), 46.10 (+, CH3).  
 
The 1H- and 13C-NMR data obtained within this study are in good agreement with the 
data published in literature (Smits et al., 2006). However, one discrepancy was found 
within the 13C-NMR data:  the 13C-NMR signal of one quaternary carbon atom (marked 
in light blue) could not be detected with our methods. As the chemical shifts of this 
carbon atom are very similar to the vicinated carbon atom marked in green, an overlay 
of the 13C-NMR signals is assumed. Derived from the HSQC, HMBC and COSY 
spectra shown above (figures 6.1 – 6.4), the following correlation between the detected 
1H- and 13C-NMR signals and the chemical structure of compound 88 is suggested 
(figure 6.5): 
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Figure 6.5. Correlation between the detected 1H- and 13C-NMR signals and the 
chemical structure of 88. 
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